ClinicalTrials.gg
CompletedNCT00814320Updated May 19, 2021Results posted

Gammagard Liquid and rHuPH20 in PID

A Phase 3 interventional study of Recombinant human hyaluronidase (rHuPH20)+ immune globulin intravenous (IGIV) and Recombinant human hyaluronidase (rHuPH20)+ immune globulin intravenous (IGIV) in Primary Immunodeficiency Diseases (PID), sponsored by Baxalta now part of Shire. Completed at 14 sites in 2 countries. Open to participants aged 2 Years and older. Per ClinicalTrials.gov, last updated 2021-05-19.

Sponsored by Baxalta now part of Shire (part of Takeda) · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
89
Allocation
Non-randomized
Ages
2 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 23 studies in Primary Immunodeficiency Diseases by Takeda — 2 open to participants now, 3 under way, 1 of them phase 3. Primary Immunodeficiency Diseases · Takeda.

Enrollment
Largest of 18
89 · median 47
Started
2008
the only one that year
Phase 3
9 of 23
none open now
Registered
5th of 23
by date

Among the 23 studies in Primary Immunodeficiency Diseases by Takeda, this one has the largest enrollment of the 18 interventional ones that give a count, is the only one that started in 2008, is one of 9 in phase 3, and was the 5th registered.

Primary Immunodeficiency Diseases

211 studies on the registry are indexed under Primary Immunodeficiency Diseases; 51 are open to participants now.

Browse Primary Immunodeficiency Diseases studies →

Open to participants now

2 of the 23 studies in Primary Immunodeficiency Diseases by Takeda are open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

All 2 open studies →

Who these studies take

Of the 35 Primary Immunodeficiency Diseases studies recruiting now, 12 (34%) set no upper age limit and 10 (29%) stop at 75 or younger; 28 take children under 18; 11 take healthy volunteers.

This study: 2 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 23 studies in Primary Immunodeficiency Diseases by Takeda, or all of them as a file.
02

Study summary

The purpose of the study is to develop a subcutaneous treatment option for participants with Primary Immunodeficiency Diseases (PID) that allows an administration of Immune Globulin Intravenous (Human), 10% at the same frequency as IV administration.

03

Conditions studied

  • Primary Immunodeficiency Diseases (PID)
04

Who can participate

Ages eligible
2 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Participant is 2 years or older at the time of screening
  • Written obtained from either the participant or the participant's legally acceptable representative prior to any study-related procedures and study product administration
  • Participant has been diagnosed with a PID disorder requiring antibody replacement as defined by WHO criteria
  • Participant has completed or is about to complete Baxter Clinical Study Protocol No. 160601 or has been receiving a regular IGIV-treatment at mean intervals of 21 ± 3 days or 28 ± 3 days, or SC at mean intervals of 5 to 16 days, over a period of at least 3 months prior to enrollment at a minimum dose of 300 mg/kg BW/4 weeks
  • Participant has a serum trough level of IgG > 4.5 g/L at the last documented determination
  • If female of , participant presents with a negative urine pregnancy test and agrees to employ adequate measures for the duration of the study
  • Participant is willing and able to comply with the requirements of the protocol

Exclusion criteria

Exclusion Criteria:

  • Participant has a known history of or is positive at enrollment or screening for one or more of the following: surface antigen (HbsAg), polymerase chain reaction (PCR) for Virus (HCV), PCR for (HIV) Type 1/2
  • Participant has levels of (ALT) or aspartate amino transferase (AST) > 2.5 times the for the testing laboratory
  • Participant has persistent severe neutropenia (defined as an [ANC] \<= 500/mm3)
  • Participant has (CLcr) values, calculated according to the formula below, which are \< 60% of normal for age and gender for males: CLcr = [(140 - Age(years)) * (body weight (kg))] / [72 * (serum creatinine (mg/dL))] for females: CLcr = [(140 - Age(years)) * (body weight(kg)) * 0.85] / [72 * (serum creatinine (mg/dL))]
  • Participant has been diagnosed with, or has a (other than adequately treated basal cell or squamous cell carcinoma of the skin or carcinoma in situ of the cervix) within the last 12 months prior to enrollment; participants treated with chemotherapeutic agents during this period are excluded
  • Participant has a history of thrombotic episodes (including deep vein thrombosis, myocardial infarction, cerebrovascular accident, pulmonary embolism) within the last 12 months
  • Participant has abnormal protein loss (protein losing enteropathy, nephrotic syndrome)
  • Participant has anemia that would preclude phlebotomy for laboratory studies
  • Participant has received any blood or blood product other than an IGIV, SC immunoglobulin, immune serum globulin (ISG) preparation, or albumin within the 6 months prior to enrollment
  • Participant has an ongoing history of or persistent reactions (urticaria, breathing difficulty, severe hypotension, or anaphylaxis) following IGIV, SC immunoglobulin, and/or ISG infusions
  • Participant has immunoglobulin A (IgA) deficiency and known anti IgA antibodies
  • Participant is on preventative (prophylactic) antibiotics and cannot stop antibiotics at the time of enrollment
  • Participant has active infection who started on antibiotic therapy for the treatment of infection within 7 days prior to screening
  • Participant has a bleeding disorder or is on anti-coagulation therapy that results in a count less than 20,000/μL or International Normalized Ration () > 2X control, or who, in the opinion of the investigator would be at significant risk of increased bleeding or bruising as a result of SC therapy
  • Participant has total protein > 9 g/dL and participants with myeloma, macroglobulinemia (IgM) and paraproteinemia
  • Participant has a known allergy to hyaluronidase
  • If female, participant is pregnant or lactating at the time of study enrollment
  • Participant has participated in another clinical study involving an product (IP) or device within 30 days prior to study enrollment or is scheduled to participate in another clinical study involving an IP or device during the course of this study; exception: Baxter Study No. 160601
  • Severe dermatitis that would preclude adequate sites for safe product administration
Terms in these criteria, in plain language(16)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Absolute neutrophil count (ANC)

The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.

It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.

Creatinine clearance (CrCl)

How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

INR, PT and aPTT (clotting tests)

Blood tests of how long blood takes to clot. The INR is the prothrombin time (PT) put on a common scale; about 1 is usual for someone not taking a blood thinner.

Criteria often make an exception for people on a blood thinner such as warfarin, whose INR is raised on purpose.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
89 participants (actual)

Study arms

  • Experimental
    1

    Efficacy and tolerability of subcutaneous (SC) infusions of immune globulin intravenous (IGIV), 10% with hyaluronidase (rHuPH20) after ramp-up

    Biological: Recombinant human hyaluronidase (rHuPH20)+ immune globulin intravenous (IGIV)

  • Experimental
    2

    Pharmacokinetics of intravenous (IV) infusions of immune globulin intravenous (IGIV), 10% and efficacy and tolerability of subcutaneous (SC) infusions of immune globulin intravenous (IGIV), 10% with hyaluronidase (rHuPH20) after ramp-up

    Biological: Recombinant human hyaluronidase (rHuPH20)+ immune globulin intravenous (IGIV)

Interventions

  • BiologicalRecombinant human hyaluronidase (rHuPH20)+ immune globulin intravenous (IGIV)

    Drug page: Hyaluronidase (human recombinant)

    Comprises subjects previously participating in Study 160601, who now only complete Study Epoch 2 (subcutaneous \[SC\] infusions) as bioavailability/exposure for intravenous (IV) treatment was already obtained in Study 160601. Study Epoch 2: Dose (calculated) of rHuPH20 followed by dose (calculated) of IGIV, 10% by SC infusion. Treatment intervals and doses are to be increased as defined, until treatment interval is the same as the pre-study treatment interval for IV treatment (ramp-up).

    Also known as: HYQVIA

  • BiologicalRecombinant human hyaluronidase (rHuPH20)+ immune globulin intravenous (IGIV)

    Drug page: Hyaluronidase (human recombinant)

    Comprises all other subjects. Study Epoch 1: IV infusion of IGIV, 10% (same dose and frequency as pre-study) to determine pharmacokinetics. Study Epoch 2: Dose (calculated) of rHuPH20 followed by dose (calculated) of IGIV, 10% by SC infusion. Treatment intervals and doses are to be increased as defined, until treatment interval is the same as the pre-study treatment interval for IV treatment (ramp-up).

06

What researchers measure

Primary outcomes

  1. Validated Acute Serious Bacterial Infection (VASBI) Rate

    Serious acute bacterial infections include bacteremia/sepsis, bacterial meningitis, osteomyelitis/septic arthritis, bacterial pneumonia, and visceral abscess that are caused by a recognized bacterial pathogen. VASBI rate is the mean number of VASBIs per participant per year, recorded for SC Administration of IGIV, 10%, with rHuPH20 after ramp-up, only. The mean number of VASBIs per participant per year and the 99% upper confidence limit for the acute serious bacterial infection rate were calculated using a Poisson model to account for the length of the observation periods per participant.

    Time frame: Throughout the study period (17 months)

Secondary outcomes

  1. Bioavailability (AUC) of IgG After Administration of IGIV, 10% Given Via IV or SC With rHuPH20 in Participants ≥12 Years

    Bioavailability expressed as pharmacokinetic (PK) equivalence of immunoglobulin (IgG) in terms of ratio of Area Under the Concentration Curve (AUC)/Week after administration of immune globulin intravenous (IGIV), 10% given via subcutaneous (SC) route with recombinant human hyaluronidase (rHuPH20) after ramp-up to intravenous (IV) route, i.e. ratio of AUC/week of SC/rHuPH20 versus IV administration of IGIV, 10%. Expressed as a percentage.

    Time frame: PK AUC evaluations: (IV: before infusion #4 [for 3-week treatment interval] or infusion #3 [for 4-week treatment interval];SC: before last SC infusion) 60 minutes pre-infusion up to 28 days (+/-2 days) post-infusion

  2. Bioavailability (Trough Levels) of IgG After Administration of IGIV, 10% Given Via IV or SC With rHuPH20 in Participants Aged 2 to < 12 Years

    Bioavailability expressed as pharmacokinetic (PK) equivalence of immunoglobulin (IgG) in terms of trough levels after administration of immune globulin intravenous (IGIV), 10% given via subcutaneous (SC) route with recombinant human hyaluronidase (rHuPH20) after ramp-up to intravenous (IV) route, i.e. ratio of AUC/week of SC/rHuPH20 versus IV administration of IGIV, 10%. Expressed as a percentage.

    Time frame: IgG trough levels measured at baseline and on day of each 3- or 4-week infusion for infusion for IV and SC (except during ramp-up for SC) and at end of study visit

  3. Bioavailability (AUC) of IgG After SC Administration of IGIV, 10%, Given With and Without rHuPH20

    Bioavailability of immunoglobulin (IgG) after subcutaneous (SC) administration of immune globulin intravenous (IGIV), 10%, with and without recombinant human hyaluronidase (rHuPH20) (from current study 160603 and study 160601, respectively), as measured by ratio of AUC of IgG per dose/kg with versus without rHuPH20. Expressed as a percentage. This was analysed for participants in Stratum A , participants in Stratum B and for all participants who received IGIV, 10% via SC administration (Stratum A plus Stratum B): Stratum A: Participants who provided data both on SC with AND without rHuPH20 ie, participants who participated in both studies 160601 and 160603; Stratum B: Participants who provided data on SC with OR without rHuPH20, but not on both (participants who participated in study 160601 OR 160603, but not in both studies).

    Time frame: PK: 160603 (IV: before infusion (inf.) #4 [3-week treatment interval] or inf. #3 [4-week treatment interval];SC: before last SC inf.) 1 hour pre-inf. ≤28 days (+/-2 days) post-inf.; 160601- 1 hour pre-inf. (before inf. #8) ≤7 days (+/-1 day) post-inf.

  4. Annual Rate of All Infections Per Participant

    Annual rate of all infections per participant after administration of immune globulin intravenous (IGIV), 10% given via intravenous (IV) or subcutaneous (SC) route with recombinant human hyaluronidase (rHuPH20) after ramp-up. Point estimates and 95% CIs for the annual rates will be calculated using a Poisson model and the same methodology including allowance for over-dispersion as described for the primary endpoint.

    Time frame: Throughout the study period (17 months)

  5. Trough Levels of IgG After Administration of IGIV, 10% Given Via IV or SC With rHuPH20

    Trough levels of immunoglobulin (IgG) after administration of immune globulin intravenous (IGIV), 10% given via intravenous (IV) or subcutaneous (SC) route with recombinant human hyaluronidase (rHuPH20) after ramp-up

    Time frame: IgG trough levels measured at baseline and on day of each 3- or 4-week infusion for IV and SC (except during ramp up for SC) and at end of study visit.

  6. Trough Levels of IgG Subclasses After Administration of IGIV, 10% Given Via IV or SC With rHuPH20

    Trough levels of immunoglobulin (IgG) subclasses after administration of immune globulin intravenous (IGIV), 10% given via intravenous (IV) or or subcutaneous (SC) route with recombinant human hyaluronidase (rHuPH20) after ramp-up by IgG subclasses 1 to 4 at end of IV treatment and end of SC treatment with rHuPH20 IgG subclass 1 (IgG 1) IgG subclass 2 (IgG 2) IgG subclass 3 (IgG 3) IgG subclass 4 (IgG 4)

    Time frame: IgG subclasses (1-4) trough levels measured at baseline and on day of each 3- or 4-week infusion for infusion for IV and SC (except during ramp up for SC) and at end of study visit

  7. Antibody Levels to Tetanus (Clostridium Tetani Toxoid)

    Antibody levels to Tetanus (Clostridium tetani toxoid) after administration of immune globulin intravenous (IGIV), 10% given via intravenous (IV) or subcutaneous (SC) route with recombinant human hyaluronidase (rHuPH20) at end of IV treatment and end of SC treatment with rHuPH20

    Time frame: IV: At baseline; SC/rHuPH20: at baseline then at infusion #1 at ramp-up and at infusions #5, 9, 13 (for 3-week treatment interval) and infusions #4, 7, 10 (for 4-week treatment interval), SC: end of SC treatment and at end of study visit

  8. Antibody Levels to Haemophilus Influenzae

    Antibody levels to Haemophilus influenzae after administration of immune globulin intravenous (IGIV), 10% given via intravenous (IV) or subcutaneous (SC) route with recombinant human hyaluronidase (rHuPH20) at end of IV treatment and end of SC treatment with rHuPH20

    Time frame: IV: At baseline; SC/rHuPH20: at baseline then at infusion #1 at ramp-up and at infusions #5, 9, 13 (for 3-week treatment interval) and infusions #4, 7, 10 (for 4-week treatment interval), SC: end of SC treatment and at end of study visit

  9. Antibody Levels to Measles

    Antibody levels to measles after administration of immune globulin intravenous (IGIV), 10% given via intravenous (IV) or subcutaneous (SC) route with recombinant human hyaluronidase (rHuPH20) at end of IV treatment and end of SC treatment with rHuPH20

    Time frame: IV: At baseline; SC/rHuPH20: at baseline then at infusion #1 at ramp-up and at infusions #5, 9, 13 (for 3-week treatment interval) and infusions #4, 7, 10 (for 4-week treatment interval), SC: end of SC treatment and at end of study visit

  10. Antibody Levels to Hepatitis B

    Antibody levels to hepatitis B after administration of immune globulin intravenous (IGIV), 10% given via intravenous (IV) or subcutaneous (SC) with recombinant human hyaluronidase (rHuPH20) at end of IV treatment and end of SC treatment with rHuPH20

    Time frame: IV: At baseline; SC/rHuPH20: at baseline then at infusion #1 at ramp-up and at infusions #5, 9, 13 (for 3-week treatment interval) and infusions #4, 7, 10 (for 4-week treatment interval), SC: end of SC treatment and at end of study visit

  11. IgG Minimum Plasma Concentration (C_min) for Participants Aged 12 Years and Older

    Minimal immunoglobulin (IgG) concentration after administration of immune globulin intravenous (IGIV), 10% given via intravenous (IV) or subcutaneous (SC) route with recombinant human hyaluronidase (rHuPH20) for participants aged 12 years and Older

    Time frame: PK evaluations: (IV: before infusion #4 [for 3-week treatment interval] or infusion #3 [for 4-week treatment interval]; SC: before last SC infusion) 60 minutes pre-infusion up to 28 days (+/-2 days) post-infusion

  12. IgG Area Under the Curve (AUC)/Week for Participants Aged 12 Years and Older

    Immunoglobulin (IgG) Area under the Curve (AUC) AUC/week after administration of immune globulin intravenous (IGIV), 10% given via intravenous (IV) or subcutaneous (SC) route with recombinant human hyaluronidase (rHuPH20) for participants aged 12 years and older. The AUC between adjacent infusions was calculated by the trapezoidal rule. Linear interpolation/extrapolation was used to calculate the AUC for the exact duration of the infusion intervals (21 days for 3-week treatment interval or 28 days for 4-week treatment interval).

    Time frame: PK evaluations: (IV: before infusion #4 [for 3-week treatment interval] or infusion #3 [for 4-week treatment interval];SC: before last SC infusion) 60 minutes pre-infusion up to 28 days (+/-2 days) post-infusion.

  13. IgG Clearance (CL) for Participants Aged 12 Years and Older

    Immunoglobulin (IgG) Clearance after administration of immune globulin intravenous (IGIV), 10% given via intravenous (IV) or subcutaneous (SC) with recombinant human hyaluronidase (rHuPH20) for participants aged 12 years and older. Clearance (CL) is provided after administration of IGIV,10% given via IV route. Apparent Clearance is provided after administration of IGIV, 10% given via SC route with rHuPH20. Clearance and apparent clearance are determined by weight adjusted dose divided by total AUC.

    Time frame: PK evaluations: (IV: before infusion #4 [for 3-week treatment interval] or infusion #3 [for 4-week treatment interval];SC: before last SC infusion) 60 minutes pre-infusion up to 28 days (+/-2 days) post-infusion.

  14. IgG Maximum Plasma Concentration (C_max) for Participants Aged 12 Years and Older

    Maximum immunoglobulin (IgG) concentration after administration of immune globulin intravenous (IGIV), 10% given via intravenous (IV) or subcutaneous (SC) route with recombinant human hyaluronidase (rHuPH20) for participants aged 12 years and older

    Time frame: PK evaluations: (IV: before infusion #4 [for 3-week treatment interval] or infusion #3 [for 4-week treatment interval]; SC: before last SC infusion) 60 minutes pre-infusion up to 28 days (+/-2 days) post-infusion.

  15. IgG Terminal Half Life (T1/2) for Participants Aged 12 Years and Older

    Terminal half life (T1/2) for immunoglobulin (IgG) after administration of immune globulin intravenous (IGIV), 10% given via intravenous (IV) or subcutaneous (SC) route with recombinant human hyaluronidase (rHuPH20) for participants aged 12 years and older. Terminal half life is the time it takes for the plasma concentration or the amount of immunoglobulin in the body to be reduced by 50% during the terminal phase

    Time frame: PK evaluations: (IV: before infusion #4 [for 3-week treatment interval] or infusion #3 [for 4-week treatment interval]; SC: before last SC infusion) 60 minutes pre-infusion up to 28 days (+/-2 days) post-infusion.

  16. Time to Maximum IgG Concentration (T-max) for Participants Aged 12 Years and Older

    Time to Maximum Immunoglobulin (IgG) Concentration (T-max) after administration of immune globulin intravenous (IGIV), 10% given via intravenous (IV) or subcutaneous (SC) route with recombinant human hyaluronidase (rHuPH20) for participants aged 12 years and older

    Time frame: PK evaluations: (IV: before infusion #4 [for 3-week treatment interval] or infusion #3 [for 4-week treatment interval]; SC: before last SC infusion) 60 minutes pre-infusion up to 28 days (+/-2 days) post-infusion.

  17. Tetanus Antibody Minimum Plasma Concentration (C_min) for Participants Aged 12 Years and Older

    Minimal tetanus (clostridium tetani toxoid) antibody concentration after administration of immune globulin intravenous (IGIV), 10% given via intravenous (IV) or subcutaneous (SC) route with recombinant human hyaluronidase (rHuPH20) for participants aged 12 years and older

    Time frame: PK evaluations: (IV: before infusion #4 [for 3-week treatment interval] or infusion #3 [for 4-week treatment interval]; SC: before last SC infusion) 60 minutes pre-infusion up to 28 days (+/-2 days) post-infusion.

  18. Tetanus Antibody Area Under the Curve (AUC)/Week for Participants Aged 12 Years and Older

    Tetanus (clostridium tetani toxoid) antibody Area under the Curve (AUC) AUC/week after administration of immune globulin intravenous (IGIV), 10% given via intravenous (IV) or subcutaneous (SC) route with recombinant human hyaluronidase (rHuPH20) for participants aged 12 years and older. The AUC between adjacent infusions was calculated by the trapezoidal rule. Linear interpolation/extrapolation was used to calculate the AUC for the exact duration of the infusion intervals (21 days for 3-week treatment interval or 28 days for 4-week treatment interval).

    Time frame: PK evaluations: (IV: before infusion #4 [for 3-week treatment interval] or infusion #3 [for 4-week treatment interval];SC: before last SC infusion) 60 minutes pre-infusion up to 28 days (+/-2 days) post-infusion.

  19. Tetanus Antibody Clearance (CL) for Participants Aged 12 Years and Older

    Tetanus (clostridium tetani toxoid) antibody Clearance after administration of immune globulin intravenous (IGIV), 10% given via intravenous (IV) or subcutaneous (SC) route with recombinant human hyaluronidase (rHuPH20) for participants aged 12 years and older. Clearance (CL) is provided after administration of IGIV,10% given via IV route. Apparent Clearance is provided after administration of IGIV, 10% given via SC route with rHuPH20. Clearance (CL) and apparent clearance are determined by weight adjusted dose divided by total AUC.

    Time frame: PK evaluations: (IV: before infusion #4 [for 3-week treatment interval] or infusion #3 [for 4-week treatment interval];SC: before last SC infusion) 60 minutes pre-infusion up to 28 days (+/-2 days) post-infusion.

  20. Tetanus Antibody Terminal Half Life (T1/2) for Participants Aged 12 Years and Older

    Terminal half life (T1/2) for tetanus (clostridium tetani toxoid) antibody after administration of immune globulin intravenous (IGIV), 10% given via intravenous (IV) or subcutaneous (SC) with recombinant human hyaluronidase (rHuPH20) for participants aged 12 years and older. Terminal half life is the time it takes for the plasma concentration or the amount of tetanus antibody in the body to be reduced by 50% during the terminal phase

    Time frame: PK evaluations: (IV: before infusion #4 [for 3-week treatment interval] or infusion #3 [for 4-week treatment interval]; SC: before last SC infusion) 60 minutes pre-infusion up to 28 days (+/-2 days) post-infusion.

  21. Tetanus Antibody Maximum Plasma Concentration (C_max) for Participants Aged 12 Years and Older

    Maximum tetanus (clostridium tetani toxoid) antibody concentration after administration of immune globulin intravenous (IGIV), 10% given via intravenous (IV) or subcutaneous (SC) with recombinant human hyaluronidase (rHuPH20) for participants aged 12 years and older

    Time frame: PK evaluations: (IV: before infusion #4 [for 3-week treatment interval] or infusion #3 [for 4-week treatment interval]; SC: before last SC infusion) 60 minutes pre-infusion up to 28 days (+/-2 days) post-infusion.

  22. Time to Maximum Tetanus Antibody Concentration (T-max) for Participants Aged 12 Years and Older

    Time to Maximum tetanus (clostridium tetani toxoid) antibody Concentration (T-max) after administration of immune globulin intravenous (IGIV), 10% given via intravenous (IV) or subcutaneous (SC) route with recombinant human hyaluronidase (rHuPH20) for participants aged 12 years and older

    Time frame: PK evaluations: (IV: before infusion #4 [for 3-week treatment interval] or infusion #3 [for 4-week treatment interval]; SC: before last SC infusion) 60 minutes pre-infusion up to 28 days (+/-2 days) post-infusion.

  23. H. Influenzae Antibody Minimum Plasma Concentration (C_min) for Participants Aged 12 Years and Older

    Minimal influenza (haemophilus influenzae) antibody concentration after administration of immune globulin intravenous (IGIV), 10% given via intravenous (IV) or subcutaneous (SC) with recombinant human hyaluronidase (rHuPH20) for participants aged 12 years and older

    Time frame: PK evaluations: (IV: before infusion #4 [for 3-week treatment interval] or infusion #3 [for 4-week treatment interval]; SC: before last SC infusion) 60 minutes pre-infusion up to 28 days (+/-2 days) post-infusion.

  24. H. Influenzae Antibody Area Under the Curve (AUC)/Week for Participants Aged 12 Years and Older

    Influenza (haemophilus influenzae) antibody Area under the Curve (AUC) AUC/week after administration of immune globulin intravenous (IGIV), 10% given via intravenous (IV) or subcutaneous (SC) route with recombinant human hyaluronidase (rHuPH20) for participants aged 12 years and older. The AUC between adjacent infusions was calculated by the trapezoidal rule. Linear interpolation/extrapolation was used to calculate the AUC for the exact duration of the infusion intervals (21 days for 3-week treatment interval or 28 days for 4-week treatment interval).

    Time frame: PK evaluations: (IV: before infusion #4 [for 3-week treatment interval] or infusion #3 [for 4-week treatment interval];SC: before last SC infusion) 60 minutes pre-infusion up to 28 days (+/-2 days) post-infusion.

  25. H. Influenzae Antibody Clearance (CL) for Participants Aged 12 Years and Older

    Influenza (haemophilus influenzae) antibody Clearance after administration of immune globulin intravenous (IGIV), 10% given via intravenous (IV) or subcutaneous (SC) with recombinant human hyaluronidase (rHuPH20) for participants aged 12 years and older. Clearance (CL) is provided after administration of IGIV,10% given via IV route. Apparent Clearance is provided after administration of IGIV, 10% given via SC route with rHuPH20. Clearance (CL) and apparent clearance are determined by weight adjusted dose divided by total AUC.

    Time frame: PK evaluations: (IV: before infusion #4 [for 3-week treatment interval] or infusion #3 [for 4-week treatment interval];SC: before last SC infusion) 60 minutes pre-infusion up to 28 days (+/-2 days) post-infusion.

  26. H. Influenzae Antibody Maximum Plasma Concentration (C_max) for Participants Aged 12 Years and Older

    Maximal influenza (haemophilus influenzae) antibody concentration after administration of immune globulin intravenous (IGIV), 10% given via intravenous (IV) or subcutaneous (SC) route with recombinant human hyaluronidase (rHuPH20) for participants aged 12 years and older

    Time frame: PK evaluations: (IV: before infusion #4 [for 3-week treatment interval] or infusion #3 [for 4-week treatment interval]; SC: before last SC infusion) 60 minutes pre-infusion up to 28 days (+/-2 days) post-infusion.

  27. H. Influenzae Antibody Terminal Half Life (T1/2) for Participants Aged 12 Years and Older

    Terminal half life (T1/2) for influenza (haemophilus influenzae) antibody after administration of immune globulin intravenous (IGIV), 10% given via intravenous (IV) or subcutaneous (SC) route with recombinant human hyaluronidase (rHuPH20) for participants aged 12 years and older. Terminal half life is the time it takes for the plasma concentration or the amount of influenza antibody in the body to be reduced by 50% during the terminal phase.

    Time frame: PK evaluations: (IV: before infusion #4 [for 3-week treatment interval] or infusion #3 [for 4-week treatment interval]; SC: before last SC infusion) 60 minutes pre-infusion up to 28 days (+/-2 days) post-infusion.

  28. Time to Maximum H. Influenzae Antibody Concentration (T-max) for Participants Aged 12 Years and Older

    Time to Maximum influenza (haemophilus influenzae) antibody Concentration (T-max) after administration of immune globulin intravenous (IGIV), 10% given via intravenous (IV) or subcutaneous (SC) route with recombinant human hyaluronidase (rHuPH20) for participants aged 12 years and older

    Time frame: PK evaluations: (IV: before infusion #4 [for 3-week treatment interval] or infusion #3 [for 4-week treatment interval]; SC: before last SC infusion) 60 minutes pre-infusion up to 28 days (+/-2 days) post-infusion.

  29. Rate of Days Off School or Work

    Monthly rate of days off school or work after administration of immune globulin intravenous (IGIV), 10% given via intravenous (IV) or subcutaneous (SC) route with recombinant human hyaluronidase (rHuPH20) after ramp-up. Point estimates and 95% CIs for the monthly rates were calculated using a Poisson model and the same methodology including allowance for over-dispersion as described for the primary outcome measures. The lengths of the month were defined as average length of the month in the Gregorian calendar, namely (365\*400+100-3)/(400\*12)= 30.436875 days.

    Time frame: Monthly, for up to 17 months

  30. Rate of Days on Antibiotics

    Monthly rate of days on antibiotics after administration of immune globulin intravenous (IGIV), 10% given via intravenous (IV) or subcutaneous (SC) route with recombinant human hyaluronidase (rHuPH20) after ramp-up. Point estimates and 95% CIs for the monthly rates were calculated using a Poisson model and the same methodology including allowance for over-dispersion as described for the primary outcome measures. The lengths of the month was defined as average length of the month in the Gregorian calendar, namely (365\*400+100-3)/(400\*12)= 30.436875 days.

    Time frame: Monthly, for up to 17 months

  31. Rate of Acute Physician Visits

    Monthly rate of acute physician visits after administration of immune globulin intravenous (IGIV), 10% given via intravenous (IV) or subcutaneous (SC) route with recombinant human hyaluronidase (rHuPH20) after ramp-up. Point estimates and 95% CIs for the monthly rates will be calculated using a Poisson model and the same methodology including allowance for over-dispersion as described for the primary outcome measures. The lengths of the month will be defined as average length of the month in the Gregorian calendar, namely (365\*400+100-3)/(400\*12)= 30.436875 days.

    Time frame: Monthly, for up to 17 months

  32. Rate of Days in Hospital

    Monthly rate of days in hospital after administration of immune globulin intravenous (IGIV), 10% given via intravenous (IV) or subcutaneous (SC) route with recombinant human hyaluronidase (rHuPH20) after ramp-up. Point estimates and 95% CIs for the monthly rates will be calculated using a Poisson model and the same methodology including allowance for over-dispersion as described for the primary outcome measures. The lengths of the month will be defined as average length of the month in the Gregorian calendar, namely (365\*400+100-3)/(400\*12)= 30.436875 days.

    Time frame: Monthly, for up to 17 months

  33. Percentage of Participants for Which the Infusion Rate Was Reduced and/or the Infusion Interrupted or Stopped for Tolerability Concerns or for Adverse Events (AEs)

    Percentage of participants for which the infusion rate was reduced and/or the infusion interrupted or stopped during administration of immune globulin intravenous (IGIV), 10% given via intravenous (IV) or subcutaneous (SC) route with recombinant human hyaluronidase (rHuPH20) after ramp-up for tolerability concerns or for adverse events (AEs). An infusion was deemed as tolerated if there are no serious Adverse Drug Reactions (ADR), no non-serious moderate or severe local ADRs that prevent completion of the infusion and no non-serious moderate or severe systemic ADRs during infusion or within 60 minutes of completion of the infusion.

    Time frame: Throughout the study period (17 months)

  34. Percentage of Infusions for Which the Infusion Rate Was Reduced and/or the Infusion Interrupted or Stopped for Tolerability Concerns or for Adverse Events (AEs)

    Percentage of infusions for which the infusion rate was reduced and/or the infusion interrupted or stopped during administration of immune globulin intravenous (IGIV), 10% given via intravenous (IV) or subcutaneous (SC) route with recombinant human hyaluronidase (rHuPH20) after ramp-up for tolerability concerns or for adverse events (AEs). IV administration of IGIV, 10%: 365 infusions; SC administration of IGIV, 10% with rHuPH20: 1129 infusions

    Time frame: Throughout the study period (17 months)

  35. Rate of Temporally Associated AEs Per Infusion

    Rate of all AEs (including and excluding infections) per infusion that began during administration of immune globulin intravenous (IGIV), 10% given via intravenous (IV) or subcutaneous (SC) route with recombinant human hyaluronidase (rHuPH20) after ramp-up (during infusion) or within 72 hours of completion of an infusion ("temporally associated")

    Time frame: During infusion or within 72 hours of completion of infusion

  36. Percentage of Participants Reporting ≥1 Temporally Associated AEs

    Percentage of participants reporting at least 1 AE (including and excluding infections) during administration of immune globulin intravenous (IGIV), 10% given via intravenous (IV) or subcutaneous (SC) route with recombinant human hyaluronidase (rHuPH20) after ramp-up (during infusion) or within 72 hours of completion of infusion ("temporally associated")

    Time frame: During infusion or within 72 hours of completion of infusion

  37. Percentage of Infusions Resulting in ≥1 Temporally Associated AEs

    Percentage of infusions resulting in at least 1 AE (including and excluding infections) during administration of immune globulin intravenous (IGIV), 10% given via intravenous (IV) or subcutaneous (SC) route with recombinant human hyaluronidase (rHuPH20) after ramp-up (during infusion) or within 72 hours of completion of infusion ("temporally associated")

    Time frame: During infusion or within 72 hours of completion of infusion

  38. Percentage of Participants Reporting ≥1 Temporally Associated Moderate or Severe AEs

    Percentage of participants reporting at least 1 Moderate or Severe AE (including and excluding infections) during administration of immune globulin intravenous (IGIV), 10% given via intravenous (IV) or subcutaneous (SC) route with recombinant human hyaluronidase (rHuPH20) after ramp-up (during infusion) or within 72 hours of completion of infusion ("temporally associated")

    Time frame: During infusion or within 72 hours of completion of infusion

  39. Percentage of Infusions Resulting in ≥1 Temporally Associated Moderate or Severe AEs Within 72 Hours of Completion of Infusion

    Percentage of infusions resulting in at least 1 moderate or severe AE (including and excluding infections) during administration of immune globulin intravenous (IGIV), 10% given via intravenous (IV) or subcutaneous (SC) route with recombinant human hyaluronidase (rHuPH20) after ramp-up (during infusion) or within 72 hours of completion of infusion ("temporally associated")

    Time frame: During infusion or within 72 hours of completion of infusion

  40. Percentage of SC Doses of IGIV, 10% and rHuPH20 Tolerated at 1 Infusion Site

    Percentage of subcutaneous (SC) doses of immune globulin intravenous (IGIV), 10% and recombinant human hyaluronidase (rHuPH20) tolerated at 1 infusion site. An infusion was deemed as tolerated if there were no serious adverse drug reactions (ADRs), no non-serious moderate or severe local ADRs that prevented completion of the infusion, and no non-serious moderate or severe systemic ADRs during or within 60 minutes of completion of the infusion.

    Time frame: During infusion or within 60 minutes of completion of the infusion

  41. Percentage of Infusions Associated With ≥1 Systemic AE During Infusion or Within 72 Hours of Completion of Infusion

    Percentage of intravenous (IV) and subcutaneous (SC) infusions associated with ≥1 systemic AE (including and excluding infections) during administration of immune globulin intravenous (IGIV), 10% given via IV or SC route with recombinant human hyaluronidase (rHuPH20) after ramp-up (during infusion) or within 72 hours of completion of infusion

    Time frame: During infusion or within 72 hours of completion of infusion

  42. Percentage of Participants With ≥1 Systemic AE (Including and Excluding Infections) During Infusion or Within 72 Hours of Completion of Infusion

    Percentage of participants with ≥1 systemic AE (including and excluding Infections) during administration of immune globulin intravenous (IGIV), 10% given via intravenous (IV) or subcutaneous (SC) route with recombinant human hyaluronidase (rHuPH20) after ramp-up (during infusion) or within 72 hours of completion of infusion

    Time frame: During infusion or within 72 hours of completion of infusion

  43. Percentage of Infusions Associated With ≥1 Local AE (Including and Excluding Infections) During Infusion or Within 72 Hours of Completion of Infusion

    Percentage of IV and SC (with recombinant human hyaluronidase \[rHuPH20\]) infusions associated with ≥1 local AE (including and excluding infections) during administration of immune globulin intravenous (IGIV), 10% given via intravenous (IV) or subcutaneous (SC) route with rHuPH20 after ramp-up (during infusion) or within 72 hours of completion of infusion

    Time frame: During infusion or within 72 hours of completion of infusion

  44. Percentage of Infusions Associated With ≥1 Local AE At Any Time During the Study

    Percentage of intravenous (IV) and subcutaneous (SC) infusions with recombinant human hyaluronidase (rHuPH20) after ramp-up of immune globulin intravenous (IGIV), 10% associated with ≥1 local AE (including and excluding infections) at any time during the study

    Time frame: At any time during the study

  45. Percentage of Participants With ≥1 Local AE During Infusion or Within 72 Hours of Completion of Infusion

    Percentage of participants With ≥1 local AE (including and excluding Infections) during administration of immune globulin intravenous (IGIV), 10% given via intravenous (IV) or subcutaneous (SC) route with recombinant human hyaluronidase (rHuPH20) after ramp-up (during infusion) or within 72 hours of completion of infusion

    Time frame: During infusion or within 72 hours of completion of infusion

  46. Percentage of Participants With ≥1 Local AE At Any Time During the Study

    Percentage of participants With ≥1 local AE (including and excluding infections) after administration of immune globulin intravenous (IGIV), 10% given via intravenous (IV) or subcutaneous (SC) route with recombinant human hyaluronidase (rHuPH20) after ramp-up at any time during the study

    Time frame: During infusion or within 72 hours of completion of infusion

  47. Rate of AEs Determined to be Related to the Study Drug by the Investigator Per Participant

    Rate of related AEs defined as the total number of AEs determined by the investigator to be related to the study drug (immune globulin intravenous \[IGIV\], 10% or recombinant human hyaluronidase \[rHuPH20\]), that occur at any time during the study divided by the total number of participants

    Time frame: Throughout the study period (17 months)

  48. Rate of AEs Determined to be Related to the Study Drug by the Investigator Per Infusion

    Rate of related AEs defined as the total number of AEs determined by the investigator to be related to the study drug (immune globulin intravenous \[IGIV\], 10% or recombinant human hyaluronidase \[rHuPH20\]), that occur at any time during the study divided by the total number of infusions

    Time frame: Throughout the study period (17 months)

  49. Frequency of Dose Corrections (If IgG Trough Levels <4.5 g/L) for Each Study Epoch (IV and SC/rHuPH20 Treatment)

    Frequency of dose corrections based on immune globulin G (IgG) trough levels \<4.5 g/L IgG, if any, for intravenous (IV) (Epoch 1) and subcutaneous with recombinant human hyaluronidase (SC/rHuPH20) after ramp-up (Epoch 2) administration of immune globulin intravenous (IGIV), 10% Defined/calculated as the number of participants requiring dose adjustments divided by the number of participants, for each respective data set.

    Time frame: Throughout the study period (17 months)

  50. Number of All AEs Categorized by MedDRA Preferred Terms, Seriousness, Relatedness to Study Drug, and Severity (A-F)

    Categories presented as Preferred term-Seriousness, Relatedness, Severity. The following codes are to be used: Seriousness: non-SAE-non-serious AE; SAE-serious AE Relationship: NR-not related to immune globulin (IGIV), 10% and recombinant human hyaluronidase (rHuPH20); RIGIV-related to IGIV, 10%; RrHu-related to rHuPH20; Rboth-related to both IGIV, 10% and rHuPH20 Severity: Mild; Mod (Moderate); Severe Preferred terms abbreviated: ADHD-Attention Deficit/Hyperactivity Disorder BP-Blood Pressure COPD- Chronic Obstructive Pulmonary Disease

    Time frame: Throughout the study period (17 months)

  51. Number of All AEs Categorized by MedDRA Preferred Terms, Seriousness, Relatedness to Study Drug, and Severity (G-M)

    Categories presented as Preferred term-Seriousness, Relatedness, Severity. The following codes are to be used: Seriousness: non-SAE-non-serious AE; SAE-serious AE Relationship: NR-not related to immune globulin (IGIV), 10% and recombinant human hyaluronidase (rHuPH20); RIGIV-related to IGIV, 10%; RrHu-related to rHuPH20; Rboth-related to both IGIV, 10% and rHuPH20 Severity: Mild; Mod (Moderate); Severe

    Time frame: Throughout the study period (17 months)

  52. Number of All AEs Categorized by MedDRA Preferred Terms, Seriousness, Relatedness to Study Drug, and Severity (N-Z)

    Categories presented as Preferred term-Seriousness, Relatedness, Severity. The following codes are to be used: Seriousness: non-SAE-non-serious AE; SAE-serious AE Relationship: NR-not related to immune globulin (IGIV), 10% and recombinant human hyaluronidase (rHuPH20); RIGIV-related to IGIV, 10%; RrHu-related to rHuPH20; Rboth-related to both IGIV, 10% and rHuPH20 Severity: Mild; Mod (Moderate); Severe Preferred terms abbreviated: Resp.-Respiratory WBC - White blood cells

    Time frame: Throughout the study period (17 months)

  53. Rate of All AEs Categorized by MedDRA Preferred Terms, Seriousness, Relatedness to Study Drug, and Severity Per Infusion (A-F)

    Categories presented as Preferred term-Seriousness, Relatedness, Severity. The following codes are to be used: Seriousness: non-SAE-non-serious AE; SAE-serious AE Relationship: NR-not related to immune globulin (IGIV), 10% and recombinant human hyaluronidase (rHuPH20); RIGIV-related to IGIV, 10%; RrHu-related to rHuPH20; Rboth-related to both IGIV, 10% and rHuPH20 Severity: Mild; Mod (Moderate); Severe Preferred terms abbreviated: ADHD-Attention Deficit/Hyperactivity Disorder BP-Blood Pressure COPD- Chronic Obstructive Pulmonary Disease

    Time frame: Throughout the study period (17 months)

  54. Rate of All AEs Categorized by MedDRA Preferred Terms, Seriousness, Relatedness to Study Drug, and Severity Per Infusion (G-M)

    Categories presented as Preferred term-Seriousness, Relatedness, Severity. The following codes are to be used: Seriousness: non-SAE-non-serious AE; SAE-serious AE Relationship: NR-not related to immune globulin (IGIV), 10% and recombinant human hyaluronidase (rHuPH20); RIGIV-related to IGIV, 10%; RrHu-related to rHuPH20; Rboth-related to both IGIV, 10% and rHuPH20 Severity: Mild; Mod (Moderate); Severe

    Time frame: Throughout the study period (17 months)

  55. Rate of All AEs Categorized by MedDRA Preferred Terms, Seriousness, Relatedness to Study Drug, and Severity Per Infusion (N-Z)

    Categories presented as Preferred term-Seriousness, Relatedness, Severity. The following codes are to be used: Seriousness: non-SAE-non-serious AE; SAE-serious AE Relationship: NR-not related to immune globulin (IGIV), 10% and recombinant human hyaluronidase (rHuPH20); ; RIGIV-related to IGIV, 10%; RrHu-related to rHuPH20; Rboth-related to both IGIV, 10% and rHuPH20 Severity: Mild; Mod (Moderate); Severe Preferred terms abbreviated: Resp.-Respiratory WBC - White blood cells

    Time frame: Throughout the study period (17 months)

  56. Rate of All AEs Categorized by MedDRA Preferred Terms, Seriousness, Relatedness to Study Drug, and Severity Per Participant (A-F)

    Categories presented as Preferred term-Seriousness, Relatedness, Severity. The following codes are to be used: Seriousness: non-SAE-non-serious AE; SAE-serious AE Relationship: NR-not related to immune globulin (IGIV), 10% and recombinant human hyaluronidase (rHuPH20); RIGIV-related to IGIV, 10%; RrHu-related to rHuPH20; Rboth-related to both IGIV, 10% and rHuPH20 Severity: Mild; Mod (Moderate); Severe Preferred terms abbreviated: ADHD-Attention Deficit/Hyperactivity Disorder BP-Blood Pressure COPD- Chronic Obstructive Pulmonary Disease

    Time frame: Throughout the study period (17 months)

  57. Rate of All AEs Categorized by MedDRA Preferred Terms, Seriousness, Relatedness to Study Drug, and Severity Per Participant (G-M)

    Categories presented as Preferred term-Seriousness, Relatedness, Severity. The following codes are to be used: Seriousness: non-SAE-non-serious AE; SAE-serious AE Relationship: NR-not related to immune globulin (IGIV), 10% and recombinant human hyaluronidase (rHuPH20); RIGIV-related to IGIV, 10%; RrHu-related to rHuPH20; Rboth-related to both IGIV, 10% and rHuPH20 Severity: Mild; Mod (Moderate); Severe

    Time frame: Throughout the study period (17 months)

  58. Rate of All AEs Categorized by MedDRA Preferred Terms, Seriousness, Relatedness to Study Drug, and Severity Per Participant (N-Z)

    Categories presented as Preferred term-Seriousness, Relatedness, Severity. The following codes are to be used: Seriousness: non-SAE-non-serious AE; SAE-serious AE Relationship: NR-not related to immune globulin (IGIV), 10% and recombinant human hyaluronidase (rHuPH20); RIGIV-related to IGIV, 10%; RrHu-related to rHuPH20; Rboth-related to both IGIV, 10% and rHuPH20 Severity: Mild; Mod (Moderate); Severe Preferred terms abbreviated: Resp.-Respiratory WBC - White blood cells

    Time frame: Throughout the study period (17 months)

  59. Percentage of Infusions Associated With ≥1 AE Related to Either or Both Study Drugs

    Percentage of Infusions Associated With ≥1 AE Related to immune globulin intravenous (IGIV), 10%, \[administered via intravenous (IV) or subcutaneous (SC) route\], recombinant human hyaluronidase (rHuPH20) or both. The percentage of affected infusions is calculated per subject and then summarized by the median of all subjects analysed.

    Time frame: Throughout the study period (17 months)

  60. Percentage of Infusions Tolerated With IV and SC Administration at Dose Used in Study Epoch 2 (SC/rHuPH20 Treatment)

    Epoch 2: subcutaneous (SC) administration of immune globulin intravenous (IGIV), 10% with recombinant human hyaluronidase (rHuPH20) after ramp-up. Dose used in Epoch 2 (after ramp-up) was 108% of dose used in intravenous (IV) administration of IGIV, 10%. The percentage of affected infusions is calculated per subject and then summarized by the median of all subjects analysed.

    Time frame: Throughout the study period (17 months)

  61. Median Rate of AEs Temporally Associated or Related to Study Drug Per Infusion

    Temporally associated defined as during infusion or within 72 hours of completion of infusion. Related defined as determined by investigator to be at least possibly related to study drug (immune globulin intravenous \[IGIV\], 10% or recombinant human hyaluronidase \[rHuPH20\]). Expressed as a percentage.

    Time frame: Throughout the study period (17 months)

  62. Number of Participants Who Developed Neutralizing Antibodies to Recombinant Human Hyaluronidase (rHuPH20)

    Time frame: Throughout the study period (17 months)

  63. Percentage of Participants Who Developed Neutralizing Antibodies to Recombinant Human Hyaluronidase (rHuPH20)

    Time frame: Throughout the study period (17 months)

  64. Number of Participants Who Experienced a Hemoglobin Drop of >2.0 g/dL, With Evidence of Hemolysis on Further Analysis

    Further analysis for incidences of potential hemolysis included direct Coombs' test, free hemoglobin, serum haptoglobin, LDH, urine hemosiderin and microscopic urinalysis

    Time frame: Throughout the study period (17 months)

  65. Percentage of Participants Who Experienced a Hemoglobin Drop of >2.0 g/dL, With Evidence of Hemolysis on Further Analysis

    Further analysis for incidences of potential hemolysis included direct Coombs' test, free hemoglobin, serum haptoglobin, LDH, urine hemosiderin and microscopic urinalysis

    Time frame: Throughout the study period (17 months)

07

Results

Posted Dec 3, 2015

Participant flow

Recruitment was conducted 14 clinical sites in the United States and 1 clinical site in Canada.

Epoch 1 (IV Treatment)
Participant flow — Epoch 1 (IV Treatment)
Milestone2 to <12 Years12 Years and Older
Started1473
Completed1371
Not completed12
Withdrew: Withdrawal by subject10
Withdrew: Participant missed 2 consecutive doses02
Between Epoch 1 (IV) and Epoch 2 Ramp-up
Participant flow — Between Epoch 1 (IV) and Epoch 2 Ramp-up
Milestone2 to <12 Years12 Years and Older
Started1371
Completed1370
Not completed01
Withdrew: Withdrawal by subject01
Epoch 2 Ramp-up ("Ramp-up")
Participant flow — Epoch 2 Ramp-up ("Ramp-up")
Milestone2 to <12 Years12 Years and Older
Started1370
Completed1170
Not completed20
Withdrew: Adverse event10
Withdrew: Geographic factor10
Epoch 2 After Ramp-up (SC/rHuPH20)
Participant flow — Epoch 2 After Ramp-up (SC/rHuPH20)
Milestone2 to <12 Years12 Years and Older
Started1170
Completed860
Not completed310
Withdrew: Adverse event14
Withdrew: Withdrawal by subject21
Withdrew: Lost to follow-up01
Withdrew: Subject felt increased infections on sc01
Withdrew: Switched to safety follow-up03

Outcome measures

PrimaryValidated Acute Serious Bacterial Infection (VASBI) Rate

Serious acute bacterial infections include bacteremia/sepsis, bacterial meningitis, osteomyelitis/septic arthritis, bacterial pneumonia, and visceral abscess that are caused by a recognized bacterial pathogen. VASBI rate is the mean number of VASBIs per participant per year, recorded for SC Administration of IGIV, 10%, with rHuPH20 after ramp-up, only. The mean number of VASBIs per participant per year and the 99% upper confidence limit for the acute serious bacterial infection rate were calculated using a Poisson model to account for the length of the observation periods per participant.

Time frame:
Throughout the study period (17 months)
Reported as:
Number · Estimated infections/year
Validated Acute Serious Bacterial Infection (VASBI) Rate
Estimated infections/yearFull Analysis Data Set (FADS)
Validated Acute Serious Bacterial Infection (VASBI) Rate0.025
Statistical analysis
  • Full Analysis Data Set (FADS) · Poisson · p = <0.0001 (Testing the null hypothesis of 1 VASBI/year against a one-sided alternative at the 0.01 level of statistical significance.) · Poisson: 0.025
SecondaryBioavailability (AUC) of IgG After Administration of IGIV, 10% Given Via IV or SC With rHuPH20 in Participants ≥12 Years

Bioavailability expressed as pharmacokinetic (PK) equivalence of immunoglobulin (IgG) in terms of ratio of Area Under the Concentration Curve (AUC)/Week after administration of immune globulin intravenous (IGIV), 10% given via subcutaneous (SC) route with recombinant human hyaluronidase (rHuPH20) after ramp-up to intravenous (IV) route, i.e. ratio of AUC/week of SC/rHuPH20 versus IV administration of IGIV, 10%. Expressed as a percentage.

Time frame:
PK AUC evaluations: (IV: before infusion #4 [for 3-week treatment interval] or infusion #3 [for 4-week treatment interval];SC: before last SC infusion) 60 minutes pre-infusion up to 28 days (+/-2 days) post-infusion
Reported as:
Number · Percentage
Bioavailability (AUC) of IgG After Administration of IGIV, 10% Given Via IV or SC With rHuPH20 in Participants ≥12 Years
Percentage% Ratio IgG AUC/Week of SC/ IV
Bioavailability (AUC) of IgG After Administration of IGIV, 10% Given Via IV or SC With rHuPH20 in Participants ≥12 Years93.3 (91.4 to 95.2)
SecondaryBioavailability (Trough Levels) of IgG After Administration of IGIV, 10% Given Via IV or SC With rHuPH20 in Participants Aged 2 to < 12 Years

Bioavailability expressed as pharmacokinetic (PK) equivalence of immunoglobulin (IgG) in terms of trough levels after administration of immune globulin intravenous (IGIV), 10% given via subcutaneous (SC) route with recombinant human hyaluronidase (rHuPH20) after ramp-up to intravenous (IV) route, i.e. ratio of AUC/week of SC/rHuPH20 versus IV administration of IGIV, 10%. Expressed as a percentage.

Time frame:
IgG trough levels measured at baseline and on day of each 3- or 4-week infusion for infusion for IV and SC (except during ramp-up for SC) and at end of study visit
Reported as:
Number · Percentage
Bioavailability (Trough Levels) of IgG After Administration of IGIV, 10% Given Via IV or SC With rHuPH20 in Participants Aged 2 to < 12 Years
Percentage%Ratio IgG Trough Level of SC/IV
Bioavailability (Trough Levels) of IgG After Administration of IGIV, 10% Given Via IV or SC With rHuPH20 in Participants Aged 2 to < 12 Years103.8 (97.5 to 115.4)
SecondaryBioavailability (AUC) of IgG After SC Administration of IGIV, 10%, Given With and Without rHuPH20

Bioavailability of immunoglobulin (IgG) after subcutaneous (SC) administration of immune globulin intravenous (IGIV), 10%, with and without recombinant human hyaluronidase (rHuPH20) (from current study 160603 and study 160601, respectively), as measured by ratio of AUC of IgG per dose/kg with versus without rHuPH20. Expressed as a percentage. This was analysed for participants in Stratum A , participants in Stratum B and for all participants who received IGIV, 10% via SC administration (Stratum A plus Stratum B): Stratum A: Participants who provided data both on SC with AND without rHuPH20 ie, participants who participated in both studies 160601 and 160603; Stratum B: Participants who provided data on SC with OR without rHuPH20, but not on both (participants who participated in study 160601 OR 160603, but not in both studies).

Time frame:
PK: 160603 (IV: before infusion (inf.) #4 [3-week treatment interval] or inf. #3 [4-week treatment interval];SC: before last SC inf.) 1 hour pre-inf. ≤28 days (+/-2 days) post-inf.; 160601- 1 hour pre-inf. (before inf. #8) ≤7 days (+/-1 day) post-inf.
Reported as:
Number · Percentage
Bioavailability (AUC) of IgG After SC Administration of IGIV, 10%, Given With and Without rHuPH20
PercentageRatio IgG AUC of SC With and Without rHuPH20
Participants in Stratum A (N=19)118.7 (113.6 to 124.1)
Participants in Stratum B (N=54)133.6 (118.3 to 150.8)
Total Participants (N=73)120.4 (115.5 to 125.5)
SecondaryAnnual Rate of All Infections Per Participant

Annual rate of all infections per participant after administration of immune globulin intravenous (IGIV), 10% given via intravenous (IV) or subcutaneous (SC) route with recombinant human hyaluronidase (rHuPH20) after ramp-up. Point estimates and 95% CIs for the annual rates will be calculated using a Poisson model and the same methodology including allowance for over-dispersion as described for the primary endpoint.

Time frame:
Throughout the study period (17 months)
Reported as:
Number · Estimated infections/year
Annual Rate of All Infections Per Participant
Estimated infections/yearIV Administration of IGIV, 10%SC Administration of IGIV, 10%, With rHuPH20 After Ramp-up
Annual Rate of All Infections Per Participant4.51 (3.50 to 5.69)2.97 (2.51 to 3.47)
SecondaryTrough Levels of IgG After Administration of IGIV, 10% Given Via IV or SC With rHuPH20

Trough levels of immunoglobulin (IgG) after administration of immune globulin intravenous (IGIV), 10% given via intravenous (IV) or subcutaneous (SC) route with recombinant human hyaluronidase (rHuPH20) after ramp-up

Time frame:
IgG trough levels measured at baseline and on day of each 3- or 4-week infusion for IV and SC (except during ramp up for SC) and at end of study visit.
Reported as:
Median · g/L
Trough Levels of IgG After Administration of IGIV, 10% Given Via IV or SC With rHuPH20
g/LParticipants Aged 2 to <12 YearsParticipants ≥12 Years
end of IV part9.63 (8.29 to 13.60)10.40 (9.63 to 11.4)
end of SC with rHuPH20 part9.95 (7.87 to 15.00)10.70 (9.46 to 11.80)
SecondaryTrough Levels of IgG Subclasses After Administration of IGIV, 10% Given Via IV or SC With rHuPH20

Trough levels of immunoglobulin (IgG) subclasses after administration of immune globulin intravenous (IGIV), 10% given via intravenous (IV) or or subcutaneous (SC) route with recombinant human hyaluronidase (rHuPH20) after ramp-up by IgG subclasses 1 to 4 at end of IV treatment and end of SC treatment with rHuPH20 IgG subclass 1 (IgG 1) IgG subclass 2 (IgG 2) IgG subclass 3 (IgG 3) IgG subclass 4 (IgG 4)

Time frame:
IgG subclasses (1-4) trough levels measured at baseline and on day of each 3- or 4-week infusion for infusion for IV and SC (except during ramp up for SC) and at end of study visit
Reported as:
Median · mg/dL
Trough Levels of IgG Subclasses After Administration of IGIV, 10% Given Via IV or SC With rHuPH20
mg/dLParticipants Aged 2 to <12 YearsParticipants ≥ 12 Years
IgG 1 end of IV treatment (N=11,69)490.0 (414.0 to 752.0)574.0 (514.0 to 638.0)
IgG 1 end of SC/rHuPH20 treatment (N=11,70)455.0 (411.0 to 805.0)548.0 (513.0 to 602.0)
IgG 2 end of IV treatment (N=11,69)327.0 (250.0 to 538.0)360.0 (334.0 to 390.0)
IgG 2 end of SC/rHuPH20 treatment (N=11,70)315.0 (280.0 to 550.0)339.0 (318.0 to 374.0)
IgG 3 end of IV treatment (N=11,69)35.0 (27.0 to 66.0)32.0 (27.0 to 37.0)
IgG 3 end of SC/rHuPH20 treatment (N=11,70)49.0 (26.0 to 83.0)36.0 (32.0 to 43.0)
IgG 4 end of IV treatment (N=11,69)24.0 (16.0 to 55.0)14.0 (13.0 to 20.0)
IgG 4 end of SC/rHuPH20 treatment (N=11,70)23.0 (15.0 to 57.0)15.0 (13.0 to 19.0)
SecondaryAntibody Levels to Tetanus (Clostridium Tetani Toxoid)

Antibody levels to Tetanus (Clostridium tetani toxoid) after administration of immune globulin intravenous (IGIV), 10% given via intravenous (IV) or subcutaneous (SC) route with recombinant human hyaluronidase (rHuPH20) at end of IV treatment and end of SC treatment with rHuPH20

Time frame:
IV: At baseline; SC/rHuPH20: at baseline then at infusion #1 at ramp-up and at infusions #5, 9, 13 (for 3-week treatment interval) and infusions #4, 7, 10 (for 4-week treatment interval), SC: end of SC treatment and at end of study visit
Reported as:
Median · IU/mL
Antibody Levels to Tetanus (Clostridium Tetani Toxoid)
IU/mLParticipants Aged 2 to <12 YearsParticipants ≥ 12 Years
End of IV treatment (N=7,25)2.230 (0.0640 to 4.230)2.320 (1.810 to 2.710)
End of SC/rHuPH20 treatment (N=10,70)2.580 (0.990 to 3.810)2.525 (2.270 to 2.850)
SecondaryAntibody Levels to Haemophilus Influenzae

Antibody levels to Haemophilus influenzae after administration of immune globulin intravenous (IGIV), 10% given via intravenous (IV) or subcutaneous (SC) route with recombinant human hyaluronidase (rHuPH20) at end of IV treatment and end of SC treatment with rHuPH20

Time frame:
IV: At baseline; SC/rHuPH20: at baseline then at infusion #1 at ramp-up and at infusions #5, 9, 13 (for 3-week treatment interval) and infusions #4, 7, 10 (for 4-week treatment interval), SC: end of SC treatment and at end of study visit
Reported as:
Median · μg/mL
Antibody Levels to Haemophilus Influenzae
μg/mLParticipants Aged 2 to <12 YearsParticipants ≥ 12 Years
Influenza antibody end of IV treatment (N=7,24)2.11 (1.59 to 13.52)2.36 (2.05 to 3.05)
Influenza antibody end of SC treatment (N=10,70)1.97 (1.69 to 4.94)2.58 (2.30 to 2.95)
SecondaryAntibody Levels to Measles

Antibody levels to measles after administration of immune globulin intravenous (IGIV), 10% given via intravenous (IV) or subcutaneous (SC) route with recombinant human hyaluronidase (rHuPH20) at end of IV treatment and end of SC treatment with rHuPH20

Time frame:
IV: At baseline; SC/rHuPH20: at baseline then at infusion #1 at ramp-up and at infusions #5, 9, 13 (for 3-week treatment interval) and infusions #4, 7, 10 (for 4-week treatment interval), SC: end of SC treatment and at end of study visit
Reported as:
Median · Titer
Antibody Levels to Measles
TiterParticipants Aged 2 to <12 YearsParticipants ≥ 12 Years
Measles antibody end of IV treatment (N=0,1)NA (NA to NA)64.0 (NA to NA)
Measles antibody end of SC treatment (N=10,70)768.0 (256.0 to 2048.0)1024.0 (512.0 to 1024.0)
SecondaryAntibody Levels to Hepatitis B

Antibody levels to hepatitis B after administration of immune globulin intravenous (IGIV), 10% given via intravenous (IV) or subcutaneous (SC) with recombinant human hyaluronidase (rHuPH20) at end of IV treatment and end of SC treatment with rHuPH20

Time frame:
IV: At baseline; SC/rHuPH20: at baseline then at infusion #1 at ramp-up and at infusions #5, 9, 13 (for 3-week treatment interval) and infusions #4, 7, 10 (for 4-week treatment interval), SC: end of SC treatment and at end of study visit
Reported as:
Median · mIU/mL
Antibody Levels to Hepatitis B
mIU/mLParticipants Aged 2 to <12 YearsParticipants ≥ 12 Years
Hepatitis B antibody end IV treatment (N=6,25)212.9 (59.5 to 291.5)222.8 (190.3 to 289.4)
Hepatitis B antibody end of SC treatment (N=10,70)242.2 (125.5 to 871.9)249.2 (225.0 to 289.3)
SecondaryIgG Minimum Plasma Concentration (C_min) for Participants Aged 12 Years and Older

Minimal immunoglobulin (IgG) concentration after administration of immune globulin intravenous (IGIV), 10% given via intravenous (IV) or subcutaneous (SC) route with recombinant human hyaluronidase (rHuPH20) for participants aged 12 years and Older

Time frame:
PK evaluations: (IV: before infusion #4 [for 3-week treatment interval] or infusion #3 [for 4-week treatment interval]; SC: before last SC infusion) 60 minutes pre-infusion up to 28 days (+/-2 days) post-infusion
Reported as:
Median · g/L
IgG Minimum Plasma Concentration (C_min) for Participants Aged 12 Years and Older
g/LIV Administration of IGIV, 10%SC Administration of IGIV, 10% With rHuPH20
IgG Minimum Plasma Concentration (C_min) for Participants Aged 12 Years and Older10.1 (9.5 to 10.9)10.4 (9.4 to 11.2)
SecondaryIgG Area Under the Curve (AUC)/Week for Participants Aged 12 Years and Older

Immunoglobulin (IgG) Area under the Curve (AUC) AUC/week after administration of immune globulin intravenous (IGIV), 10% given via intravenous (IV) or subcutaneous (SC) route with recombinant human hyaluronidase (rHuPH20) for participants aged 12 years and older. The AUC between adjacent infusions was calculated by the trapezoidal rule. Linear interpolation/extrapolation was used to calculate the AUC for the exact duration of the infusion intervals (21 days for 3-week treatment interval or 28 days for 4-week treatment interval).

Time frame:
PK evaluations: (IV: before infusion #4 [for 3-week treatment interval] or infusion #3 [for 4-week treatment interval];SC: before last SC infusion) 60 minutes pre-infusion up to 28 days (+/-2 days) post-infusion.
Reported as:
Median · g*days/L
IgG Area Under the Curve (AUC)/Week for Participants Aged 12 Years and Older
g*days/LIV Administration of IGIV, 10%SC Administration of IGIV, 10% With rHuPH20
IgG Area Under the Curve (AUC)/Week for Participants Aged 12 Years and Older93.9 (89.1 to 102.1)90.5 (83.8 to 98.4)
SecondaryIgG Clearance (CL) for Participants Aged 12 Years and Older

Immunoglobulin (IgG) Clearance after administration of immune globulin intravenous (IGIV), 10% given via intravenous (IV) or subcutaneous (SC) with recombinant human hyaluronidase (rHuPH20) for participants aged 12 years and older. Clearance (CL) is provided after administration of IGIV,10% given via IV route. Apparent Clearance is provided after administration of IGIV, 10% given via SC route with rHuPH20. Clearance and apparent clearance are determined by weight adjusted dose divided by total AUC.

Time frame:
PK evaluations: (IV: before infusion #4 [for 3-week treatment interval] or infusion #3 [for 4-week treatment interval];SC: before last SC infusion) 60 minutes pre-infusion up to 28 days (+/-2 days) post-infusion.
Reported as:
Median · mL/kg/day
IgG Clearance (CL) for Participants Aged 12 Years and Older
mL/kg/dayIV Administration of IGIV, 10%SC Administration of IGIV, 10% With rHuPH20
IgG Clearance (CL) for Participants Aged 12 Years and Older1.4 (1.2 to 1.4)1.6 (1.4 to 1.7)
SecondaryIgG Maximum Plasma Concentration (C_max) for Participants Aged 12 Years and Older

Maximum immunoglobulin (IgG) concentration after administration of immune globulin intravenous (IGIV), 10% given via intravenous (IV) or subcutaneous (SC) route with recombinant human hyaluronidase (rHuPH20) for participants aged 12 years and older

Time frame:
PK evaluations: (IV: before infusion #4 [for 3-week treatment interval] or infusion #3 [for 4-week treatment interval]; SC: before last SC infusion) 60 minutes pre-infusion up to 28 days (+/-2 days) post-infusion.
Reported as:
Median · g/L
IgG Maximum Plasma Concentration (C_max) for Participants Aged 12 Years and Older
g/LIV Administration of IGIV, 10%SC Administration of IGIV, 10% With rHuPH20
IgG Maximum Plasma Concentration (C_max) for Participants Aged 12 Years and Older21.9 (20.7 to 23.9)15.5 (14.5 to 17.1)
SecondaryIgG Terminal Half Life (T1/2) for Participants Aged 12 Years and Older

Terminal half life (T1/2) for immunoglobulin (IgG) after administration of immune globulin intravenous (IGIV), 10% given via intravenous (IV) or subcutaneous (SC) route with recombinant human hyaluronidase (rHuPH20) for participants aged 12 years and older. Terminal half life is the time it takes for the plasma concentration or the amount of immunoglobulin in the body to be reduced by 50% during the terminal phase

Time frame:
PK evaluations: (IV: before infusion #4 [for 3-week treatment interval] or infusion #3 [for 4-week treatment interval]; SC: before last SC infusion) 60 minutes pre-infusion up to 28 days (+/-2 days) post-infusion.
Reported as:
Median · Days
IgG Terminal Half Life (T1/2) for Participants Aged 12 Years and Older
DaysIV Administration of IGIV, 10%SC Administration of IGIV, 10% With rHuPH20
IgG Terminal Half Life (T1/2) for Participants Aged 12 Years and Older35.7 (32.4 to 40.4)45.3 (41.0 to 60.2)
SecondaryTime to Maximum IgG Concentration (T-max) for Participants Aged 12 Years and Older

Time to Maximum Immunoglobulin (IgG) Concentration (T-max) after administration of immune globulin intravenous (IGIV), 10% given via intravenous (IV) or subcutaneous (SC) route with recombinant human hyaluronidase (rHuPH20) for participants aged 12 years and older

Time frame:
PK evaluations: (IV: before infusion #4 [for 3-week treatment interval] or infusion #3 [for 4-week treatment interval]; SC: before last SC infusion) 60 minutes pre-infusion up to 28 days (+/-2 days) post-infusion.
Reported as:
Median · Days
Time to Maximum IgG Concentration (T-max) for Participants Aged 12 Years and Older
DaysIV Administration of IGIV, 10%SC Administration of IGIV, 10% With rHuPH20
Time to Maximum IgG Concentration (T-max) for Participants Aged 12 Years and Older0.1 (0.1 to 0.1)5.0 (3.3 to 5.1)
SecondaryTetanus Antibody Minimum Plasma Concentration (C_min) for Participants Aged 12 Years and Older

Minimal tetanus (clostridium tetani toxoid) antibody concentration after administration of immune globulin intravenous (IGIV), 10% given via intravenous (IV) or subcutaneous (SC) route with recombinant human hyaluronidase (rHuPH20) for participants aged 12 years and older

Time frame:
PK evaluations: (IV: before infusion #4 [for 3-week treatment interval] or infusion #3 [for 4-week treatment interval]; SC: before last SC infusion) 60 minutes pre-infusion up to 28 days (+/-2 days) post-infusion.
Reported as:
Median · IU/mL
Tetanus Antibody Minimum Plasma Concentration (C_min) for Participants Aged 12 Years and Older
IU/mLIV Administration of IGIV, 10%SC Administration of IGIV, 10% With rHuPH20
Tetanus Antibody Minimum Plasma Concentration (C_min) for Participants Aged 12 Years and Older2.3 (2.2 to 2.7)2.1 (1.9 to 2.4)
SecondaryTetanus Antibody Area Under the Curve (AUC)/Week for Participants Aged 12 Years and Older

Tetanus (clostridium tetani toxoid) antibody Area under the Curve (AUC) AUC/week after administration of immune globulin intravenous (IGIV), 10% given via intravenous (IV) or subcutaneous (SC) route with recombinant human hyaluronidase (rHuPH20) for participants aged 12 years and older. The AUC between adjacent infusions was calculated by the trapezoidal rule. Linear interpolation/extrapolation was used to calculate the AUC for the exact duration of the infusion intervals (21 days for 3-week treatment interval or 28 days for 4-week treatment interval).

Time frame:
PK evaluations: (IV: before infusion #4 [for 3-week treatment interval] or infusion #3 [for 4-week treatment interval];SC: before last SC infusion) 60 minutes pre-infusion up to 28 days (+/-2 days) post-infusion.
Reported as:
Median · IU*days/mL
Tetanus Antibody Area Under the Curve (AUC)/Week for Participants Aged 12 Years and Older
IU*days/mLIV Administration of IGIV, 10%SC Administration of IGIV, 10% With rHuPH20
Tetanus Antibody Area Under the Curve (AUC)/Week for Participants Aged 12 Years and Older28.0 (27.0 to 32.2)22.6 (19.9 to 25.6)
SecondaryTetanus Antibody Clearance (CL) for Participants Aged 12 Years and Older

Tetanus (clostridium tetani toxoid) antibody Clearance after administration of immune globulin intravenous (IGIV), 10% given via intravenous (IV) or subcutaneous (SC) route with recombinant human hyaluronidase (rHuPH20) for participants aged 12 years and older. Clearance (CL) is provided after administration of IGIV,10% given via IV route. Apparent Clearance is provided after administration of IGIV, 10% given via SC route with rHuPH20. Clearance (CL) and apparent clearance are determined by weight adjusted dose divided by total AUC.

Time frame:
PK evaluations: (IV: before infusion #4 [for 3-week treatment interval] or infusion #3 [for 4-week treatment interval];SC: before last SC infusion) 60 minutes pre-infusion up to 28 days (+/-2 days) post-infusion.
Reported as:
Median · nL/IU/day
Tetanus Antibody Clearance (CL) for Participants Aged 12 Years and Older
nL/IU/dayIV Administration of IGIV, 10%SC Administration of IGIV, 10% With rHuPH20
Tetanus Antibody Clearance (CL) for Participants Aged 12 Years and Older4.5 (3.9 to 5.1)5.8 (5.4 to 7.0)
SecondaryTetanus Antibody Terminal Half Life (T1/2) for Participants Aged 12 Years and Older

Terminal half life (T1/2) for tetanus (clostridium tetani toxoid) antibody after administration of immune globulin intravenous (IGIV), 10% given via intravenous (IV) or subcutaneous (SC) with recombinant human hyaluronidase (rHuPH20) for participants aged 12 years and older. Terminal half life is the time it takes for the plasma concentration or the amount of tetanus antibody in the body to be reduced by 50% during the terminal phase

Time frame:
PK evaluations: (IV: before infusion #4 [for 3-week treatment interval] or infusion #3 [for 4-week treatment interval]; SC: before last SC infusion) 60 minutes pre-infusion up to 28 days (+/-2 days) post-infusion.
Reported as:
Median · Days
Tetanus Antibody Terminal Half Life (T1/2) for Participants Aged 12 Years and Older
DaysIV Administration of IGIV, 10%SC Administration of IGIV, 10% With rHuPH20
Tetanus Antibody Terminal Half Life (T1/2) for Participants Aged 12 Years and Older22.7 (20.0 to 28.1)30.4 (25.7 to 37.2)
SecondaryTetanus Antibody Maximum Plasma Concentration (C_max) for Participants Aged 12 Years and Older

Maximum tetanus (clostridium tetani toxoid) antibody concentration after administration of immune globulin intravenous (IGIV), 10% given via intravenous (IV) or subcutaneous (SC) with recombinant human hyaluronidase (rHuPH20) for participants aged 12 years and older

Time frame:
PK evaluations: (IV: before infusion #4 [for 3-week treatment interval] or infusion #3 [for 4-week treatment interval]; SC: before last SC infusion) 60 minutes pre-infusion up to 28 days (+/-2 days) post-infusion.
Reported as:
Median · IU/mL
Tetanus Antibody Maximum Plasma Concentration (C_max) for Participants Aged 12 Years and Older
IU/mLIV Administration of IGIV, 10%SC Administration of IGIV, 10% With rHuPH20
Tetanus Antibody Maximum Plasma Concentration (C_max) for Participants Aged 12 Years and Older7.3 (6.8 to 8.1)5.0 (4.4 to 5.6)
SecondaryTime to Maximum Tetanus Antibody Concentration (T-max) for Participants Aged 12 Years and Older

Time to Maximum tetanus (clostridium tetani toxoid) antibody Concentration (T-max) after administration of immune globulin intravenous (IGIV), 10% given via intravenous (IV) or subcutaneous (SC) route with recombinant human hyaluronidase (rHuPH20) for participants aged 12 years and older

Time frame:
PK evaluations: (IV: before infusion #4 [for 3-week treatment interval] or infusion #3 [for 4-week treatment interval]; SC: before last SC infusion) 60 minutes pre-infusion up to 28 days (+/-2 days) post-infusion.
Reported as:
Median · Days
Time to Maximum Tetanus Antibody Concentration (T-max) for Participants Aged 12 Years and Older
DaysIV Administration of IGIV, 10%SC Administration of IGIV, 10% With rHuPH20
Time to Maximum Tetanus Antibody Concentration (T-max) for Participants Aged 12 Years and Older0.1 (0.1 to 0.2)5.1 (4.0 to 6.0)
SecondaryH. Influenzae Antibody Minimum Plasma Concentration (C_min) for Participants Aged 12 Years and Older

Minimal influenza (haemophilus influenzae) antibody concentration after administration of immune globulin intravenous (IGIV), 10% given via intravenous (IV) or subcutaneous (SC) with recombinant human hyaluronidase (rHuPH20) for participants aged 12 years and older

Time frame:
PK evaluations: (IV: before infusion #4 [for 3-week treatment interval] or infusion #3 [for 4-week treatment interval]; SC: before last SC infusion) 60 minutes pre-infusion up to 28 days (+/-2 days) post-infusion.
Reported as:
Median · μg/mL
H. Influenzae Antibody Minimum Plasma Concentration (C_min) for Participants Aged 12 Years and Older
μg/mLIV Administration of IGIV, 10%SC Administration of IGIV, 10% With rHuPH20
H. Influenzae Antibody Minimum Plasma Concentration (C_min) for Participants Aged 12 Years and Older2.1 (2.0 to 2.6)2.2 (1.8 to 2.6)
SecondaryH. Influenzae Antibody Area Under the Curve (AUC)/Week for Participants Aged 12 Years and Older

Influenza (haemophilus influenzae) antibody Area under the Curve (AUC) AUC/week after administration of immune globulin intravenous (IGIV), 10% given via intravenous (IV) or subcutaneous (SC) route with recombinant human hyaluronidase (rHuPH20) for participants aged 12 years and older. The AUC between adjacent infusions was calculated by the trapezoidal rule. Linear interpolation/extrapolation was used to calculate the AUC for the exact duration of the infusion intervals (21 days for 3-week treatment interval or 28 days for 4-week treatment interval).

Time frame:
PK evaluations: (IV: before infusion #4 [for 3-week treatment interval] or infusion #3 [for 4-week treatment interval];SC: before last SC infusion) 60 minutes pre-infusion up to 28 days (+/-2 days) post-infusion.
Reported as:
Median · μg*days/mL
H. Influenzae Antibody Area Under the Curve (AUC)/Week for Participants Aged 12 Years and Older
μg*days/mLIV Administration of IGIV, 10%SC Administration of IGIV, 10% With rHuPH20
H. Influenzae Antibody Area Under the Curve (AUC)/Week for Participants Aged 12 Years and Older22.4 (21.1 to 26.6)22.5 (20.8 to 24.3)
SecondaryH. Influenzae Antibody Clearance (CL) for Participants Aged 12 Years and Older

Influenza (haemophilus influenzae) antibody Clearance after administration of immune globulin intravenous (IGIV), 10% given via intravenous (IV) or subcutaneous (SC) with recombinant human hyaluronidase (rHuPH20) for participants aged 12 years and older. Clearance (CL) is provided after administration of IGIV,10% given via IV route. Apparent Clearance is provided after administration of IGIV, 10% given via SC route with rHuPH20. Clearance (CL) and apparent clearance are determined by weight adjusted dose divided by total AUC.

Time frame:
PK evaluations: (IV: before infusion #4 [for 3-week treatment interval] or infusion #3 [for 4-week treatment interval];SC: before last SC infusion) 60 minutes pre-infusion up to 28 days (+/-2 days) post-infusion.
Reported as:
Median · L/kg/day
H. Influenzae Antibody Clearance (CL) for Participants Aged 12 Years and Older
L/kg/dayIV Administration of IGIV, 10%SC Administration of IGIV, 10% With rHuPH20
H. Influenzae Antibody Clearance (CL) for Participants Aged 12 Years and Older5.8 (5.3 to 6.5)6.4 (5.8 to 7.1)
SecondaryH. Influenzae Antibody Maximum Plasma Concentration (C_max) for Participants Aged 12 Years and Older

Maximal influenza (haemophilus influenzae) antibody concentration after administration of immune globulin intravenous (IGIV), 10% given via intravenous (IV) or subcutaneous (SC) route with recombinant human hyaluronidase (rHuPH20) for participants aged 12 years and older

Time frame:
PK evaluations: (IV: before infusion #4 [for 3-week treatment interval] or infusion #3 [for 4-week treatment interval]; SC: before last SC infusion) 60 minutes pre-infusion up to 28 days (+/-2 days) post-infusion.
Reported as:
Median · μg/mL
H. Influenzae Antibody Maximum Plasma Concentration (C_max) for Participants Aged 12 Years and Older
μg/mLIV Administration of IGIV, 10%SC Administration of IGIV, 10% With rHuPH20
H. Influenzae Antibody Maximum Plasma Concentration (C_max) for Participants Aged 12 Years and Older5.5 (5.1 to 6.8)4.1 (3.8 to 4.5)
SecondaryH. Influenzae Antibody Terminal Half Life (T1/2) for Participants Aged 12 Years and Older

Terminal half life (T1/2) for influenza (haemophilus influenzae) antibody after administration of immune globulin intravenous (IGIV), 10% given via intravenous (IV) or subcutaneous (SC) route with recombinant human hyaluronidase (rHuPH20) for participants aged 12 years and older. Terminal half life is the time it takes for the plasma concentration or the amount of influenza antibody in the body to be reduced by 50% during the terminal phase.

Time frame:
PK evaluations: (IV: before infusion #4 [for 3-week treatment interval] or infusion #3 [for 4-week treatment interval]; SC: before last SC infusion) 60 minutes pre-infusion up to 28 days (+/-2 days) post-infusion.
Reported as:
Median · Days
H. Influenzae Antibody Terminal Half Life (T1/2) for Participants Aged 12 Years and Older
DaysIV Administration of IGIV, 10%SC Administration of IGIV, 10% With rHuPH20
H. Influenzae Antibody Terminal Half Life (T1/2) for Participants Aged 12 Years and Older33.8 (25.6 to 45.3)35.0 (32.3 to 41.0)
SecondaryTime to Maximum H. Influenzae Antibody Concentration (T-max) for Participants Aged 12 Years and Older

Time to Maximum influenza (haemophilus influenzae) antibody Concentration (T-max) after administration of immune globulin intravenous (IGIV), 10% given via intravenous (IV) or subcutaneous (SC) route with recombinant human hyaluronidase (rHuPH20) for participants aged 12 years and older

Time frame:
PK evaluations: (IV: before infusion #4 [for 3-week treatment interval] or infusion #3 [for 4-week treatment interval]; SC: before last SC infusion) 60 minutes pre-infusion up to 28 days (+/-2 days) post-infusion.
Reported as:
Median · Days
Time to Maximum H. Influenzae Antibody Concentration (T-max) for Participants Aged 12 Years and Older
DaysIV Administration of IGIV, 10%SC Administration of IGIV, 10% With rHuPH20
Time to Maximum H. Influenzae Antibody Concentration (T-max) for Participants Aged 12 Years and Older0.1 (0.1 to 0.2)4.8 (3.3 to 5.0)
SecondaryRate of Days Off School or Work

Monthly rate of days off school or work after administration of immune globulin intravenous (IGIV), 10% given via intravenous (IV) or subcutaneous (SC) route with recombinant human hyaluronidase (rHuPH20) after ramp-up. Point estimates and 95% CIs for the monthly rates were calculated using a Poisson model and the same methodology including allowance for over-dispersion as described for the primary outcome measures. The lengths of the month were defined as average length of the month in the Gregorian calendar, namely (365\*400+100-3)/(400\*12)= 30.436875 days.

Time frame:
Monthly, for up to 17 months
Reported as:
Number · Days off per month
Rate of Days Off School or Work
Days off per monthIV Administration of IGIV, 10%SC Administration of IGIV, 10% With rHuPH20 After Ramp-up
Rate of Days Off School or Work0.23 (0.15 to 0.34)0.28 (0.20 to 0.37)
SecondaryRate of Days on Antibiotics

Monthly rate of days on antibiotics after administration of immune globulin intravenous (IGIV), 10% given via intravenous (IV) or subcutaneous (SC) route with recombinant human hyaluronidase (rHuPH20) after ramp-up. Point estimates and 95% CIs for the monthly rates were calculated using a Poisson model and the same methodology including allowance for over-dispersion as described for the primary outcome measures. The lengths of the month was defined as average length of the month in the Gregorian calendar, namely (365\*400+100-3)/(400\*12)= 30.436875 days.

Time frame:
Monthly, for up to 17 months
Reported as:
Number · Days on antibiotics per month
Rate of Days on Antibiotics
Days on antibiotics per monthIV Administration of IGIV, 10%SC Administration of IGIV, 10% With rHuPH20 After Ramp-up
Rate of Days on Antibiotics3.15 (2.19 to 4.35)1.69 (1.29 to 2.16)
SecondaryRate of Acute Physician Visits

Monthly rate of acute physician visits after administration of immune globulin intravenous (IGIV), 10% given via intravenous (IV) or subcutaneous (SC) route with recombinant human hyaluronidase (rHuPH20) after ramp-up. Point estimates and 95% CIs for the monthly rates will be calculated using a Poisson model and the same methodology including allowance for over-dispersion as described for the primary outcome measures. The lengths of the month will be defined as average length of the month in the Gregorian calendar, namely (365\*400+100-3)/(400\*12)= 30.436875 days.

Time frame:
Monthly, for up to 17 months
Reported as:
Number · Visits per month
Rate of Acute Physician Visits
Visits per monthIV Administration of IGIV, 10%SC Administration of IGIV, 10% With rHuPH20 After Ramp-up
Rate of Acute Physician Visits0.33 (0.23 to 0.45)0.40 (0.32 to 0.49)
SecondaryRate of Days in Hospital

Monthly rate of days in hospital after administration of immune globulin intravenous (IGIV), 10% given via intravenous (IV) or subcutaneous (SC) route with recombinant human hyaluronidase (rHuPH20) after ramp-up. Point estimates and 95% CIs for the monthly rates will be calculated using a Poisson model and the same methodology including allowance for over-dispersion as described for the primary outcome measures. The lengths of the month will be defined as average length of the month in the Gregorian calendar, namely (365\*400+100-3)/(400\*12)= 30.436875 days.

Time frame:
Monthly, for up to 17 months
Reported as:
Number · Days per month
Rate of Days in Hospital
Days per monthIV Administration of IGIV, 10%SC Administration of IGIV, 10% With rHuPH20 After Ramp-up
Rate of Days in Hospital0.06 (0.03 to 0.10)0.02 (0.01 to 0.03)
SecondaryPercentage of Participants for Which the Infusion Rate Was Reduced and/or the Infusion Interrupted or Stopped for Tolerability Concerns or for Adverse Events (AEs)

Percentage of participants for which the infusion rate was reduced and/or the infusion interrupted or stopped during administration of immune globulin intravenous (IGIV), 10% given via intravenous (IV) or subcutaneous (SC) route with recombinant human hyaluronidase (rHuPH20) after ramp-up for tolerability concerns or for adverse events (AEs). An infusion was deemed as tolerated if there are no serious Adverse Drug Reactions (ADR), no non-serious moderate or severe local ADRs that prevent completion of the infusion and no non-serious moderate or severe systemic ADRs during infusion or within 60 minutes of completion of the infusion.

Time frame:
Throughout the study period (17 months)
Reported as:
Number · Percentage of participants
Percentage of Participants for Which the Infusion Rate Was Reduced and/or the Infusion Interrupted or Stopped for Tolerability Concerns or for Adverse Events (AEs)
Percentage of participantsIV Administration of IGIV, 10%SC Administration of IGIV, 10% With rHuPH20 After Ramp-up
% participants with reduced infusion rate only6.99.9
% participants with interrupted infusion rate only4.64.9
% participants with infusion stopped only0.01.2
% participants with no changes to infusion rate88.584.0
SecondaryPercentage of Infusions for Which the Infusion Rate Was Reduced and/or the Infusion Interrupted or Stopped for Tolerability Concerns or for Adverse Events (AEs)

Percentage of infusions for which the infusion rate was reduced and/or the infusion interrupted or stopped during administration of immune globulin intravenous (IGIV), 10% given via intravenous (IV) or subcutaneous (SC) route with recombinant human hyaluronidase (rHuPH20) after ramp-up for tolerability concerns or for adverse events (AEs). IV administration of IGIV, 10%: 365 infusions; SC administration of IGIV, 10% with rHuPH20: 1129 infusions

Time frame:
Throughout the study period (17 months)
Reported as:
Number · Percentage of infusions
Percentage of Infusions for Which the Infusion Rate Was Reduced and/or the Infusion Interrupted or Stopped for Tolerability Concerns or for Adverse Events (AEs)
Percentage of infusionsIV Administration of IGIV, 10%SC Administration of IGIV, 10% With rHuPH20 After Ramp-up
% infusions with infusion rate reduced only2.71.7
% infusions with interrupted infusion rate only1.40.4
% infusions with infusion stopped only0.00.2
% infusions with no changes to infusion rate95.997.7
SecondaryRate of Temporally Associated AEs Per Infusion

Rate of all AEs (including and excluding infections) per infusion that began during administration of immune globulin intravenous (IGIV), 10% given via intravenous (IV) or subcutaneous (SC) route with recombinant human hyaluronidase (rHuPH20) after ramp-up (during infusion) or within 72 hours of completion of an infusion ("temporally associated")

Time frame:
During infusion or within 72 hours of completion of infusion
Reported as:
Median · Number of AEs per infusion
Rate of Temporally Associated AEs Per Infusion
Number of AEs per infusionIV Administration of IGIV, 10%SC Administration of IGIV, 10% With rHuPH20 After Ramp-up
Including infections0.25 (0.20 to 0.50)0.21 (0.13 to 0.31)
Excluding infections0.25 (0.20 to 0.40)0.17 (0.09 to 0.26)
SecondaryPercentage of Participants Reporting ≥1 Temporally Associated AEs

Percentage of participants reporting at least 1 AE (including and excluding infections) during administration of immune globulin intravenous (IGIV), 10% given via intravenous (IV) or subcutaneous (SC) route with recombinant human hyaluronidase (rHuPH20) after ramp-up (during infusion) or within 72 hours of completion of infusion ("temporally associated")

Time frame:
During infusion or within 72 hours of completion of infusion
Reported as:
Number · Percentage of participants
Percentage of Participants Reporting ≥1 Temporally Associated AEs
Percentage of participantsIV Administration of IGIV, 10%SC Administration of IGIV, 10% With rHuPH20 After Ramp-up
Including infections66.786.4
Excluding infections63.282.7
SecondaryPercentage of Infusions Resulting in ≥1 Temporally Associated AEs

Percentage of infusions resulting in at least 1 AE (including and excluding infections) during administration of immune globulin intravenous (IGIV), 10% given via intravenous (IV) or subcutaneous (SC) route with recombinant human hyaluronidase (rHuPH20) after ramp-up (during infusion) or within 72 hours of completion of infusion ("temporally associated")

Time frame:
During infusion or within 72 hours of completion of infusion
Reported as:
Number · Percentage of infusions
Percentage of Infusions Resulting in ≥1 Temporally Associated AEs
Percentage of infusionsIV Administration of IGIV, 10%SC Administration of IGIV, 10% With rHuPH20 After Ramp-up
Including infections30.124.5
Excluding infections28.822.8
SecondaryPercentage of Participants Reporting ≥1 Temporally Associated Moderate or Severe AEs

Percentage of participants reporting at least 1 Moderate or Severe AE (including and excluding infections) during administration of immune globulin intravenous (IGIV), 10% given via intravenous (IV) or subcutaneous (SC) route with recombinant human hyaluronidase (rHuPH20) after ramp-up (during infusion) or within 72 hours of completion of infusion ("temporally associated")

Time frame:
During infusion or within 72 hours of completion of infusion
Reported as:
Number · Percentage of participants
Percentage of Participants Reporting ≥1 Temporally Associated Moderate or Severe AEs
Percentage of participantsIV Administration of IGIV, 10%SC Administration of IGIV, 10% With rHuPH20 Including Ramp-up
Including infections36.854.3
Excluding infections34.546.9
SecondaryPercentage of Infusions Resulting in ≥1 Temporally Associated Moderate or Severe AEs Within 72 Hours of Completion of Infusion

Percentage of infusions resulting in at least 1 moderate or severe AE (including and excluding infections) during administration of immune globulin intravenous (IGIV), 10% given via intravenous (IV) or subcutaneous (SC) route with recombinant human hyaluronidase (rHuPH20) after ramp-up (during infusion) or within 72 hours of completion of infusion ("temporally associated")

Time frame:
During infusion or within 72 hours of completion of infusion
Reported as:
Median · Percentage of infusions
Percentage of Infusions Resulting in ≥1 Temporally Associated Moderate or Severe AEs Within 72 Hours of Completion of Infusion
Percentage of infusionsIV Administration of IGIV, 10%SC Administration of IGIV, 10% With rHuPH20 After Ramp-up
Including infections0.0 (0.0 to 0.0)5.9 (0.0 to 7.1)
Excluding infections0.0 (0.0 to 0.0)0.0 (0.0 to 6.3)
SecondaryPercentage of SC Doses of IGIV, 10% and rHuPH20 Tolerated at 1 Infusion Site

Percentage of subcutaneous (SC) doses of immune globulin intravenous (IGIV), 10% and recombinant human hyaluronidase (rHuPH20) tolerated at 1 infusion site. An infusion was deemed as tolerated if there were no serious adverse drug reactions (ADRs), no non-serious moderate or severe local ADRs that prevented completion of the infusion, and no non-serious moderate or severe systemic ADRs during or within 60 minutes of completion of the infusion.

Time frame:
During infusion or within 60 minutes of completion of the infusion
Reported as:
Median · Percentage of infusions
Percentage of SC Doses of IGIV, 10% and rHuPH20 Tolerated at 1 Infusion Site
Percentage of infusionsSC Administration of IGIV, 10% With rHuPH20 at Ramp-upSC Administration of IGIV, 10% With rHuPH20 After Ramp-up
Percentage of SC Doses of IGIV, 10% and rHuPH20 Tolerated at 1 Infusion Site100.0 (100.0 to 100.0)100.0 (100.0 to 100.0)
SecondaryPercentage of Infusions Associated With ≥1 Systemic AE During Infusion or Within 72 Hours of Completion of Infusion

Percentage of intravenous (IV) and subcutaneous (SC) infusions associated with ≥1 systemic AE (including and excluding infections) during administration of immune globulin intravenous (IGIV), 10% given via IV or SC route with recombinant human hyaluronidase (rHuPH20) after ramp-up (during infusion) or within 72 hours of completion of infusion

Time frame:
During infusion or within 72 hours of completion of infusion
Reported as:
Median · Percentage of infusions
Percentage of Infusions Associated With ≥1 Systemic AE During Infusion or Within 72 Hours of Completion of Infusion
Percentage of infusionsIV Administration of IGIV, 10%SC Administration of IGIV, 10% With rHuPH20 After Ramp-up
Including infections25.0 (20.0 to 25.0)8.3 (7.7 to 12.5)
Excluding infections25.0 (16.7 to 25.0)8.3 (6.3 to 10.0)
SecondaryPercentage of Participants With ≥1 Systemic AE (Including and Excluding Infections) During Infusion or Within 72 Hours of Completion of Infusion

Percentage of participants with ≥1 systemic AE (including and excluding Infections) during administration of immune globulin intravenous (IGIV), 10% given via intravenous (IV) or subcutaneous (SC) route with recombinant human hyaluronidase (rHuPH20) after ramp-up (during infusion) or within 72 hours of completion of infusion

Time frame:
During infusion or within 72 hours of completion of infusion
Reported as:
Number · Percentage of participants
Percentage of Participants With ≥1 Systemic AE (Including and Excluding Infections) During Infusion or Within 72 Hours of Completion of Infusion
Percentage of participantsIV Administration of IGIV, 10%SC Administration of IGIV, 10% With rHuPH20 After Ramp-up
Including infections64.475.3
Excluding infections60.967.9
SecondaryPercentage of Infusions Associated With ≥1 Local AE (Including and Excluding Infections) During Infusion or Within 72 Hours of Completion of Infusion

Percentage of IV and SC (with recombinant human hyaluronidase \[rHuPH20\]) infusions associated with ≥1 local AE (including and excluding infections) during administration of immune globulin intravenous (IGIV), 10% given via intravenous (IV) or subcutaneous (SC) route with rHuPH20 after ramp-up (during infusion) or within 72 hours of completion of infusion

Time frame:
During infusion or within 72 hours of completion of infusion
Reported as:
Median · Percentage of infusions
Percentage of Infusions Associated With ≥1 Local AE (Including and Excluding Infections) During Infusion or Within 72 Hours of Completion of Infusion
Percentage of infusionsIV Administration of IGIV, 10%SC Administration of IGIV, 10% With rHuPH20 After Ramp-up
Including infections0.0 (0.0 to 0.0)5.9 (0.0 to 8.3)
Excluding infections0.0 (0.0 to 0.0)5.9 (0.0 to 8.3)
SecondaryPercentage of Infusions Associated With ≥1 Local AE At Any Time During the Study

Percentage of intravenous (IV) and subcutaneous (SC) infusions with recombinant human hyaluronidase (rHuPH20) after ramp-up of immune globulin intravenous (IGIV), 10% associated with ≥1 local AE (including and excluding infections) at any time during the study

Time frame:
At any time during the study
Reported as:
Median · Percentage of infusions
Percentage of Infusions Associated With ≥1 Local AE At Any Time During the Study
Percentage of infusionsIV Administration of IGIV, 10%SC Administration of IGIV, 10% With rHuPH20 After Ramp-up
Including infections0.0 (0.0 to 0.0)5.9 (0.0 to 8.3)
Excluding infections0.0 (0.0 to 0.0)5.9 (0.0 to 8.3)
SecondaryPercentage of Participants With ≥1 Local AE During Infusion or Within 72 Hours of Completion of Infusion

Percentage of participants With ≥1 local AE (including and excluding Infections) during administration of immune globulin intravenous (IGIV), 10% given via intravenous (IV) or subcutaneous (SC) route with recombinant human hyaluronidase (rHuPH20) after ramp-up (during infusion) or within 72 hours of completion of infusion

Time frame:
During infusion or within 72 hours of completion of infusion
Reported as:
Number · Percentage of participants
Percentage of Participants With ≥1 Local AE During Infusion or Within 72 Hours of Completion of Infusion
Percentage of participantsIV Administration of IGIV, 10%SC Administration of IGIV, 10% With rHuPH20 After Ramp-up
Including infections4.651.9
Excluding infections4.651.9
SecondaryPercentage of Participants With ≥1 Local AE At Any Time During the Study

Percentage of participants With ≥1 local AE (including and excluding infections) after administration of immune globulin intravenous (IGIV), 10% given via intravenous (IV) or subcutaneous (SC) route with recombinant human hyaluronidase (rHuPH20) after ramp-up at any time during the study

Time frame:
During infusion or within 72 hours of completion of infusion
Reported as:
Number · Percentage of participants
Percentage of Participants With ≥1 Local AE At Any Time During the Study
Percentage of participantsIV Administration of IGIV, 10%SC Administration of IGIV, 10% With rHuPH20 After Ramp-up
Including infections5.753.1
Excluding infections5.753.1
SecondaryRate of AEs Determined to be Related to the Study Drug by the Investigator Per Participant

Rate of related AEs defined as the total number of AEs determined by the investigator to be related to the study drug (immune globulin intravenous \[IGIV\], 10% or recombinant human hyaluronidase \[rHuPH20\]), that occur at any time during the study divided by the total number of participants

Time frame:
Throughout the study period (17 months)
Reported as:
Median · Number of AEs per participant
Rate of AEs Determined to be Related to the Study Drug by the Investigator Per Participant
Number of AEs per participantIV Administration of IGIV, 10%SC Administration of IGIV, 10% With rHuPH20 Including Ramp-up
Including infections0.00 (0.00 to 0.25)0.09 (0.07 to 0.25)
Excluding infections0.00 (0.00 to 0.25)0.09 (0.07 to 0.25)
SecondaryRate of AEs Determined to be Related to the Study Drug by the Investigator Per Infusion

Rate of related AEs defined as the total number of AEs determined by the investigator to be related to the study drug (immune globulin intravenous \[IGIV\], 10% or recombinant human hyaluronidase \[rHuPH20\]), that occur at any time during the study divided by the total number of infusions

Time frame:
Throughout the study period (17 months)
Reported as:
Median · Number of AEs per infusion
Rate of AEs Determined to be Related to the Study Drug by the Investigator Per Infusion
Number of AEs per infusionIV Administration of IGIV, 10%SC Administration of IGIV, 10% With rHuPH20 After Ramp-up
Including infections0.25 (0.25 to 0.50)0.22 (0.13 to 0.31)
Excluding infections0.25 (0.20 to 0.50)0.18 (0.12 to 0.26)
SecondaryFrequency of Dose Corrections (If IgG Trough Levels <4.5 g/L) for Each Study Epoch (IV and SC/rHuPH20 Treatment)

Frequency of dose corrections based on immune globulin G (IgG) trough levels \<4.5 g/L IgG, if any, for intravenous (IV) (Epoch 1) and subcutaneous with recombinant human hyaluronidase (SC/rHuPH20) after ramp-up (Epoch 2) administration of immune globulin intravenous (IGIV), 10% Defined/calculated as the number of participants requiring dose adjustments divided by the number of participants, for each respective data set.

Time frame:
Throughout the study period (17 months)
Reported as:
Number · Percentage of participants
Frequency of Dose Corrections (If IgG Trough Levels <4.5 g/L) for Each Study Epoch (IV and SC/rHuPH20 Treatment)
Percentage of participantsStudy Epoch 1Study Epoch 2
Frequency of Dose Corrections (If IgG Trough Levels <4.5 g/L) for Each Study Epoch (IV and SC/rHuPH20 Treatment)0.00.0
SecondaryNumber of All AEs Categorized by MedDRA Preferred Terms, Seriousness, Relatedness to Study Drug, and Severity (A-F)

Categories presented as Preferred term-Seriousness, Relatedness, Severity. The following codes are to be used: Seriousness: non-SAE-non-serious AE; SAE-serious AE Relationship: NR-not related to immune globulin (IGIV), 10% and recombinant human hyaluronidase (rHuPH20); RIGIV-related to IGIV, 10%; RrHu-related to rHuPH20; Rboth-related to both IGIV, 10% and rHuPH20 Severity: Mild; Mod (Moderate); Severe Preferred terms abbreviated: ADHD-Attention Deficit/Hyperactivity Disorder BP-Blood Pressure COPD- Chronic Obstructive Pulmonary Disease

Time frame:
Throughout the study period (17 months)
Reported as:
Number · Number of AEs
Number of All AEs Categorized by MedDRA Preferred Terms, Seriousness, Relatedness to Study Drug, and Severity (A-F)
Number of AEsIV Administration of IGIV, 10%SC Administration of IGIV, 10% With rHuPH20 After Ramp-up
Abdominal Discomfort-non-SAE, NR, Mod01
Abdominal Distension-non-SAE, Rboth, Mild01
Abdominal Hernia-non-SAE, NR, Mild01
Abdominal Pain-non-SAE, NR, Mild12
Abdominal Pain-non-SAE, NR, Mod01
Abdominal Pain-non-SAE, Rboth, Mild03
Abdominal Pain-non-SAE, Rboth, Mod01
Abdominal Pain Lower-non-SAE, NR, Mild01
Abdominal Pain Upper-non-SAE, NR, Mild15
Abdominal Pain Upper-non-SAE, NR, Mod10
Abdominal Pain Upper-non-SAE, RIGIV, Mild01
Abdominal Pain Upper-non-SAE, RIGIV, Mod10
Abdominal Pain Upper-non-SAE, Rboth, Mild02
Abdominal Tenderness-non-SAE, NR, Mod10
Abdominal Tenderness-non-SAE, RIGIV, Mild01
Abdominal Tenderness-non-SAE, RIGIV, Mod02
Acarodermatitis-non-SAE, NR, Mild01
Acne-non-SAE, NR, Mild11
Acute Sinusitis-non-SAE, NR, Mild10
Acute Sinusitis-non-SAE, NR, Mod04
Adenoidal Hypertrophy-non-SAE, NR, Mod01
Adnexa Uteri Cyst-non-SAE, NR, Mild10
Adrenocortical Insufficiency Acute-SAE, NR, Mod01
Allergic Respiratory Symptom-non-SAE, NR, Mild01
Allergic Sinusitis-non-SAE, NR, Mild10
Alopecia-non-SAE, NR, Mild10
Animal Bite-non-SAE, NR, Mod10
Antibody Test Positive-non-SAE, Rboth, Mod01
Anxiety-non-SAE, NR, Mild01
Anxiety-non-SAE, NR, Mod10
Aphthous Stomatitis-non-SAE, NR, Mild21
Aphthous Stomatitis-non-SAE, NR, Mod01
Arteriosclerosis Coronary Artery-non-SAE, NR, Mild01
Arthralgia-non-SAE, NR, Mild05
Arthralgia-non-SAE, NR, Mod16
Arthralgia-non-SAE, RIGIV, Mild01
Arthralgia-non-SAE, RIGIV, Mod02
Arthritis-non-SAE, NR, Mod11
Arthropathy-non-SAE, NR, Mod10
Arthropod Bite-non-SAE, NR, Mild22
Arthropod Sting-non-SAE, NR, Mild01
Arthropod Sting-non-SAE, NR, Mod10
Aspiration-non-SAE, NR, Mild01
Asthenia-non-SAE, NR, Mild03
Asthenia-non-SAE, NR, Mod10
Asthenia-non-SAE, RIGIV, Mild01
Asthma-non-SAE, NR, Mild04
Asthma-non-SAE, NR, Mod821
Asthma-non-SAE, NR, Severe01
ADHD-non-SAE, NR, Mod01
Back Injury-non-SAE, NR, Mod10
Back Injury-SAE, NR, Severe01
Back Pain-non-SAE, NR, Mild12
Back Pain-non-SAE, NR, Mod15
Bacterial Prostatitis-non-SAE, NR, Mild01
Blepharitis-non-SAE, NR, Mod10
Blister-non-SAE, NR, Mild01
Blood Pressure Decreased-non-SAE, NR, Mild01
Blood Pressure Decreased-non-SAE, Rboth, Mild01
Blood Pressure Increased-non-SAE, NR, Mod01
Blood Pressure Increased-non-SAE, RIGIV, Mild01
Blood Pressure Increased-non-SAE, RIGIV, Mod01
Blood Pressure Increased-non-SAE, RrHu, Mild01
BP Systolic Increased-non-SAE, RIGIV, Mild10
Blood Urea Increased-non-SAE, NR, Mild01
Body Fat Disorder-non-SAE, NR, Mild01
Body Tinea-non-SAE, NR, Mild10
Body Tinea-non-SAE, NR, Mod01
Bone Pain-non-SAE, NR, Mild01
Breast Pain-non-SAE, NR, Mild10
Bronchal Hyperreactivity-non-SAE, NR, Mild01
Bronchitis-non-SAE, NR, Mild42
Bronchitis-non-SAE, NR, Mod28
Bronchitis-SAE, NR, Mod10
Bronchospasm-non-SAE, NR, Mod01
Burn Infection-non-SAE, NR, Mild01
Burning Sensation-non-SAE, RIGIV, Mild01
Burning Sensation-non-SAE, RIGIV, Mod01
Burning Sensation-non-SAE, RrHu, Mild01
Bursitis-non-SAE, NR, Mild10
Bursitis-non-SAE, NR, Mod01
Candidiasis-non-SAE, NR, Mild10
Candidiasis-non-SAE, NR, Mod11
Cardiac Murmur-non-SAE, NR, Mild01
Cellulitis-non-SAE, NR, Mild01
Cellulitis-non-SAE, NR, Mod03
Cellulitis-non-SAE, Rboth, Mod01
Cerumen Impaction-non-SAE, NR, Mild02
Cervical Dysplasia-SAE, NR, Mild11
Cheilitis-non-SAE, NR, Mild20
Chest Pain-non-SAE, NR, Mild02
Chills-non-SAE, NR, Mild03
Chills-non-SAE, RIGIV, Mild61
Chills-non-SAE, RIGIV, Mod30
Chills-non-SAE, Rboth, Mild01
COPD-non-SAE, NR, Mod02
COPD-non-SAE, NR, Severe10
Chronic Sinusitis-non-SAE, NR, Mild04
Chronic Sinusitis-non-SAE, NR, Mod11
Concussion-non-SAE, NR, Mod10
Confusional State-non-SAE, NR, Mod01
Confusional State-non-SAE, RIGIV, Mild10
Conjunctivitis-non-SAE, NR, Mild12
Conjunctivitis Allergic-non-SAE, NR, Mild10
Conjunctivitis Allergic-non-SAE, NR, Mod10
Conjunctivitis Bacterial-non-SAE, NR, Mild11
Conjunctivitis Bacterial-non-SAE, NR, Mod01
Conjunctivitis Bacterial-non-SAE, NR, Severe01
Constipation-non-SAE, NR, Mild03
Contusion-non-SAE, NR, Mild15
Contusion-non-SAE, NR, Mod10
Contusion-non-SAE, RIGIV, Mod01
Coombs Test Positive-non-SAE, RIGIV, Mild01
Costochondritis-non-SAE, NR, Mod01
Cough-non-SAE, NR, Mild36
Cough-non-SAE, NR, Mod02
Cough-non-SAE, RIGIV, Mild10
Cushingoid-non-SAE, NR, Mild01
Cystitis-non-SAE, NR, Mild01
Deafness Neurosensory-non-SAE, NR, Mild10
Decreased Appetite-non-SAE, NR, Mild11
Decreased Appetite-non-SAE, RrHu, Mild01
Decreased Appetite-non-SAE, Rboth, Mild02
Dehydration-non-SAE, NR, Mod02
Dental Caries-non-SAE, NR, Mild02
Dental Caries-non-SAE, NR, Mod03
Depressed Mood-non-SAE, NR, Mild01
Depression-non-SAE, NR, Severe01
Dermal Cyst-non-SAE, NR, Mild01
Dermatitis-non-SAE, NR, Mild02
Dermatitis-non-SAE, NR, Mod10
Dermatitis Acneiform-non-SAE, NR, Mod10
Dermatitis Contact-non-SAE, NR, Mild02
Dermatitis Contact-non-SAE, NR, Mod22
Dermatitis Infected-non-SAE, NR, Mild02
Dermatitis Infected-non-SAE, NR, Mod01
Dermatitis Infected-non-SAE, NR, Severe01
Device Failure-non-SAE, NR, Mild21
Device Failure-non-SAE, NR, Mod02
Diarrhoea-non-SAE, NR, Mild36
Diarrhoea-non-SAE, NR, Mod24
Diarrhoea-non-SAE, RIGIV, Mild11
Diarrhoea-non-SAE, RIGIV, Mod10
Diarrhoea Haemorrhagic-non-SAE, NR, Mild10
Diarrhoea Infectious-non-SAE, NR, Mild01
Diastolic Dysfunction-non-SAE, NR, Mild01
Disaccharide Metabolism Disorder-non-SAE, NR, Mild01
Disturbance in Attention-non-SAE, NR, Mild02
Diverticulitis-non-SAE, NR, Mod10
Dizziness-non-SAE, NR, Mild27
Dizziness-non-SAE, NR, Mod02
Dizziness-non-SAE, RIGIV, Mild03
Dizziness-non-SAE, RIGIV, Mod10
Drug Eruption-non-SAE, NR, Mod10
Dry Eye-non-SAE, NR, Mod01
Dry Mouth-non-SAE, NR, Mild01
Dry Skin-non-SAE, NR, Mild03
Dysmenorrhoea-non-SAE, NR, Mild01
Dyspepsia-non-SAE, NR, Mild02
Dyspepsia-non-SAE, NR, Mod01
Dyspepsia-non-SAE, RIGIV, Mild10
Dysphagia-non-SAE, NR, Mild01
Dysphagia-non-SAE, NR, Mod01
Dyspnoea-non-SAE, NR, Mild10
Dyspnoea-non-SAE, NR, Mod10
Dyspnoea-non-SAE, RIGIV, Mild10
Dysuria-non-SAE, NR, Mild02
Ear Infection-non-SAE, NR, Mild22
Ear Infection-non-SAE, NR, Mod11
Ear Pain-non-SAE, NR, Mild32
Ear Pain-non-SAE, NR, Mod01
Ecchymosis-non-SAE, NR, Mild01
Eczema-non-SAE, NR, Mild01
Eczema-non-SAE, NR, Mod01
Eczema-non-SAE, NR, Severe10
Eosinophil Count-non-SAE, NR, Mild01
Epitaxis-non-SAE, NR, Mild23
Epitaxis-non-SAE, NR, Mod22
Erythema-non-SAE, NR, Mild10
Erythema-non-SAE, RIGIV, Mod01
Erythema-non-SAE, RrHu, Mild01
Erythema-non-SAE, Rboth, Mild01
Erythema-non-SAE, Rboth, Mod01
Eustachian Tube Dysfunction-non-SAE, NR, Mild10
Excoriation-non-SAE, NR, Mild22
Extravasation Blood-non-SAE, Rboth, Mild01
Eye Irritation-non-SAE, NR, Mild01
Eye Pruritus-non-SAE, NR, Mod01
Eye Swelling-non-SAE, NR, Mod01
Fall-non-SAE, NR, Mild01
Fall-non-SAE, NR, Mod01
Fatigue-non-SAE, NR, Mild15
Fatigue-non-SAE, NR, Mod12
Fatigue-non-SAE, RIGIV, Mild88
Fatigue-non-SAE, RIGIV, Mod03
Fatigue-non-SAE, Rboth, Mild03
Feeling Abnormal-non-SAE, Rboth, Mod01
Feeling Cold-non-SAE, RIGIV, Mild20
Flatulence-non-SAE, NR, Mild01
Flatulence-non-SAE, NR, Mod01
Food Poisoning-non-SAE, NR, Mod01
Free Haemoglobin Present-non-SAE, NR, Mild11
Free Haemoglobin Present-non-SAE, NR, Severe10
SecondaryNumber of All AEs Categorized by MedDRA Preferred Terms, Seriousness, Relatedness to Study Drug, and Severity (G-M)

Categories presented as Preferred term-Seriousness, Relatedness, Severity. The following codes are to be used: Seriousness: non-SAE-non-serious AE; SAE-serious AE Relationship: NR-not related to immune globulin (IGIV), 10% and recombinant human hyaluronidase (rHuPH20); RIGIV-related to IGIV, 10%; RrHu-related to rHuPH20; Rboth-related to both IGIV, 10% and rHuPH20 Severity: Mild; Mod (Moderate); Severe

Time frame:
Throughout the study period (17 months)
Reported as:
Number · Number of AEs
Number of All AEs Categorized by MedDRA Preferred Terms, Seriousness, Relatedness to Study Drug, and Severity (G-M)
Number of AEsIV Administration of IGIV, 10%SC Administration of IGIV, 10% With rHuPH20 After Ramp-up
Gait Disturbance-non-SAE, NR, Mild01
Gastroenteritis-non-SAE, NR, Mild03
Gastroenteritis-non-SAE, NR, Mod22
Gastroenteritis-non-SAE, RIGIV, Mild10
Gastroenteritis-SAE, NR, Mod01
Gastroenteritis Bacterial-non-SAE, NR, Mod01
Gastroenteritis Viral-non-SAE, NR, Mild36
Gastroenteritis Viral-non-SAE, NR, Mod05
Gastroenteritis Viral-non-SAE, RIGIV, Mild01
Gastrointestinal Haemorrhage-non-SAE, NR, Severe01
Gastrooesophageal Reflux Disease-non-SAE, NR, Mild12
Gastrooesophageal Reflux Disease-non-SAE, NR, Mod10
Genital Herpes-non-SAE, NR, Mild10
Genital Swelling-non-SAE, Rboth, Mod01
Goitre-non-SAE, NR, Mild10
Gout-non-SAE, NR, Mild01
Grand Mal Convulsion-non-SAE, NR, Severe10
Grand Mal Convulsion-SAE, NR, Severe01
Gravitational Oedema-non-SAE, Rboth, Mod01
Groin Pain-non-SAE, NR, Mild01
Groin Pain-non-SAE, RIGIV, Mild01
Groin Pain-non-SAE, RrHu, Mod01
Haematoma-non-SAE, NR, Mild11
Haematoma-non-SAE, NR, Mod01
Haematuria-non-SAE, NR, Mild01
Haemoglobin Abnormal-non-SAE, NR, Mild01
Haemorrhoids-non-SAE, NR, Mild02
Hand Fracture-non-SAE, NR, Mod01
Headache-non-SAE, NR, Mild1316
Headache-non-SAE, NR, Mod13
Headache-non-SAE, NR, Severe10
Headache-non-SAE, RIGIV, Mild2514
Headache-non-SAE, RIGIV, Mod125
Headache-non-SAE, RIGIV, Severe10
Headache-non-SAE, Rboth, Mild09
Headache-non-SAE, Rboth, Mod08
Headache-SAE, NR, Severe01
Hearing Impaired-non-SAE, NR, Mild01
Heart Rate Increased-non-SAE, RIGIV, Mild40
Heat Rash-non-SAE, NR, Mild01
Heat Stroke-non-SAE, NR, Mod01
Herpes Simplex Ophthalmic-non-SAE, NR, Mod01
Herpes Zoster-non-SAE, NR, Mod01
Hiatus Hernia-non-SAE, NR, Mod01
Hot Flush-non-SAE, RIGIV, Mild10
Hyperaesthesia-non-SAE, NR, Mild01
Hypercholesterolaemia-non-SAE, NR, Mod01
Hyperkeratosis-non-SAE, NR, Mild01
Hypertension-non-SAE, NR, Mod04
Hypertension-non-SAE, RIGIV, Mild02
Hypertension-non-SAE, RIGIV, Mod01
Hypertonia-non-SAE, NR, Mild01
Hypothyroidism-non-SAE, NR, Mild01
Idiopathic Urticaria-non-SAE, NR, Mod10
Increased Upper Airway Secretion-non-SAE, NR, Mild20
Infected Bites-non-SAE, NR, Mild02
Infected Bites-non-SAE, NR, Mod11
Infection-non-SAE, NR, Mod02
Influenza-non-SAE, NR, Mild12
Influenza-non-SAE, NR, Mod43
Influenza Like Illness-non-SAE, NR, Mild01
Infusion Related Reaction-non-SAE, RIGIV, Mild01
Infusion Related Reaction-non-SAE, RIGIV, Mod10
Infusion Related Reaction-non-SAE, Rboth, Mild01
Infusion Related Reaction-non-SAE, Rboth, Mod01
Infusion Site Discomfort-non-SAE, RIGIV, Mild06
Infusion Site Discomfort-non-SAE, RrHu, Mod01
Infusion Site Discomfort-non-SAE, Rboth, Mild015
Infusion Site Discomfort-non-SAE, Rboth, Mod08
Infusion Site Erythema-non-SAE, RIGIV, Mild01
Infusion Site Erythema-non-SAE, RrHu, Mild02
Infusion Site Erythema-non-SAE, Rboth, Mild020
Infusion Site Erythema-non-SAE, Rboth, Mod05
Infusion Site Extravasation-non-SAE, NR, Mild20
Infusion Site Haematoma-non-SAE, RIGIV, Mild01
Infusion Site Haemorrhage-non-SAE, Rboth, Mild01
Infusion Site Hypersensitivity-non-SAE, NR, Severe01
Infusion Site Hypersensitivity-non-SAE, Rboth, Mod01
Infusion Site Mass-non-SAE, RIGIV, Mild01
Infusion Site Mass-non-SAE, Rboth, Mild02
Infusion Site Oedema-non-SAE, Rboth, Mild04
Infusion Site Oedema-non-SAE, Rboth, Mod05
Infusion Site Pain-non-SAE, NR, Mild02
Infusion Site Pain-non-SAE, RIGIV, Mild112
Infusion Site Pain-non-SAE, RIGIV, Mod06
Infusion Site Pain-non-SAE, RrHu, Mild035
Infusion Site Pain-non-SAE, RrHu, Mod01
Infusion Site Pain-non-SAE, Rboth, Mild019
Infusion Site Pain-non-SAE, Rboth, Mod016
Infusion Site Pain-non-SAE, Rboth, Severe01
Infusion Site Pruritus-non-SAE, RIGIV, Mild02
Infusion Site Pruritus-non-SAE, RrHu, Mild05
Infusion Site Pruritus-non-SAE, Rboth, Mild06
Infusion Site Pruritus-non-SAE, Rboth, Mod04
Infusion Site Reaction-non-SAE, Rboth, Mild01
Infusion Site Reaction-non-SAE, Rboth, Mod02
Infusion Site Swelling-non-SAE, RIGIV, Mild02
Infusion Site Swelling-non-SAE, Rboth, Mild03
Infusion Site Swelling-non-SAE, Rboth, Mod04
Infusion Site Swelling-non-SAE, Rboth, Severe01
Infusion Site Warmth-non-SAE, Rboth, Mild02
Ingrowing Nail-non-SAE, NR, Mod01
Injection Site Erythema-non-SAE, RIGIV, Mild01
Injury-non-SAE, NR, Mild10
Insomnia-non-SAE, NR, Mild10
Intervertebral Disc Protrusion-non-SAE, NR, Mod10
Irritable Bowel Syndrome-non-SAE, NR, Mild01
Irritable Bowel Syndrome-non-SAE, NR, Mod02
Joint Effusion-non-SAE, NR, Mild01
Joint Effusion-non-SAE, NR, Mod01
Joint Injury-non-SAE, NR, Mod11
Joint Range of Motion Decreased-non-SAE, NR, Mod02
Joint Sprain-non-SAE, NR, Mild01
Joint Sprain-non-SAE, NR, Mod02
Joint Swelling-non-SAE, NR, Mild01
Jugular Vein Distension-non-SAE, NR, Mild01
Lethargy-non-SAE, NR, Mild01
Lethargy-non-SAE, RIGIV, Mod10
Ligament Injury-non-SAE, NR, Mod01
Ligament Sprain-non-SAE, NR, Mod01
Limb Injury-non-SAE, NR, Mild10
Lip Injury-non-SAE, NR, Mild01
Lip Ulceration-non-SAE, NR, Mild01
Local Swelling-non-SAE, RIGIV, Mild03
Local Swelling-non-SAE, Rboth, Mild03
Localised Infection-non-SAE, NR, Mild01
Localised Oedema-non-SAE, RIGIV, Mild01
Localised Oedema-non-SAE, Rboth, Mod01
Lung Infection-non-SAE, NR, Mod10
Lung Infection-non-SAE, NR, Severe10
Lymph Gland Infection-non-SAE, NR, Mod10
Lymph Node Pain-non-SAE, NR, Mild10
Lymph Node Pain-non-SAE, NR, Mod01
Lymph Node Palpable-non-SAE, NR, Mild10
Lymphadenitis-non-SAE, NR, Mod10
Lymphadenopathy-non-SAE, NR, Mild28
Lymphangitis-non-SAE, NR, Mod01
Lymphocyte Count Decreased-non-SAE, RIGIV, Mild01
Lymphoedema-non-SAE, NR, Severe10
Malaise-non-SAE, NR, Mild02
Malaise-non-SAE, NR, Mod01
Malaise-non-SAE, RIGIV, Mod10
Malaise-non-SAE, RrHu, Mild01
Malaise-non-SAE, RrHu, Mod01
Memory Impairment-non-SAE, NR, Mod01
Migraine-non-SAE, NR, Mild11
Migraine-non-SAE, NR, Mod02
Migraine-non-SAE, NR, Severe10
Migraine-non-SAE, RIGIV, Mild11
Migraine-non-SAE, RIGIV, Mod14
Migraine-non-SAE, RIGIV, Severe01
Migraine-non-SAE, Rboth, Mod01
Molluscum Contagiosum-non-SAE, NR, Mild20
Mouth Ulceration-non-SAE, NR, Mild10
Multiple Sclerosis Relapse-non-SAE, NR, Mod01
Muscle Fatigue-non-SAE, NR, Mild01
Muscle Injury-non-SAE, NR, Mild02
Muscle Spasms-non-SAE, NR, Mild01
Muscle Spasms-non-SAE, RIGIV, Mild10
Muscle Strain-non-SAE, NR, Mild11
Muscle Strain-non-SAE, NR, Mod01
Muscular Weakness-non-SAE, NR, Mild10
Musculoskeletal Chest Pain-non-SAE, NR, Mild01
Musculoskeletal Chest Pain-non-SAE, RIGIV, Mild01
Musculoskeletal Pain-non-SAE, NR, Mild20
Musculoskeletal Pain-non-SAE, NR, Mod11
Musculoskeletal Stiffness-non-SAE, NR, Mild11
Myalgia-non-SAE, NR, Mild35
Myalgia-non-SAE, NR, Mod14
Myalgia-non-SAE, NR, Severe01
Myalgia-non-SAE, RIGIV, Mild06
Myalgia-non-SAE, RIGIV, Mod11
Myalgia-non-SAE, Rboth, Mild03
SecondaryNumber of All AEs Categorized by MedDRA Preferred Terms, Seriousness, Relatedness to Study Drug, and Severity (N-Z)

Categories presented as Preferred term-Seriousness, Relatedness, Severity. The following codes are to be used: Seriousness: non-SAE-non-serious AE; SAE-serious AE Relationship: NR-not related to immune globulin (IGIV), 10% and recombinant human hyaluronidase (rHuPH20); RIGIV-related to IGIV, 10%; RrHu-related to rHuPH20; Rboth-related to both IGIV, 10% and rHuPH20 Severity: Mild; Mod (Moderate); Severe Preferred terms abbreviated: Resp.-Respiratory WBC - White blood cells

Time frame:
Throughout the study period (17 months)
Reported as:
Number · Number of AEs
Number of All AEs Categorized by MedDRA Preferred Terms, Seriousness, Relatedness to Study Drug, and Severity (N-Z)
Number of AEsIV Administration of IGIV, 10%SC Administration of IGIV, 10% With rHuPH20 After Ramp-up
Nasal Congestion-non-SAE, NR, Mild43
Nasal Congestion-non-SAE, NR, Mod02
Nasal Congestion-non-SAE, RIGIV, Mild03
Nasal Discomfort-non-SAE, NR, Mild01
Nasal Mucosal Discolouration-non-SAE, NR, Mild01
Nasal Turbinate Hypertrophy-non-SAE, NR, Mild01
Nasopharyngitis-non-SAE, NR, Mild48
Nausea-non-SAE, NR, Mild317
Nausea-non-SAE, NR, Mod23
Nausea-non-SAE, RIGIV, Mild71
Nausea-non-SAE, RIGIV, Mod10
Nausea-non-SAE, Rboth, Mild04
Neck Pain-non-SAE, NR, Mild11
Night Sweats-non-SAE, NR, Mild10
Night Sweats-non-SAE, NR, Mod01
Nodule-non-SAE, Rboth, Mild02
Oedema-non-SAE, RIGIV, Mild01
Oedema Genital-non-SAE, Rboth, Severe01
Oedema Peripheral-non-SAE, NR, Mild01
Oedema Peripheral-non-SAE, NR, Mod01
Oedema Peripheral-non-SAE, Rboth, Mod02
Oesophagitis-non-SAE, NR, Mild01
Onychomycosis-non-SAE, NR, Mild01
Oral Candidiasis-non-SAE, NR, Mod01
Oral Fungal Infection-non-SAE, NR, Mild01
Oral Herpes-non-SAE, NR, Mild12
Oral Herpes-non-SAE, NR, Mod01
Oral Pain-non-SAE, NR, Mild01
Oral Pain-non-SAE, RrHu, Severe01
Oropharyngeal Pain-non-SAE, NR, Mild14
Oropharyngeal Pain-non-SAE, NR, Mod21
Osteoarthritis-non-SAE, NR, Mod01
Osteopenia-non-SAE, NR, Mild01
Osteopenia-non-SAE, NR, Mod01
Osteoporosis-non-SAE, NR, Mild01
Otitis Externa-non-SAE, NR, Mild01
Otitis Externa-non-SAE, NR, Mod01
Otitis Media-non-SAE, NR, Mod11
Pain-non-SAE, NR, Mild15
Pain-non-SAE, NR, Mod11
Pain-non-SAE, RIGIV, Mild01
Pain-non-SAE, RIGIV, Mod21
Pain-non-SAE, Rboth, Mild01
Pain-non-SAE, Rboth, Mod01
Pain in Extremity-non-SAE, NR, Mild21
Pain in Extremity-non-SAE, NR, Mod12
Pain in Extremity-non-SAE, RIGIV, Mod20
Pain in Extremity-non-SAE, RIGIV, Severe10
Pain in Extremity-non-SAE, Rboth, Mild03
Pain in Extremity-non-SAE, Rboth, Mod02
Palpitations-non-SAE, NR, Mild11
Papule-non-SAE, NR, Mild01
Peptic Ulcer Haemorrhage-SAE, NR, Severe10
Periorbital Haematoma-non-SAE, NR, Mild01
Peripheral Nerve Injury-non-SAE, NR, Mild01
Pertussis-non-SAE, NR, Mod01
Petit Mal Epilepsy-SAE, NR, Severe01
Pharyngeal Erythema-non-SAE, NR, Mild13
Pharyngitis-non-SAE, NR, Mild14
Pharyngitis-non-SAE, NR, Mod10
Pharyngitis Streptococcal-non-SAE, NR, Mod04
Pneumonia-non-SAE, NR, Mild01
Pneumonia-non-SAE, NR, Mod01
Pneumonia Bacterial-non-SAE, NR, Mod01
Post Procedural Infection-non-SAE, NR, Mild12
Post Procedural Infection-non-SAE, NR, Mod05
Postictal Paralysis-non-SAE, NR, Mod01
Postoperative Wound Infection-non-SAE, NR, Mod01
Procedural Pain-non-SAE, NR, Mild02
Procedural Pain-non-SAE, NR, Mod01
Productive Cough-non-SAE, NR, Mild11
Pruritus-non-SAE, NR, Mild10
Pruritus-non-SAE, RIGIV, Mild10
Pruritus-non-SAE, Rboth, Mild01
Pruritus-non-SAE, Rboth, Mod01
Pruritus Generalized-non-SAE, NR, Mild10
Pseudomonas Infection-non-SAE, NR, Mod01
Psoriasis-non-SAE, NR, Mod01
Pyrexia-non-SAE, NR, Mild311
Pyrexia-non-SAE, NR, Mod21
Pyrexia-non-SAE, RIGIV, Mild46
Pyrexia-non-SAE, RIGIV, Mod22
Pyrexia-non-SAE, Rboth, Mild02
Rales-non-SAE, NR, Mild01
Rales-non-SAE, NR, Mod01
Rash-non-SAE, NR, Mild25
Rash-non-SAE, NR, Mod01
Rash Erythematous-non-SAE, NR, Mild01
Rash Macro-Papular-non-SAE, Rboth, Mild01
Rash Pustular-non-SAE, NR, Mild01
Rash Pustular-non-SAE, NR, Mod10
Rash Papular-non-SAE, NR, Mild01
Respiratory Failure-SAE, NR, Severe01
Respiratory Rate Increased-non-SAE, NR, Mild01
Respiratory Tract Congestion-non-SAE, NR, Mild01
Respiratory Tract Infection-non-SAE, NR, Mild11
Respiratory Tract Infection-non-SAE, NR, Mod13
Respiratory Tract Infection Viral-non-SAE, NR, Mod10
Rhinitis Allergic-non-SAE, NR, Mild13
Rhinitis Allergic-non-SAE, NR, Mod31
Rhinitis Allergic-non-SAE, RIGIV, Mod10
Rhinorrhoea-non-SAE, NR, Mild11
Road Traffic Accident-non-SAE, NR, Mod02
Scleritis-non-SAE, NR, Mild11
Scleritis-non-SAE, NR, Mod01
Scratch-non-SAE, NR, Mild10
Seborrhoeic Dermatitis-non-SAE, NR, Mild01
Sicca Syndrome-non-SAE, NR, Mod01
Sinus Congestion-non-SAE, NR, Mild10
Sinus Headache-non-SAE, NR, Mild10
Sinusitis-non-SAE, NR, Mild625
Sinusitis-non-SAE, NR, Mod1326
Sinusitis-non-SAE, NR, Severe01
Sinusitis-non-SAE, RIGIV, Mod01
Skeletal Injury-non-SAE, NR, Mild01
Skeletal Injury-non-SAE, NR, Mod01
Skin Hyperpigmentation-non-SAE, Rboth, Mild01
Skin Laceration-non-SAE, NR, Mild01
Skin Laceration-non-SAE, NR, Mod01
Skin Lesion-non-SAE, NR, Mild21
Skin Lesion-non-SAE, NR, Mod10
Skin Lesion-non-SAE, RIGIV, Mild02
Skin Papilloma-non-SAE, NR, Mod10
Spinal Osteoarthritis-non-SAE, NR, Mild02
Squamous Cell Carcinoma-non-SAE, NR, Mod11
Status Epilepticus-SAE, NR, Severe01
Suicidal Ideation-non-SAE, NR, Mild10
Sunburn-non-SAE, NR, Mild01
Swelling-non-SAE, Rboth, Mild01
Swelling-non-SAE, Rboth, Mod03
Syncope-non-SAE, NR, Mild01
Tachycardia-non-SAE, NR, Mild03
Tachycardia-non-SAE, NR, Mod01
Therapy Cessation-non-SAE, NR, Severe01
Thrombosis-non-SAE, NR, Severe01
Thrombosis-SAE, NR, Mod01
Tinea Infection-non-SAE, NR, Mild20
Tongue Coated-non-SAE, NR, Mild01
Tonsillar Hypertrophy-non-SAE, NR, Mod01
Tonsillar Hypertrophy-SAE, NR, Mild01
Tooth Abscess-non-SAE, NR, Mild10
Tooth Abscess-non-SAE, NR, Mod01
Tooth Impacted-non-SAE, NR, Mod01
Tooth Infection-non-SAE, NR, Mod01
Toothache-non-SAE, NR, Mod01
Tongue Injury-non-SAE, NR, Mild01
Tremor-non-SAE, NR, Mild01
Tricuspid Valve Incompetence-non-SAE, NR, Mild01
Tympanic Membrane Disorder-non-SAE, NR, Mild10
Tympanic Membrane Hyperaemia-non-SAE, NR, Mild02
Upper Airway Cough Syndrome-non-SAE, NR, Mild01
Upper Resp. Tract Infection-non-SAE, NR, Mild734
Upper Resp. Tract Infection-non-SAE, NR, Mod210
Urinary Tract Infection-non-SAE, NR, Mild12
Urinary Tract Infection-non-SAE, NR, Mod54
Urine Analysis Abnormal-non-SAE, NR, Mild01
Urticaria-non-SAE, NR, Mild05
Urticaria-non-SAE, NR, Mod01
Urticaria-non-SAE, RIGIV, Mild10
Uterine Polyp-non-SAE, NR, Mod01
Vaginal Haemorrhage-non-SAE, NR, Mod01
Vascular Access Complication-non-SAE, NR, Mild10
Vertigo-non-SAE, NR, Mod01
Viral Diarrhoea-non-SAE, NR, Mild01
Viral Infection-non-SAE, NR, Mild37
Viral Infection-non-SAE, NR, Mod33
Viral Infection-SAE, NR, Mild10
Viral Upper Resp. Tract Infection-non-SAE, NR Mild18
Viral Upper Resp. Tract Infection-non-SAE, NR, Mod11
Vision Blurred-non-SAE, NR, Mild01
Vitamin D Deficiency-non-SAE, NR, Mild10
Vitamin D Deficiency-non-SAE, NR, Mod02
Vomiting-non-SAE, NR, Mild57
Vomiting-non-SAE, NR, Mod03
Vomiting-non-SAE, RIGIV, Mild43
Vomiting-non-SAE, RIGIV, Mod14
Vomiting-non-SAE, RIGIV, Severe10
Vomiting-non-SAE, Rboth, Mod01
Vulvovaginal Pruritus-non-SAE, RIGIV, Mild01
Weight Decreased-non-SAE, RrHu, Mild01
Weight Decreased-non-SAE, RrHu, Mod01
Wheezing-non-SAE, NR, Mod01
WBC Count Decreased-non-SAE, RIGIV, Mild01
White Blood Cells Urine Positive-non-SAE, NR, Mild01
WBC Urine Positive-non-SAE, RIGIV Mild10
SecondaryRate of All AEs Categorized by MedDRA Preferred Terms, Seriousness, Relatedness to Study Drug, and Severity Per Infusion (A-F)

Categories presented as Preferred term-Seriousness, Relatedness, Severity. The following codes are to be used: Seriousness: non-SAE-non-serious AE; SAE-serious AE Relationship: NR-not related to immune globulin (IGIV), 10% and recombinant human hyaluronidase (rHuPH20); RIGIV-related to IGIV, 10%; RrHu-related to rHuPH20; Rboth-related to both IGIV, 10% and rHuPH20 Severity: Mild; Mod (Moderate); Severe Preferred terms abbreviated: ADHD-Attention Deficit/Hyperactivity Disorder BP-Blood Pressure COPD- Chronic Obstructive Pulmonary Disease

Time frame:
Throughout the study period (17 months)
Reported as:
Number · Number of AEs per infusion
Rate of All AEs Categorized by MedDRA Preferred Terms, Seriousness, Relatedness to Study Drug, and Severity Per Infusion (A-F)
Number of AEs per infusionIV Administration of IGIV, 10%SC Administration of IGIV, 10% With rHuPH20 After Ramp-up
Abdominal Discomfort-non-SAE, NR, Mod00.001
Abdominal Distension-non-SAE, Rboth, Mild00.001
Abdominal Hernia-non-SAE, NR, Mild00.001
Abdominal Pain-non-SAE, NR, Mild0.0030.002
Abdominal Pain-non-SAE, NR, Mod00.001
Abdominal Pain-non-SAE, Rboth, Mild00.003
Abdominal Pain-non-SAE, Rboth, Mod00.001
Abdominal Pain Lower-non-SAE, NR, Mild00.001
Abdominal Pain Upper-non-SAE, NR, Mild0.0030.004
Abdominal Pain Upper-non-SAE, NR, Mod0.0030
Abdominal Pain Upper-non-SAE, RIGIV, Mild00.001
Abdominal Pain Upper-non-SAE, RIGIV, Mod0.0030
Abdominal Pain Upper-non-SAE, Rboth, Mild00.002
Abdominal Tenderness-non-SAE, NR, Mod0.0030
Abdominal Tenderness-non-SAE, RIGIV, Mild00.001
Abdominal Tenderness-non-SAE, RIGIV, Mod00.002
Acarodermatitis-non-SAE, NR, Mild00.001
Acne-non-SAE, NR, Mild0.0030.001
Acute Sinusitis-non-SAE, NR, Mild0.0030
Acute Sinusitis-non-SAE, NR, Mod00.004
Adenoidal Hypertrophy-non-SAE, NR, Mod00.001
Adnexa Uteri Cyst-non-SAE, NR, Mild0.0030
Adrenocortical Insufficiency Acute-SAE, NR, Mod00.001
Allergic Respiratory Symptom-non-SAE, NR, Mild00.001
Allergic Sinusitis-non-SAE, NR, Mild0.0030
Alopecia-non-SAE, NR, Mild0.0030
Animal Bite-non-SAE, NR, Mod0.0030
Antibody Test Positive-non-SAE, Rboth, Mod00.001
Anxiety-non-SAE, NR, Mild00.001
Anxiety-non-SAE, NR, Mod0.0030
Aphthous Stomatitis-non-SAE, NR, Mild0.0050.001
Aphthous Stomatitis-non-SAE, NR, Mod00.001
Arteriosclerosis Coronary Artery-non-SAE, NR, Mild00.001
Arthralgia-non-SAE, NR, Mild00.004
Arthralgia-non-SAE, NR, Mod0.0030.005
Arthralgia-non-SAE, RIGIV, Mild00.001
Arthralgia-non-SAE, RIGIV, Mod00.002
Arthritis-non-SAE, NR, Mod0.0030.001
Arthropathy-non-SAE, NR, Mod0.0030
Arthropod Bite-non-SAE, NR, Mild0.0050.002
Arthropod Sting-non-SAE, NR, Mild00.001
Arthropod Sting-non-SAE, NR, Mod0.0030
Aspiration-non-SAE, NR, Mild00.001
Asthenia-non-SAE, NR, Mild00.003
Asthenia-non-SAE, NR, Mod0.0030
Asthenia-non-SAE, RIGIV, Mild00.001
Asthma-non-SAE, NR, Mild00.004
Asthma-non-SAE, NR, Mod0.0220.019
Asthma-non-SAE, NR, Severe00.001
ADHD-non-SAE, NR, Mod00.001
Back Injury-non-SAE, NR, Mod0.0030
Back Injury-SAE, NR, Severe00.001
Back Pain-non-SAE, NR, Mild0.0030.002
Back Pain-non-SAE, NR, Mod0.0030.004
Bacterial Prostatitis-non-SAE, NR, Mild00.001
Blepharitis-non-SAE, NR, Mod0.0030
Blister-non-SAE, NR, Mild00.001
Blood Pressure Decreased-non-SAE, NR, Mild00.001
Blood Pressure Decreased-non-SAE, Rboth, Mild00.001
Blood Pressure Increased-non-SAE, NR, Mod00.001
Blood Pressure Increased-non-SAE, RIGIV, Mild00.001
Blood Pressure Increased-non-SAE, RIGIV, Mod00.001
Blood Pressure Increased-non-SAE, RrHu, Mild00.001
BP Systolic Increased-non-SAE, RIGIV, Mild0.0030
Blood Urea Increased-non-SAE, NR, Mild00.001
Body Fat Disorder-non-SAE, NR, Mild00.001
Body Tinea-non-SAE, NR, Mild0.0030
Body Tinea-non-SAE, NR, Mod00.001
Bone Pain-non-SAE, NR, Mild00.001
Breast Pain-non-SAE, NR, Mild0.0030
Bronchal Hyperreactivity-non-SAE, NR, Mild00.001
Bronchitis-non-SAE, NR, Mild0.0110.002
Bronchitis-non-SAE, NR, Mod0.0050.007
Bronchitis-SAE, NR, Mod0.0030
Bronchospasm-non-SAE, NR, Mod00.001
Burn Infection-non-SAE, NR, Mild00.001
Burning Sensation-non-SAE, RIGIV, Mild00.001
Burning Sensation-non-SAE, RIGIV, Mod00.001
Burning Sensation-non-SAE, RrHu, Mild00.001
Bursitis-non-SAE, NR, Mild0.0030
Bursitis-non-SAE, NR, Mod00.001
Candidiasis-non-SAE, NR, Mild0.0030
Candidiasis-non-SAE, NR, Mod0.0030.001
Cardiac Murmur-non-SAE, NR, Mild00.001
Cellulitis-non-SAE, NR, Mild00.001
Cellulitis-non-SAE, NR, Mod00.003
Cellulitis-non-SAE, Rboth, Mod00.001
Cerumen Impaction-non-SAE, NR, Mild00.002
Cervical Dysplasia-SAE, NR, Mild0.0030.001
Cheilitis-non-SAE, NR, Mild0.0050
Chest Pain-non-SAE, NR, Mild00.002
Chills-non-SAE, NR, Mild00.003
Chills-non-SAE, RIGIV, Mild0.0160.001
Chills-non-SAE, RIGIV, Mod0.0080
Chills-non-SAE, Rboth, Mild00.001
COPD-non-SAE, NR, Mod00.002
COPD-non-SAE, NR, Severe0.0030
Chronic Sinusitis-non-SAE, NR, Mild00.004
Chronic Sinusitis-non-SAE, NR, Mod0.0030.001
Concussion-non-SAE, NR, Mod0.0030
Confusional State-non-SAE, NR, Mod00.001
Confusional State-non-SAE, RIGIV, Mild0.0030
Conjunctivitis-non-SAE, NR, Mild0.0030.002
Conjunctivitis Allergic-non-SAE, NR, Mild0.0030
Conjunctivitis Allergic-non-SAE, NR, Mod0.0030
Conjunctivitis Bacterial-non-SAE, NR, Mild0.0030.001
Conjunctivitis Bacterial-non-SAE, NR, Mod00.001
Conjunctivitis Bacterial-non-SAE, NR, Severe00.001
Constipation-non-SAE, NR, Mild00.003
Contusion-non-SAE, NR, Mild0.0030.004
Contusion-non-SAE, NR, Mod0.0030
Contusion-non-SAE, RIGIV, Mod00.001
Coombs Test Positive-non-SAE, RIGIV, Mild00.001
Costochondritis-non-SAE, NR, Mod00.001
Cough-non-SAE, NR, Mild0.0080.005
Cough-non-SAE, NR, Mod00.002
Cough-non-SAE, RIGIV, Mild0.0030
Cushingoid-non-SAE, NR, Mild00.001
Cystitis-non-SAE, NR, Mild00.001
Deafness Neurosensory-non-SAE, NR, Mild0.0030
Decreased Appetite-non-SAE, NR, Mild0.0030.001
Decreased Appetite-non-SAE, RrHu, Mild00.001
Decreased Appetite-non-SAE, Rboth, Mild00.002
Dehydration-non-SAE, NR, Mod00.002
Dental Caries-non-SAE, NR, Mild00.002
Dental Caries-non-SAE, NR, Mod00.003
Depressed Mood-non-SAE, NR, Mild00.001
Depression-non-SAE, NR, Severe00.001
Dermal Cyst-non-SAE, NR, Mild00.001
Dermatitis-non-SAE, NR, Mild00.002
Dermatitis-non-SAE, NR, Mod0.0030
Dermatitis Acneiform-non-SAE, NR, Mod0.0030
Dermatitis Contact-non-SAE, NR, Mild00.002
Dermatitis Contact-non-SAE, NR, Mod0.0050.002
Dermatitis Infected-non-SAE, NR, Mild00.002
Dermatitis Infected-non-SAE, NR, Mod00.001
Dermatitis Infected-non-SAE, NR, Severe00.001
Device Failure-non-SAE, NR, Mild0.0050.001
Device Failure-non-SAE, NR, Mod00.002
Diarrhoea-non-SAE, NR, Mild0.0080.005
Diarrhoea-non-SAE, NR, Mod0.0050.004
Diarrhoea-non-SAE, RIGIV, Mild0.0030.001
Diarrhoea-non-SAE, RIGIV, Mod0.0030
Diarrhoea Haemorrhagic-non-SAE, NR, Mild0.0030
Diarrhoea Infectious-non-SAE, NR, Mild00.001
Diastolic Dysfunction-non-SAE, NR, Mild00.001
Disaccharide Metabolism Disorder-non-SAE, NR, Mild00.001
Disturbance in Attention-non-SAE, NR, Mild00.002
Diverticulitis-non-SAE, NR, Mod0.0030
Dizziness-non-SAE, NR, Mild0.0050.006
Dizziness-non-SAE, NR, Mod00.002
Dizziness-non-SAE, RIGIV, Mild00.003
Dizziness-non-SAE, RIGIV, Mod0.0030
Drug Eruption-non-SAE, NR, Mod0.0030
Dry Eye-non-SAE, NR, Mod00.001
Dry Mouth-non-SAE, NR, Mild00.001
Dry Skin-non-SAE, NR, Mild00.003
Dysmenorrhoea-non-SAE, NR, Mild00.001
Dyspepsia-non-SAE, NR, Mild00.002
Dyspepsia-non-SAE, NR, Mod00.001
Dyspepsia-non-SAE, RIGIV, Mild0.0030
Dysphagia-non-SAE, NR, Mild00.001
Dysphagia-non-SAE, NR, Mod00.001
Dyspnoea-non-SAE, NR, Mild0.0030
Dyspnoea-non-SAE, NR, Mod0.0030
Dyspnoea-non-SAE, RIGIV, Mild0.0030
Dysuria-non-SAE, NR, Mild00.002
Ear Infection-non-SAE, NR, Mild0.0050.002
Ear Infection-non-SAE, NR, Mod0.0030.001
Ear Pain-non-SAE, NR, Mild0.0080.002
Ear Pain-non-SAE, NR, Mod00.001
Ecchymosis-non-SAE, NR, Mild00.001
Eczema-non-SAE, NR, Mild00.001
Eczema-non-SAE, NR, Mod00.001
Eczema-non-SAE, NR, Severe0.0030
Eosinophil Count-non-SAE, NR, Mild00.001
Epitaxis-non-SAE, NR, Mild0.0050.003
Epitaxis-non-SAE, NR, Mod0.0050.002
Erythema-non-SAE, NR, Mild0.0030
Erythema-non-SAE, RIGIV, Mod00.001
Erythema-non-SAE, RrHu, Mild00.001
Erythema-non-SAE, Rboth, Mild00.001
Erythema-non-SAE, Rboth, Mod00.001
Eustachian Tube Dysfunction-non-SAE, NR, Mild0.0030
Excoriation-non-SAE, NR, Mild0.0050.002
Extravasation Blood-non-SAE, Rboth, Mild00.001
Eye Irritation-non-SAE, NR, Mild00.001
Eye Pruritus-non-SAE, NR, Mod00.001
Eye Swelling-non-SAE, NR, Mod00.001
Fall-non-SAE, NR, Mild00.001
Fall-non-SAE, NR, Mod00.001
Fatigue-non-SAE, NR, Mild0.0030.004
Fatigue-non-SAE, NR, Mod0.0030.002
Fatigue-non-SAE, RIGIV, Mild0.0220.007
Fatigue-non-SAE, RIGIV, Mod00.003
Fatigue-non-SAE, Rboth, Mild00.003
Feeling Abnormal-non-SAE, Rboth, Mod00.001
Feeling Cold-non-SAE, RIGIV, Mild0.0050
Flatulence-non-SAE, NR, Mild00.001
Flatulence-non-SAE, NR, Mod00.001
Food Poisoning-non-SAE, NR, Mod00.001
Free Haemoglobin Present-non-SAE, NR, Mild0.0030.001
Free Haemoglobin Present-non-SAE, NR, Severe0.0030
SecondaryRate of All AEs Categorized by MedDRA Preferred Terms, Seriousness, Relatedness to Study Drug, and Severity Per Infusion (G-M)

Categories presented as Preferred term-Seriousness, Relatedness, Severity. The following codes are to be used: Seriousness: non-SAE-non-serious AE; SAE-serious AE Relationship: NR-not related to immune globulin (IGIV), 10% and recombinant human hyaluronidase (rHuPH20); RIGIV-related to IGIV, 10%; RrHu-related to rHuPH20; Rboth-related to both IGIV, 10% and rHuPH20 Severity: Mild; Mod (Moderate); Severe

Time frame:
Throughout the study period (17 months)
Reported as:
Number · Number of AEs per infusion
Rate of All AEs Categorized by MedDRA Preferred Terms, Seriousness, Relatedness to Study Drug, and Severity Per Infusion (G-M)
Number of AEs per infusionIV Administration of IGIV, 10%SC Administration of IGIV, 10% With rHuPH20 After Ramp-up
Gait Disturbance-non-SAE, NR, Mild00.001
Gastroenteritis-non-SAE, NR, Mild00.003
Gastroenteritis-non-SAE, NR, Mod0.0050.002
Gastroenteritis-non-SAE, RIGIV, Mild0.0030
Gastroenteritis-SAE, NR, Mod00.001
Gastroenteritis Bacterial-non-SAE, NR, Mod00.001
Gastroenteritis Viral-non-SAE, NR, Mild0.0080.005
Gastroenteritis Viral-non-SAE, NR, Mod00.004
Gastroenteritis Viral-non-SAE, RIGIV, Mild00.001
Gastrointestinal Haemorrhage-non-SAE, NR, Severe00.001
Gastrooesophageal Reflux Disease-non-SAE, NR, Mild0.0030.002
Gastrooesophageal Reflux Disease-non-SAE, NR, Mod0.0030
Genital Herpes-non-SAE, NR, Mild0.0030
Genital Swelling-non-SAE, Rboth, Mod00.001
Goitre-non-SAE, NR, Mild0.0030
Gout-non-SAE, NR, Mild00.001
Grand Mal Convulsion-non-SAE, NR, Severe0.0030
Grand Mal Convulsion-SAE, NR, Severe00.001
Gravitational Oedema-non-SAE, Rboth, Mod00.001
Groin Pain-non-SAE, NR, Mild00.001
Groin Pain-non-SAE, RIGIV, Mild00.001
Groin Pain-non-SAE, RrHu, Mod00.001
Haematoma-non-SAE, NR, Mild0.0030.001
Haematoma-non-SAE, NR, Mod00.001
Haematuria-non-SAE, NR, Mild00.001
Haemoglobin Abnormal-non-SAE, NR, Mild00.001
Haemorrhoids-non-SAE, NR, Mild00.002
Hand Fracture-non-SAE, NR, Mod00.001
Headache-non-SAE, NR, Mild0.0360.014
Headache-non-SAE, NR, Mod0.0030.003
Headache-non-SAE, NR, Severe0.0030
Headache-non-SAE, RIGIV, Mild0.0680.012
Headache-non-SAE, RIGIV, Mod0.0330.004
Headache-non-SAE, RIGIV, Severe0.0030
Headache-non-SAE, Rboth, Mild00.008
Headache-non-SAE, Rboth, Mod00.007
Headache-SAE, NR, Severe00.001
Hearing Impaired-non-SAE, NR, Mild00.001
Heart Rate Increased-non-SAE, RIGIV, Mild0.0110
Heat Rash-non-SAE, NR, Mild00.001
Heat Stroke-non-SAE, NR, Mod00.001
Herpes Simplex Ophthalmic-non-SAE, NR, Mod00.001
Herpes Zoster-non-SAE, NR, Mod00.001
Hiatus Hernia-non-SAE, NR, Mod00.001
Hot Flush-non-SAE, RIGIV, Mild0.0030
Hyperaesthesia-non-SAE, NR, Mild00.001
Hypercholesterolaemia-non-SAE, NR, Mod00.001
Hyperkeratosis-non-SAE, NR, Mild00.001
Hypertension-non-SAE, NR, Mod00.004
Hypertension-non-SAE, RIGIV, Mild00.002
Hypertension-non-SAE, RIGIV, Mod00.001
Hypertonia-non-SAE, NR, Mild00.001
Hypothyroidism-non-SAE, NR, Mild00.001
Idiopathic Urticaria-non-SAE, NR, Mod0.0030
Increased Upper Airway Secretion-non-SAE, NR, Mild0.0050
Infected Bites-non-SAE, NR, Mild00.002
Infected Bites-non-SAE, NR, Mod0.0030.001
Infection-non-SAE, NR, Mod00.002
Influenza-non-SAE, NR, Mild0.0030.002
Influenza-non-SAE, NR, Mod0.0110.003
Influenza Like Illness-non-SAE, NR, Mild00.001
Infusion Related Reaction-non-SAE, RIGIV, Mild00.001
Infusion Related Reaction-non-SAE, RIGIV, Mod0.0030
Infusion Related Reaction-non-SAE, Rboth, Mild00.001
Infusion Related Reaction-non-SAE, Rboth, Mod00.001
Infusion Site Discomfort-non-SAE, RIGIV, Mild00.005
Infusion Site Discomfort-non-SAE, RrHu, Mod00.001
Infusion Site Discomfort-non-SAE, Rboth, Mild00.013
Infusion Site Discomfort-non-SAE, Rboth, Mod00.007
Infusion Site Erythema-non-SAE, RIGIV, Mild00.001
Infusion Site Erythema-non-SAE, RrHu, Mild00.002
Infusion Site Erythema-non-SAE, Rboth, Mild00.018
Infusion Site Erythema-non-SAE, Rboth, Mod00.004
Infusion Site Extravasation-non-SAE, NR, Mild0.0050
Infusion Site Haematoma-non-SAE, RIGIV, Mild00.001
Infusion Site Haemorrhage-non-SAE, Rboth, Mild00.001
Infusion Site Hypersensitivity-non-SAE, NR, Severe00.001
Infusion Site Hypersensitivity-non-SAE, Rboth, Mod00.001
Infusion Site Mass-non-SAE, RIGIV, Mild00.001
Infusion Site Mass-non-SAE, Rboth, Mild00.002
Infusion Site Oedema-non-SAE, Rboth, Mild00.004
Infusion Site Oedema-non-SAE, Rboth, Mod00.004
Infusion Site Pain-non-SAE, NR, Mild00.002
Infusion Site Pain-non-SAE, RIGIV, Mild0.0030.011
Infusion Site Pain-non-SAE, RIGIV, Mod00.005
Infusion Site Pain-non-SAE, RrHu, Mild00.031
Infusion Site Pain-non-SAE, RrHu, Mod00.001
Infusion Site Pain-non-SAE, Rboth, Mild00.017
Infusion Site Pain-non-SAE, Rboth, Mod00.014
Infusion Site Pain-non-SAE, Rboth, Severe00.001
Infusion Site Pruritus-non-SAE, RIGIV, Mild00.002
Infusion Site Pruritus-non-SAE, RrHu, Mild00.004
Infusion Site Pruritus-non-SAE, Rboth, Mild00.005
Infusion Site Pruritus-non-SAE, Rboth, Mod00.004
Infusion Site Reaction-non-SAE, Rboth, Mild00.001
Infusion Site Reaction-non-SAE, Rboth, Mod00.002
Infusion Site Swelling-non-SAE, RIGIV, Mild00.002
Infusion Site Swelling-non-SAE, Rboth, Mild00.003
Infusion Site Swelling-non-SAE, Rboth, Mod00.004
Infusion Site Swelling-non-SAE, Rboth, Severe00.001
Infusion Site Warmth-non-SAE, Rboth, Mild00.002
Ingrowing Nail-non-SAE, NR, Mod00.001
Injection Site Erythema-non-SAE, RIGIV, Mild00.001
Injury-non-SAE, NR, Mild0.0030
Insomnia-non-SAE, NR, Mild0.0030
Intervertebral Disc Protrusion-non-SAE, NR, Mod0.0030
Irritable Bowel Syndrome-non-SAE, NR, Mild00.001
Irritable Bowel Syndrome-non-SAE, NR, Mod00.002
Joint Effusion-non-SAE, NR, Mild00.001
Joint Effusion-non-SAE, NR, Mod00.001
Joint Injury-non-SAE, NR, Mod0.0030.001
Joint Range of Motion Decreased-non-SAE, NR, Mod00.002
Joint Sprain-non-SAE, NR, Mild00.001
Joint Sprain-non-SAE, NR, Mod00.002
Joint Swelling-non-SAE, NR, Mild00.001
Jugular Vein Distension-non-SAE, NR, Mild00.001
Lethargy-non-SAE, NR, Mild00.001
Lethargy-non-SAE, RIGIV, Mod0.0030
Ligament Injury-non-SAE, NR, Mod00.001
Ligament Sprain-non-SAE, NR, Mod00.001
Limb Injury-non-SAE, NR, Mild0.0030
Lip Injury-non-SAE, NR, Mild00.001
Lip Ulceration-non-SAE, NR, Mild00.001
Local Swelling-non-SAE, RIGIV, Mild00.003
Local Swelling-non-SAE, Rboth, Mild00.003
Localised Infection-non-SAE, NR, Mild00.001
Localised Oedema-non-SAE, RIGIV, Mild00.001
Localised Oedema-non-SAE, Rboth, Mod00.001
Lung Infection-non-SAE, NR, Mod0.0030
Lung Infection-non-SAE, NR, Severe0.0030
Lymph Gland Infection-non-SAE, NR, Mod0.0030
Lymph Node Pain-non-SAE, NR, Mild0.0030
Lymph Node Pain-non-SAE, NR, Mod00.001
Lymph Node Palpable-non-SAE, NR, Mild0.0030
Lymphadenitis-non-SAE, NR, Mod0.0030
Lymphadenopathy-non-SAE, NR, Mild0.0050.007
Lymphangitis-non-SAE, NR, Mod00.001
Lymphocyte Count Decreased-non-SAE, RIGIV, Mild00.001
Lymphoedema-non-SAE, NR, Severe0.0030
Malaise-non-SAE, NR, Mild00.002
Malaise-non-SAE, NR, Mod00.001
Malaise-non-SAE, RIGIV, Mod0.0030
Malaise-non-SAE, RrHu, Mild00.001
Malaise-non-SAE, RrHu, Mod00.001
Memory Impairment-non-SAE, NR, Mod00.001
Migraine-non-SAE, NR, Mild0.0030.001
Migraine-non-SAE, NR, Mod00.002
Migraine-non-SAE, NR, Severe0.0030
Migraine-non-SAE, RIGIV, Mild0.0030.001
Migraine-non-SAE, RIGIV, Mod0.0030.004
Migraine-non-SAE, RIGIV, Severe00.001
Migraine-non-SAE, Rboth, Mod00.001
Molluscum Contagiosum-non-SAE, NR, Mild0.0050
Mouth Ulceration-non-SAE, NR, Mild0.0030
Multiple Sclerosis Relapse-non-SAE, NR, Mod00.001
Muscle Fatigue-non-SAE, NR, Mild00.001
Muscle Injury-non-SAE, NR, Mild00.002
Muscle Spasms-non-SAE, NR, Mild00.001
Muscle Spasms-non-SAE, RIGIV, Mild0.0030
Muscle Strain-non-SAE, NR, Mild0.0030.001
Muscle Strain-non-SAE, NR, Mod00.001
Muscular Weakness-non-SAE, NR, Mild0.0030
Musculoskeletal Chest Pain-non-SAE, NR, Mild00.001
Musculoskeletal Chest Pain-non-SAE, RIGIV, Mild00.001
Musculoskeletal Pain-non-SAE, NR, Mild0.0050
Musculoskeletal Pain-non-SAE, NR, Mod0.0030.001
Musculoskeletal Stiffness-non-SAE, NR, Mild0.0030.001
Myalgia-non-SAE, NR, Mild0.0080.004
Myalgia-non-SAE, NR, Mod0.0030.004
Myalgia-non-SAE, NR, Severe00.001
Myalgia-non-SAE, RIGIV, Mild00.005
Myalgia-non-SAE, RIGIV, Mod0.0030.001
Myalgia-non-SAE, Rboth, Mild00.003
SecondaryRate of All AEs Categorized by MedDRA Preferred Terms, Seriousness, Relatedness to Study Drug, and Severity Per Infusion (N-Z)

Categories presented as Preferred term-Seriousness, Relatedness, Severity. The following codes are to be used: Seriousness: non-SAE-non-serious AE; SAE-serious AE Relationship: NR-not related to immune globulin (IGIV), 10% and recombinant human hyaluronidase (rHuPH20); ; RIGIV-related to IGIV, 10%; RrHu-related to rHuPH20; Rboth-related to both IGIV, 10% and rHuPH20 Severity: Mild; Mod (Moderate); Severe Preferred terms abbreviated: Resp.-Respiratory WBC - White blood cells

Time frame:
Throughout the study period (17 months)
Reported as:
Number · Number of AEs per infusion
Rate of All AEs Categorized by MedDRA Preferred Terms, Seriousness, Relatedness to Study Drug, and Severity Per Infusion (N-Z)
Number of AEs per infusionIV Administration of IGIV, 10%SC Administration of IGIV, 10% With rHuPH20 After Ramp-up
Nasal Congestion-non-SAE, NR, Mild0.0110.003
Nasal Congestion-non-SAE, NR, Mod00.002
Nasal Congestion-non-SAE, RIGIV, Mild00.003
Nasal Discomfort-non-SAE, NR, Mild00.001
Nasal Mucosal Discolouration-non-SAE, NR, Mild00.001
Nasal Turbinate Hypertrophy-non-SAE, NR, Mild00.001
Nasopharyngitis-non-SAE, NR, Mild0.0110.007
Nausea-non-SAE, NR, Mild0.0080.015
Nausea-non-SAE, NR, Mod0.0050.003
Nausea-non-SAE, RIGIV, Mild0.0190.001
Nausea-non-SAE, RIGIV, Mod0.0030
Nausea-non-SAE, Rboth, Mild00.004
Neck Pain-non-SAE, NR, Mild0.0030.001
Night Sweats-non-SAE, NR, Mild0.0030
Night Sweats-non-SAE, NR, Mod00.001
Nodule-non-SAE, Rboth, Mild00.002
Oedema-non-SAE, RIGIV, Mild00.001
Oedema Genital-non-SAE, Rboth, Severe00.001
Oedema Peripheral-non-SAE, NR, Mild00.001
Oedema Peripheral-non-SAE, NR, Mod00.001
Oedema Peripheral-non-SAE, Rboth, Mod00.002
Oesophagitis-non-SAE, NR, Mild00.001
Onychomycosis-non-SAE, NR, Mild00.001
Oral Candidiasis-non-SAE, NR, Mod00.001
Oral Fungal Infection-non-SAE, NR, Mild00.001
Oral Herpes-non-SAE, NR, Mild0.0030.002
Oral Herpes-non-SAE, NR, Mod00.001
Oral Pain-non-SAE, NR, Mild00.001
Oral Pain-non-SAE, RrHu, Severe00.001
Oropharyngeal Pain-non-SAE, NR, Mild0.0030.004
Oropharyngeal Pain-non-SAE, NR, Mod0.0050.001
Osteoarthritis-non-SAE, NR, Mod00.001
Osteopenia-non-SAE, NR, Mild00.001
Osteopenia-non-SAE, NR, Mod00.001
Osteoporosis-non-SAE, NR, Mild00.001
Otitis Externa-non-SAE, NR, Mild00.001
Otitis Externa-non-SAE, NR, Mod00.001
Otitis Media-non-SAE, NR, Mod0.0030.001
Pain-non-SAE, NR, Mild0.0030.004
Pain-non-SAE, NR, Mod0.0030.001
Pain-non-SAE, RIGIV, Mild00.001
Pain-non-SAE, RIGIV, Mod0.0050.001
Pain-non-SAE, Rboth, Mild00.001
Pain-non-SAE, Rboth, Mod00.001
Pain in Extremity-non-SAE, NR, Mild0.0050.001
Pain in Extremity-non-SAE, NR, Mod0.0030.002
Pain in Extremity-non-SAE, RIGIV, Mod0.0050
Pain in Extremity-non-SAE, RIGIV, Severe0.0030
Pain in Extremity-non-SAE, Rboth, Mild00.003
Pain in Extremity-non-SAE, Rboth, Mod00.002
Palpitations-non-SAE, NR, Mild0.0030.001
Papule-non-SAE, NR, Mild00.001
Peptic Ulcer Haemorrhage-SAE, NR, Severe0.0030
Periorbital Haematoma-non-SAE, NR, Mild00.001
Peripheral Nerve Injury-non-SAE, NR, Mild00.001
Pertussis-non-SAE, NR, Mod00.001
Petit Mal Epilepsy-SAE, NR, Severe00.001
Pharyngeal Erythema-non-SAE, NR, Mild0.0030.003
Pharyngitis-non-SAE, NR, Mild0.0030.004
Pharyngitis-non-SAE, NR, Mod0.0030
Pharyngitis Streptococcal-non-SAE, NR, Mod00.004
Pneumonia-non-SAE, NR, Mild00.001
Pneumonia-non-SAE, NR, Mod00.001
Pneumonia Bacterial-non-SAE, NR, Mod00.001
Post Procedural Infection-non-SAE, NR, Mild0.0030.002
Post Procedural Infection-non-SAE, NR, Mod00.004
Postictal Paralysis-non-SAE, NR, Mod00.001
Postoperative Wound Infection-non-SAE, NR, Mod00.001
Procedural Pain-non-SAE, NR, Mild00.002
Procedural Pain-non-SAE, NR, Mod00.001
Productive Cough-non-SAE, NR, Mild0.0030.001
Pruritus-non-SAE, NR, Mild0.0030
Pruritus-non-SAE, RIGIV, Mild0.0030
Pruritus-non-SAE, Rboth, Mild00.001
Pruritus-non-SAE, Rboth, Mod00.001
Pruritus Generalized-non-SAE, NR, Mild0.0030
Pseudomonas Infection-non-SAE, NR, Mod00.001
Psoriasis-non-SAE, NR, Mod00.001
Pyrexia-non-SAE, NR, Mild0.0080.010
Pyrexia-non-SAE, NR, Mod0.0050.001
Pyrexia-non-SAE, RIGIV, Mild0.0110.005
Pyrexia-non-SAE, RIGIV, Mod0.0050.002
Pyrexia-non-SAE, Rboth, Mild00.002
Rales-non-SAE, NR, Mild00.001
Rales-non-SAE, NR, Mod00.001
Rash-non-SAE, NR, Mild0.0050.004
Rash-non-SAE, NR, Mod00.001
Rash Erythematous-non-SAE, NR, Mild00.001
Rash Maculo-Papular-non-SAE, Rboth, Mild00.001
Rash Pustular-non-SAE, NR, Mild00.001
Rash Pustular-non-SAE, NR, Mod0.0030
Rash Papular-non-SAE, NR, Mild00.001
Respiratory Failure-SAE, NR, Severe00.001
Respiratory Rate Increased-non-SAE, NR, Mild00.001
Respiratory Tract Congestion-non-SAE, NR, Mild00.001
Respiratory Tract Infection-non-SAE, NR, Mild0.0030.001
Respiratory Tract Infection-non-SAE, NR, Mod0.0030.003
Respiratory Tract Infection Viral-non-SAE, NR, Mod0.0030
Rhinitis Allergic-non-SAE, NR, Mild0.0030.003
Rhinitis Allergic-non-SAE, NR, Mod0.0080.001
Rhinitis Allergic-non-SAE, RIGIV, Mod0.0030
Rhinorrhoea-non-SAE, NR, Mild0.0030.001
Road Traffic Accident-non-SAE, NR, Mod00.002
Scleritis-non-SAE, NR, Mild0.0030.001
Scleritis-non-SAE, NR, Mod00.001
Scratch-non-SAE, NR, Mild0.0030
Seborrhoeic Dermatitis-non-SAE, NR, Mild00.001
Sicca Syndrome-non-SAE, NR, Mod00.001
Sinus Congestion-non-SAE, NR, Mild0.0030
Sinus Headache-non-SAE, NR, Mild0.0030
Sinusitis-non-SAE, NR, Mild0.0160.022
Sinusitis-non-SAE, NR, Mod0.0360.023
Sinusitis-non-SAE, NR, Severe00.001
Sinusitis-non-SAE, RIGIV, Mod00.001
Skeletal Injury-non-SAE, NR, Mild00.001
Skeletal Injury-non-SAE, NR, Mod00.001
Skin Hyperpigmentation-non-SAE, Rboth, Mild00.001
Skin Laceration-non-SAE, NR, Mild00.001
Skin Laceration-non-SAE, NR, Mod00.001
Skin Lesion-non-SAE, NR, Mild0.0050.001
Skin Lesion-non-SAE, NR, Mod0.0030
Skin Lesion-non-SAE, RIGIV, Mild00.002
Skin Papilloma-non-SAE, NR, Mod0.0030
Spinal Osteoarthritis-non-SAE, NR, Mild00.002
Squamous Cell Carcinoma-non-SAE, NR, Mod0.0030.001
Status Epilepticus-SAE, NR, Severe00.001
Suicidal Ideation-non-SAE, NR, Mild0.0030
Sunburn-non-SAE, NR, Mild00.001
Swelling-non-SAE, Rboth, Mild00.001
Swelling-non-SAE, Rboth, Mod00.003
Syncope-non-SAE, NR, Mild00.001
Tachycardia-non-SAE, NR, Mild00.003
Tachycardia-non-SAE, NR, Mod00.001
Therapy Cessation-non-SAE, NR, Severe00.001
Thrombosis-non-SAE, NR, Severe00.001
Thrombosis-SAE, NR, Mod00.001
Tinea Infection-non-SAE, NR, Mild0.0050
Tongue Coated-non-SAE, NR, Mild00.001
Tonsillar Hypertrophy-non-SAE, NR, Mod00.001
Tonsillar Hypertrophy-SAE, NR, Mild00.001
Tooth Abscess-non-SAE, NR, Mild0.0030
Tooth Abscess-non-SAE, NR, Mod00.001
Tooth Impacted-non-SAE, NR, Mod00.001
Tooth Infection-non-SAE, NR, Mod00.001
Toothache-non-SAE, NR, Mod00.001
Tongue Injury-non-SAE, NR, Mild00.001
Tremor-non-SAE, NR, Mild00.001
Tricuspid Valve Incompetence-non-SAE, NR, Mild00.001
Tympanic Membrane Disorder-non-SAE, NR, Mild0.0030
Tympanic Membrane Hyperaemia-non-SAE, NR, Mild00.002
Upper Airway Cough Syndrome-non-SAE, NR, Mild00.001
Upper Resp. Tract Infection-non-SAE, NR, Mild0.0190.030
Upper Resp. Tract Infection-non-SAE, NR, Mod0.0050.009
Urinary Tract Infection-non-SAE, NR, Mild0.0030.002
Urinary Tract Infection-non-SAE, NR, Mod0.0140.004
Urine Analysis Abnormal-non-SAE, NR, Mild00.001
Urticaria-non-SAE, NR, Mild00.004
Urticaria-non-SAE, NR, Mod00.001
Urticaria-non-SAE, RIGIV, Mild0.0030
Uterine Polyp-non-SAE, NR, Mod00.001
Vaginal Haemorrhage-non-SAE, NR, Mod00.001
Vascular Access Complication-non-SAE, NR, Mild0.0030
Vertigo-non-SAE, NR, Mod00.001
Viral Diarrhoea-non-SAE, NR, Mild00.001
Viral Infection-non-SAE, NR, Mild00080.006
Viral Infection-non-SAE, NR, Mod0.0080.003
Viral Infection-SAE, NR, Mild0.0030
Viral Upper Resp. Tract Infection-non-SAE, NR Mild0.0030.007
Viral Upper Resp. Tract Infection-non-SAE, NR, Mod0.0030.001
Vision Blurred-non-SAE, NR, Mild00.001
Vitamin D Deficiency-non-SAE, NR, Mild0.0030
Vitamin D Deficiency-non-SAE, NR, Mod00.002
Vomiting-non-SAE, NR, Mild0.0140.006
Vomiting-non-SAE, NR, Mod00.003
Vomiting-non-SAE, RIGIV, Mild0.0110.003
Vomiting-non-SAE, RIGIV, Mod0.0030.004
Vomiting-non-SAE, RIGIV, Severe0.0030
Vomiting-non-SAE, Rboth, Mod00.001
Vulvovaginal Pruritus-non-SAE, RIGIV, Mild00.001
Weight Decreased-non-SAE, RrHu, Mild00.001
Weight Decreased-non-SAE, RrHu, Mod00.001
Wheezing-non-SAE, NR, Mod00.001
WBC Count Decreased-non-SAE, RIGIV, Mild00.001
White Blood Cells Urine Positive-non-SAE, NR, Mild00.001
WBC Urine Positive-non-SAE, RIGIV Mild0.0030
SecondaryRate of All AEs Categorized by MedDRA Preferred Terms, Seriousness, Relatedness to Study Drug, and Severity Per Participant (A-F)

Categories presented as Preferred term-Seriousness, Relatedness, Severity. The following codes are to be used: Seriousness: non-SAE-non-serious AE; SAE-serious AE Relationship: NR-not related to immune globulin (IGIV), 10% and recombinant human hyaluronidase (rHuPH20); RIGIV-related to IGIV, 10%; RrHu-related to rHuPH20; Rboth-related to both IGIV, 10% and rHuPH20 Severity: Mild; Mod (Moderate); Severe Preferred terms abbreviated: ADHD-Attention Deficit/Hyperactivity Disorder BP-Blood Pressure COPD- Chronic Obstructive Pulmonary Disease

Time frame:
Throughout the study period (17 months)
Reported as:
Number · Number of AEs per participant
Rate of All AEs Categorized by MedDRA Preferred Terms, Seriousness, Relatedness to Study Drug, and Severity Per Participant (A-F)
Number of AEs per participantIV Administration of IGIV, 10%SC Administration of IGIV, 10% With rHuPH20 After Ramp-up
Abdominal Discomfort-non-SAE, NR, Mod00.012
Abdominal Distension-non-SAE, Rboth, Mild00.012
Abdominal Hernia-non-SAE, NR, Mild00.012
Abdominal Pain-non-SAE, NR, Mild0.0110.025
Abdominal Pain-non-SAE, NR, Mod00.012
Abdominal Pain-non-SAE, Rboth, Mild00.037
Abdominal Pain-non-SAE, Rboth, Mod00.012
Abdominal Pain Lower-non-SAE, NR, Mild00.012
Abdominal Pain Upper-non-SAE, NR, Mild0.0110.062
Abdominal Pain Upper-non-SAE, NR, Mod0.0110
Abdominal Pain Upper-non-SAE, RIGIV, Mild00.012
Abdominal Pain Upper-non-SAE, RIGIV, Mod0.0110
Abdominal Pain Upper-non-SAE, Rboth, Mild00.025
Abdominal Tenderness-non-SAE, NR, Mod0.0110
Abdominal Tenderness-non-SAE, RIGIV, Mild00.012
Abdominal Tenderness-non-SAE, RIGIV, Mod00.025
Acarodermatitis-non-SAE, NR, Mild00.012
Acne-non-SAE, NR, Mild0.0110.012
Acute Sinusitis-non-SAE, NR, Mild0.0110
Acute Sinusitis-non-SAE, NR, Mod00.049
Adenoidal Hypertrophy-non-SAE, NR, Mod00.012
Adnexa Uteri Cyst-non-SAE, NR, Mild0.0110
Adrenocortical Insufficiency Acute-SAE, NR, Mod00.012
Allergic Respiratory Symptom-non-SAE, NR, Mild00.012
Allergic Sinusitis-non-SAE, NR, Mild0.0110
Alopecia-non-SAE, NR, Mild0.0110
Animal Bite-non-SAE, NR, Mod0.0110
Antibody Test Positive-non-SAE, Rboth, Mod00.012
Anxiety-non-SAE, NR, Mild00.012
Anxiety-non-SAE, NR, Mod0.0110
Aphthous Stomatitis-non-SAE, NR, Mild0.0230.012
Aphthous Stomatitis-non-SAE, NR, Mod00.012
Arteriosclerosis Coronary Artery-non-SAE, NR, Mild00.012
Arthralgia-non-SAE, NR, Mild00.062
Arthralgia-non-SAE, NR, Mod0.0110.074
Arthralgia-non-SAE, RIGIV, Mild00.012
Arthralgia-non-SAE, RIGIV, Mod00.025
Arthritis-non-SAE, NR, Mod0.0110.012
Arthropathy-non-SAE, NR, Mod0.0110
Arthropod Bite-non-SAE, NR, Mild0.0230.025
Arthropod Sting-non-SAE, NR, Mild00.012
Arthropod Sting-non-SAE, NR, Mod0.0110
Aspiration-non-SAE, NR, Mild00.012
Asthenia-non-SAE, NR, Mild00.037
Asthenia-non-SAE, NR, Mod0.0110
Asthenia-non-SAE, RIGIV, Mild00.012
Asthma-non-SAE, NR, Mild00.049
Asthma-non-SAE, NR, Mod0.0920.259
Asthma-non-SAE, NR, Severe00.012
ADHD-non-SAE, NR, Mod00.012
Back Injury-non-SAE, NR, Mod0.0110
Back Injury-SAE, NR, Severe00.012
Back Pain-non-SAE, NR, Mild0.0110.025
Back Pain-non-SAE, NR, Mod0.0110.062
Bacterial Prostatitis-non-SAE, NR, Mild00.012
Blepharitis-non-SAE, NR, Mod0.0110
Blister-non-SAE, NR, Mild00.012
Blood Pressure Decreased-non-SAE, NR, Mild00.012
Blood Pressure Decreased-non-SAE, Rboth, Mild00.012
Blood Pressure Increased-non-SAE, NR, Mod00.012
Blood Pressure Increased-non-SAE, RIGIV, Mild00.012
Blood Pressure Increased-non-SAE, RIGIV, Mod00.012
Blood Pressure Increased-non-SAE, RrHu, Mild00.012
BP Systolic Increased-non-SAE, RIGIV, Mild0.0110
Blood Urea Increased-non-SAE, NR, Mild00.012
Body Fat Disorder-non-SAE, NR, Mild00.012
Body Tinea-non-SAE, NR, Mild0.0110
Body Tinea-non-SAE, NR, Mod00.012
Bone Pain-non-SAE, NR, Mild00.012
Breast Pain-non-SAE, NR, Mild0.0110
Bronchal Hyperreactivity-non-SAE, NR, Mild00.012
Bronchitis-non-SAE, NR, Mild0.0460.025
Bronchitis-non-SAE, NR, Mod0.0230.099
Bronchitis-SAE, NR, Mod0.0110
Bronchospasm-non-SAE, NR, Mod00.012
Burn Infection-non-SAE, NR, Mild00.012
Burning Sensation-non-SAE, RIGIV, Mild00.012
Burning Sensation-non-SAE, RIGIV, Mod00.012
Burning Sensation-non-SAE, RrHu, Mild00.012
Bursitis-non-SAE, NR, Mild0.0110
Bursitis-non-SAE, NR, Mod00.012
Candidiasis-non-SAE, NR, Mild0.0110
Candidiasis-non-SAE, NR, Mod0.0110.012
Cardiac Murmur-non-SAE, NR, Mild00.012
Cellulitis-non-SAE, NR, Mild00.012
Cellulitis-non-SAE, NR, Mod00.037
Cellulitis-non-SAE, Rboth, Mod00.012
Cerumen Impaction-non-SAE, NR, Mild00.025
Cervical Dysplasia-SAE, NR, Mild0.0110.012
Cheilitis-non-SAE, NR, Mild0.0230
Chest Pain-non-SAE, NR, Mild00.025
Chills-non-SAE, NR, Mild00.037
Chills-non-SAE, RIGIV, Mild0.0690.012
Chills-non-SAE, RIGIV, Mod0.0340
Chills-non-SAE, Rboth, Mild00.012
COPD-non-SAE, NR, Mod00.025
COPD-non-SAE, NR, Severe0.0110
Chronic Sinusitis-non-SAE, NR, Mild00.049
Chronic Sinusitis-non-SAE, NR, Mod0.0110.012
Concussion-non-SAE, NR, Mod0.0110
Confusional State-non-SAE, NR, Mod00.012
Confusional State-non-SAE, RIGIV, Mild0.0110
Conjunctivitis-non-SAE, NR, Mild0.0110.025
Conjunctivitis Allergic-non-SAE, NR, Mild0.0110
Conjunctivitis Allergic-non-SAE, NR, Mod0.0110
Conjunctivitis Bacterial-non-SAE, NR, Mild0.0110.012
Conjunctivitis Bacterial-non-SAE, NR, Mod00.012
Conjunctivitis Bacterial-non-SAE, NR, Severe00.012
Constipation-non-SAE, NR, Mild00.037
Contusion-non-SAE, NR, Mild0.0110.062
Contusion-non-SAE, NR, Mod0.0110
Contusion-non-SAE, RIGIV, Mod00.012
Coombs Test Positive-non-SAE, RIGIV, Mild00.012
Costochondritis-non-SAE, NR, Mod00.012
Cough-non-SAE, NR, Mild0.0340.074
Cough-non-SAE, NR, Mod00.025
Cough-non-SAE, RIGIV, Mild0.0110
Cushingoid-non-SAE, NR, Mild00.012
Cystitis-non-SAE, NR, Mild00.012
Deafness Neurosensory-non-SAE, NR, Mild0.0110
Decreased Appetite-non-SAE, NR, Mild0.0110.012
Decreased Appetite-non-SAE, RrHu, Mild00.012
Decreased Appetite-non-SAE, Rboth, Mild00.025
Dehydration-non-SAE, NR, Mod00.025
Dental Caries-non-SAE, NR, Mild00.025
Dental Caries-non-SAE, NR, Mod00.037
Depressed Mood-non-SAE, NR, Mild00.012
Depression-non-SAE, NR, Severe00.012
Dermal Cyst-non-SAE, NR, Mild00.012
Dermatitis-non-SAE, NR, Mild00.025
Dermatitis-non-SAE, NR, Mod0.0110
Dermatitis Acneiform-non-SAE, NR, Mod0.0110
Dermatitis Contact-non-SAE, NR, Mild00.025
Dermatitis Contact-non-SAE, NR, Mod0.0230.025
Dermatitis Infected-non-SAE, NR, Mild00.025
Dermatitis Infected-non-SAE, NR, Mod00.012
Dermatitis Infected-non-SAE, NR, Severe00.012
Device Failure-non-SAE, NR, Mild0.0230.012
Device Failure-non-SAE, NR, Mod00.025
Diarrhoea-non-SAE, NR, Mild0.0340.074
Diarrhoea-non-SAE, NR, Mod0.0230.049
Diarrhoea-non-SAE, RIGIV, Mild0.0110.012
Diarrhoea-non-SAE, RIGIV, Mod0.0110
Diarrhoea Haemorrhagic-non-SAE, NR, Mild0.0110
Diarrhoea Infectious-non-SAE, NR, Mild00.012
Diastolic Dysfunction-non-SAE, NR, Mild00.012
Disaccharide Metabolism Disorder-non-SAE, NR, Mild00.012
Disturbance in Attention-non-SAE, NR, Mild00.025
Diverticulitis-non-SAE, NR, Mod0.0110
Dizziness-non-SAE, NR, Mild0.0230.086
Dizziness-non-SAE, NR, Mod00.025
Dizziness-non-SAE, RIGIV, Mild00.037
Dizziness-non-SAE, RIGIV, Mod0.0110
Drug Eruption-non-SAE, NR, Mod0.0110
Dry Eye-non-SAE, NR, Mod00.012
Dry Mouth-non-SAE, NR, Mild00.012
Dry Skin-non-SAE, NR, Mild00.037
Dysmenorrhoea-non-SAE, NR, Mild00.012
Dyspepsia-non-SAE, NR, Mild00.025
Dyspepsia-non-SAE, NR, Mod00.012
Dyspepsia-non-SAE, RIGIV, Mild0.0110
Dysphagia-non-SAE, NR, Mild00.012
Dysphagia-non-SAE, NR, Mod00.012
Dyspnoea-non-SAE, NR, Mild0.0110
Dyspnoea-non-SAE, NR, Mod0.0110
Dyspnoea-non-SAE, RIGIV, Mild0.0110
Dysuria-non-SAE, NR, Mild00.025
Ear Infection-non-SAE, NR, Mild0.0230.025
Ear Infection-non-SAE, NR, Mod0.0110.012
Ear Pain-non-SAE, NR, Mild0.0340.025
Ear Pain-non-SAE, NR, Mod00.012
Ecchymosis-non-SAE, NR, Mild00.012
Eczema-non-SAE, NR, Mild00.012
Eczema-non-SAE, NR, Mod00.012
Eczema-non-SAE, NR, Severe0.0110
Eosinophil Count-non-SAE, NR, Mild00.012
Epitaxis-non-SAE, NR, Mild0.0230.037
Epitaxis-non-SAE, NR, Mod0.0230.025
Erythema-non-SAE, NR, Mild0.0110
Erythema-non-SAE, RIGIV, Mod00.012
Erythema-non-SAE, RrHu, Mild00.012
Erythema-non-SAE, Rboth, Mild00.012
Erythema-non-SAE, Rboth, Mod00.012
Eustachian Tube Dysfunction-non-SAE, NR, Mild0.0110
Excoriation-non-SAE, NR, Mild0.0250.025
Extravasation Blood-non-SAE, Rboth, Mild00.012
Eye Irritation-non-SAE, NR, Mild00.012
Eye Pruritus-non-SAE, NR, Mod00.012
Eye Swelling-non-SAE, NR, Mod00.012
Fall-non-SAE, NR, Mild00.012
Fall-non-SAE, NR, Mod00.012
Fatigue-non-SAE, NR, Mild0.0110.062
Fatigue-non-SAE, NR, Mod0.0110.025
Fatigue-non-SAE, RIGIV, Mild0.0920.099
Fatigue-non-SAE, RIGIV, Mod00.037
Fatigue-non-SAE, Rboth, Mild00.037
Feeling Abnormal-non-SAE, Rboth, Mod00.012
Feeling Cold-non-SAE, RIGIV, Mild0.0230
Flatulence-non-SAE, NR, Mild00.012
Flatulence-non-SAE, NR, Mod00.012
Food Poisoning-non-SAE, NR, Mod00.012
Free Haemoglobin Present-non-SAE, NR, Mild0.0110.012
Free Haemoglobin Present-non-SAE, NR, Severe0.0110
SecondaryRate of All AEs Categorized by MedDRA Preferred Terms, Seriousness, Relatedness to Study Drug, and Severity Per Participant (G-M)

Categories presented as Preferred term-Seriousness, Relatedness, Severity. The following codes are to be used: Seriousness: non-SAE-non-serious AE; SAE-serious AE Relationship: NR-not related to immune globulin (IGIV), 10% and recombinant human hyaluronidase (rHuPH20); RIGIV-related to IGIV, 10%; RrHu-related to rHuPH20; Rboth-related to both IGIV, 10% and rHuPH20 Severity: Mild; Mod (Moderate); Severe

Time frame:
Throughout the study period (17 months)
Reported as:
Number · Number of AEs per participant
Rate of All AEs Categorized by MedDRA Preferred Terms, Seriousness, Relatedness to Study Drug, and Severity Per Participant (G-M)
Number of AEs per participantIV Administration of IGIV, 10%SC Administration of IGIV, 10% With rHuPH20 After Ramp-up
Gait Disturbance-non-SAE, NR, Mild00.012
Gastroenteritis-non-SAE, NR, Mild00.037
Gastroenteritis-non-SAE, NR, Mod0.0230.025
Gastroenteritis-non-SAE, RIGIV, Mild0.0110
Gastroenteritis-SAE, NR, Mod00.012
Gastroenteritis Bacterial-non-SAE, NR, Mod00.012
Gastroenteritis Viral-non-SAE, NR, Mild0.0340.074
Gastroenteritis Viral-non-SAE, NR, Mod00.062
Gastroenteritis Viral-non-SAE, RIGIV, Mild00.012
Gastrointestinal Haemorrhage-non-SAE, NR, Severe00.012
Gastrooesophageal Reflux Disease-non-SAE, NR, Mild0.0110.025
Gastrooesophageal Reflux Disease-non-SAE, NR, Mod0.0110
Genital Herpes-non-SAE, NR, Mild0.0110
Genital Swelling-non-SAE, Rboth, Mod00.012
Goitre-non-SAE, NR, Mild0.0110
Gout-non-SAE, NR, Mild00.012
Grand Mal Convulsion-non-SAE, NR, Severe0.0110
Grand Mal Convulsion-SAE, NR, Severe00.012
Gravitational Oedema-non-SAE, Rboth, Mod00.012
Groin Pain-non-SAE, NR, Mild00.012
Groin Pain-non-SAE, RIGIV, Mild00.012
Groin Pain-non-SAE, RrHu, Mod00.012
Haematoma-non-SAE, NR, Mild0.0110.012
Haematoma-non-SAE, NR, Mod00.012
Haematuria-non-SAE, NR, Mild00.012
Haemoglobin Abnormal-non-SAE, NR, Mild00.012
Haemorrhoids-non-SAE, NR, Mild00.025
Hand Fracture-non-SAE, NR, Mod00.012
Headache-non-SAE, NR, Mild0.1490.198
Headache-non-SAE, NR, Mod0.0110.037
Headache-non-SAE, NR, Severe0.0110
Headache-non-SAE, RIGIV, Mild0.2870.173
Headache-non-SAE, RIGIV, Mod0.1380.062
Headache-non-SAE, RIGIV, Severe0.0110
Headache-non-SAE, Rboth, Mild00.011
Headache-non-SAE, Rboth, Mod00.099
Headache-SAE, NR, Severe00.012
Hearing Impaired-non-SAE, NR, Mild00.012
Heart Rate Increased-non-SAE, RIGIV, Mild0.0460
Heat Rash-non-SAE, NR, Mild00.012
Heat Stroke-non-SAE, NR, Mod00.012
Herpes Simplex Ophthalmic-non-SAE, NR, Mod00.012
Herpes Zoster-non-SAE, NR, Mod00.012
Hiatus Hernia-non-SAE, NR, Mod00.012
Hot Flush-non-SAE, RIGIV, Mild0.0110
Hyperaesthesia-non-SAE, NR, Mild00.012
Hypercholesterolaemia-non-SAE, NR, Mod00.012
Hyperkeratosis-non-SAE, NR, Mild00.012
Hypertension-non-SAE, NR, Mod00.049
Hypertension-non-SAE, RIGIV, Mild00.025
Hypertension-non-SAE, RIGIV, Mod00.012
Hypertonia-non-SAE, NR, Mild00.012
Hypothyroidism-non-SAE, NR, Mild00.012
Idiopathic Urticaria-non-SAE, NR, Mod0.0110
Increased Upper Airway Secretion-non-SAE, NR, Mild0.0230
Infected Bites-non-SAE, NR, Mild00.025
Infected Bites-non-SAE, NR, Mod0.0110.012
Infection-non-SAE, NR, Mod00.025
Influenza-non-SAE, NR, Mild0.0110.025
Influenza-non-SAE, NR, Mod0.0460.037
Influenza Like Illness-non-SAE, NR, Mild00.012
Infusion Related Reaction-non-SAE, RIGIV, Mild00.012
Infusion Related Reaction-non-SAE, RIGIV, Mod0.0110
Infusion Related Reaction-non-SAE, Rboth, Mild00.012
Infusion Related Reaction-non-SAE, Rboth, Mod00.012
Infusion Site Discomfort-non-SAE, RIGIV, Mild00.074
Infusion Site Discomfort-non-SAE, RrHu, Mod00.012
Infusion Site Discomfort-non-SAE, Rboth, Mild00.185
Infusion Site Discomfort-non-SAE, Rboth, Mod00.099
Infusion Site Erythema-non-SAE, RIGIV, Mild00.012
Infusion Site Erythema-non-SAE, RrHu, Mild00.025
Infusion Site Erythema-non-SAE, Rboth, Mild00.247
Infusion Site Erythema-non-SAE, Rboth, Mod00.062
Infusion Site Extravasation-non-SAE, NR, Mild0.0230
Infusion Site Haematoma-non-SAE, RIGIV, Mild00.012
Infusion Site Haemorrhage-non-SAE, Rboth, Mild00.012
Infusion Site Hypersensitivity-non-SAE, NR, Severe00.012
Infusion Site Hypersensitivity-non-SAE, Rboth, Mod00.012
Infusion Site Mass-non-SAE, RIGIV, Mild00.012
Infusion Site Mass-non-SAE, Rboth, Mild00.025
Infusion Site Oedema-non-SAE, Rboth, Mild00.049
Infusion Site Oedema-non-SAE, Rboth, Mod00.062
Infusion Site Pain-non-SAE, NR, Mild00.025
Infusion Site Pain-non-SAE, RIGIV, Mild0.0110.148
Infusion Site Pain-non-SAE, RIGIV, Mod00.074
Infusion Site Pain-non-SAE, RrHu, Mild00.432
Infusion Site Pain-non-SAE, RrHu, Mod00.012
Infusion Site Pain-non-SAE, Rboth, Mild00.235
Infusion Site Pain-non-SAE, Rboth, Mod00.198
Infusion Site Pain-non-SAE, Rboth, Severe00.012
Infusion Site Pruritus-non-SAE, RIGIV, Mild00.025
Infusion Site Pruritus-non-SAE, RrHu, Mild00.062
Infusion Site Pruritus-non-SAE, Rboth, Mild00.074
Infusion Site Pruritus-non-SAE, Rboth, Mod00.049
Infusion Site Reaction-non-SAE, Rboth, Mild00.012
Infusion Site Reaction-non-SAE, Rboth, Mod00.025
Infusion Site Swelling-non-SAE, RIGIV, Mild00.025
Infusion Site Swelling-non-SAE, Rboth, Mild00.037
Infusion Site Swelling-non-SAE, Rboth, Mod00.049
Infusion Site Swelling-non-SAE, Rboth, Severe00.012
Infusion Site Warmth-non-SAE, Rboth, Mild00.025
Ingrowing Nail-non-SAE, NR, Mod00.012
Injection Site Erythema-non-SAE, RIGIV, Mild00.012
Injury-non-SAE, NR, Mild0.0110
Insomnia-non-SAE, NR, Mild0.0110
Intervertebral Disc Protrusion-non-SAE, NR, Mod0.0110
Irritable Bowel Syndrome-non-SAE, NR, Mild00.012
Irritable Bowel Syndrome-non-SAE, NR, Mod00.025
Joint Effusion-non-SAE, NR, Mild00.012
Joint Effusion-non-SAE, NR, Mod00.012
Joint Injury-non-SAE, NR, Mod0.0110.012
Joint Range of Motion Decreased-non-SAE, NR, Mod00.025
Joint Sprain-non-SAE, NR, Mild00.012
Joint Sprain-non-SAE, NR, Mod00.025
Joint Swelling-non-SAE, NR, Mild00.012
Jugular Vein Distension-non-SAE, NR, Mild00.012
Lethargy-non-SAE, NR, Mild00.012
Lethargy-non-SAE, RIGIV, Mod00.011
Ligament Injury-non-SAE, NR, Mod00.012
Ligament Sprain-non-SAE, NR, Mod00.012
Limb Injury-non-SAE, NR, Mild0.0110
Lip Injury-non-SAE, NR, Mild00.012
Lip Ulceration-non-SAE, NR, Mild00.012
Local Swelling-non-SAE, RIGIV, Mild00.037
Local Swelling-non-SAE, Rboth, Mild00.037
Localised Infection-non-SAE, NR, Mild00.012
Localised Oedema-non-SAE, RIGIV, Mild00.012
Localised Oedema-non-SAE, Rboth, Mod00.012
Lung Infection-non-SAE, NR, Mod0.0110
Lung Infection-non-SAE, NR, Severe0.0110
Lymph Gland Infection-non-SAE, NR, Mod0.0110
Lymph Node Pain-non-SAE, NR, Mild0.0110
Lymph Node Pain-non-SAE, NR, Mod00.012
Lymph Node Palpable-non-SAE, NR, Mild0.0110
Lymphadenitis-non-SAE, NR, Mod0.0110
Lymphadenopathy-non-SAE, NR, Mild0.0230.099
Lymphangitis-non-SAE, NR, Mod00.012
Lymphocyte Count Decreased-non-SAE, RIGIV, Mild00.012
Lymphoedema-non-SAE, NR, Severe0.0110
Malaise-non-SAE, NR, Mild00.025
Malaise-non-SAE, NR, Mod00.012
Malaise-non-SAE, RIGIV, Mod0.0110
Malaise-non-SAE, RrHu, Mild00.012
Malaise-non-SAE, RrHu, Mod00.012
Memory Impairment-non-SAE, NR, Mod00.012
Migraine-non-SAE, NR, Mild0.0110.012
Migraine-non-SAE, NR, Mod00.025
Migraine-non-SAE, NR, Severe0.0110
Migraine-non-SAE, RIGIV, Mild0.0110.012
Migraine-non-SAE, RIGIV, Mod0.0110.049
Migraine-non-SAE, RIGIV, Severe00.012
Migraine-non-SAE, Rboth, Mod00.012
Molluscum Contagiosum-non-SAE, NR, Mild0.0230
Mouth Ulceration-non-SAE, NR, Mild0.0110
Multiple Sclerosis Relapse-non-SAE, NR, Mod00.012
Muscle Fatigue-non-SAE, NR, Mild00.012
Muscle Injury-non-SAE, NR, Mild00.025
Muscle Spasms-non-SAE, NR, Mild00.012
Muscle Spasms-non-SAE, RIGIV, Mild0.0110
Muscle Strain-non-SAE, NR, Mild0.0110.012
Muscle Strain-non-SAE, NR, Mod00.012
Muscular Weakness-non-SAE, NR, Mild0.0110
Musculoskeletal Chest Pain-non-SAE, NR, Mild00.012
Musculoskeletal Chest Pain-non-SAE, RIGIV, Mild00.012
Musculoskeletal Pain-non-SAE, NR, Mild0.0230
Musculoskeletal Pain-non-SAE, NR, Mod0.0110.012
Musculoskeletal Stiffness-non-SAE, NR, Mild0.0110.012
Myalgia-non-SAE, NR, Mild0.0340.062
Myalgia-non-SAE, NR, Mod0.0110.049
Myalgia-non-SAE, NR, Severe00.012
Myalgia-non-SAE, RIGIV, Mild00.074
Myalgia-non-SAE, RIGIV, Mod0.0110.012
Myalgia-non-SAE, Rboth, Mild00.037
SecondaryRate of All AEs Categorized by MedDRA Preferred Terms, Seriousness, Relatedness to Study Drug, and Severity Per Participant (N-Z)

Categories presented as Preferred term-Seriousness, Relatedness, Severity. The following codes are to be used: Seriousness: non-SAE-non-serious AE; SAE-serious AE Relationship: NR-not related to immune globulin (IGIV), 10% and recombinant human hyaluronidase (rHuPH20); RIGIV-related to IGIV, 10%; RrHu-related to rHuPH20; Rboth-related to both IGIV, 10% and rHuPH20 Severity: Mild; Mod (Moderate); Severe Preferred terms abbreviated: Resp.-Respiratory WBC - White blood cells

Time frame:
Throughout the study period (17 months)
Reported as:
Number · Number of AEs per participant
Rate of All AEs Categorized by MedDRA Preferred Terms, Seriousness, Relatedness to Study Drug, and Severity Per Participant (N-Z)
Number of AEs per participantIV Administration of IGIV, 10%SC Administration of IGIV, 10% With rHuPH20 After Ramp-up
Nasal Congestion-non-SAE, NR, Mild0.0460.037
Nasal Congestion-non-SAE, NR, Mod00.025
Nasal Congestion-non-SAE, RIGIV, Mild00.037
Nasal Discomfort-non-SAE, NR, Mild00.012
Nasal Mucosal Discolouration-non-SAE, NR, Mild00.012
Nasal Turbinate Hypertrophy-non-SAE, NR, Mild00.012
Nasopharyngitis-non-SAE, NR, Mild0.0460.099
Nausea-non-SAE, NR, Mild0.0340.210
Nausea-non-SAE, NR, Mod0.0230.037
Nausea-non-SAE, RIGIV, Mild0.0800.012
Nausea-non-SAE, RIGIV, Mod0.0110
Nausea-non-SAE, Rboth, Mild00.049
Neck Pain-non-SAE, NR, Mild0.0110.012
Night Sweats-non-SAE, NR, Mild0.0110
Night Sweats-non-SAE, NR, Mod00.012
Nodule-non-SAE, Rboth, Mild00.025
Oedema-non-SAE, RIGIV, Mild00.012
Oedema Genital-non-SAE, Rboth, Severe00.012
Oedema Peripheral-non-SAE, NR, Mild00.012
Oedema Peripheral-non-SAE, NR, Mod00.012
Oedema Peripheral-non-SAE, Rboth, Mod00.025
Oesophagitis-non-SAE, NR, Mild00.012
Onychomycosis-non-SAE, NR, Mild00.012
Oral Candidiasis-non-SAE, NR, Mod00.012
Oral Fungal Infection-non-SAE, NR, Mild00.012
Oral Herpes-non-SAE, NR, Mild0.0110.025
Oral Herpes-non-SAE, NR, Mod00.012
Oral Pain-non-SAE, NR, Mild00.012
Oral Pain-non-SAE, RrHu, Severe00.012
Oropharyngeal Pain-non-SAE, NR, Mild0.0110.049
Oropharyngeal Pain-non-SAE, NR, Mod0.0230.012
Osteoarthritis-non-SAE, NR, Mod00.012
Osteopenia-non-SAE, NR, Mild00.012
Osteopenia-non-SAE, NR, Mod00.012
Osteoporosis-non-SAE, NR, Mild00.012
Otitis Externa-non-SAE, NR, Mild00.012
Otitis Externa-non-SAE, NR, Mod00.012
Otitis Media-non-SAE, NR, Mod0.0110.012
Pain-non-SAE, NR, Mild0.0110.062
Pain-non-SAE, NR, Mod0.0110.012
Pain-non-SAE, RIGIV, Mild00.012
Pain-non-SAE, RIGIV, Mod0.0230.012
Pain-non-SAE, Rboth, Mild00.012
Pain-non-SAE, Rboth, Mod00.012
Pain in Extremity-non-SAE, NR, Mild0.0230.012
Pain in Extremity-non-SAE, NR, Mod0.0110.025
Pain in Extremity-non-SAE, RIGIV, Mod0.0230
Pain in Extremity-non-SAE, RIGIV, Severe0.0110
Pain in Extremity-non-SAE, Rboth, Mild00.037
Pain in Extremity-non-SAE, Rboth, Mod00.025
Palpitations-non-SAE, NR, Mild0.0110.012
Papule-non-SAE, NR, Mild00.012
Peptic Ulcer Haemorrhage-SAE, NR, Severe0.0110
Periorbital Haematoma-non-SAE, NR, Mild00.012
Peripheral Nerve Injury-non-SAE, NR, Mild00.012
Pertussis-non-SAE, NR, Mod00.012
Petit Mal Epilepsy-SAE, NR, Severe00.012
Pharyngeal Erythema-non-SAE, NR, Mild0.0110.037
Pharyngitis-non-SAE, NR, Mild0.0110.049
Pharyngitis-non-SAE, NR, Mod0.0110
Pharyngitis Streptococcal-non-SAE, NR, Mod00.049
Pneumonia-non-SAE, NR, Mild00.012
Pneumonia-non-SAE, NR, Mod00.012
Pneumonia Bacterial-non-SAE, NR, Mod00.012
Post Procedural Infection-non-SAE, NR, Mild0.0110.025
Post Procedural Infection-non-SAE, NR, Mod00.062
Postictal Paralysis-non-SAE, NR, Mod00.012
Postoperative Wound Infection-non-SAE, NR, Mod00.012
Procedural Pain-non-SAE, NR, Mild00.025
Procedural Pain-non-SAE, NR, Mod00.012
Productive Cough-non-SAE, NR, Mild0.0110.012
Pruritus-non-SAE, NR, Mild0.0110
Pruritus-non-SAE, RIGIV, Mild0.0110
Pruritus-non-SAE, Rboth, Mild00.012
Pruritus-non-SAE, Rboth, Mod00.012
Pruritus Generalized-non-SAE, NR, Mild0.0110
Pseudomonas Infection-non-SAE, NR, Mod00.012
Psoriasis-non-SAE, NR, Mod00.012
Pyrexia-non-SAE, NR, Mild0.0340.136
Pyrexia-non-SAE, NR, Mod0.0230.012
Pyrexia-non-SAE, RIGIV, Mild0.0460.074
Pyrexia-non-SAE, RIGIV, Mod0.0230.025
Pyrexia-non-SAE, Rboth, Mild00.025
Rales-non-SAE, NR, Mild00.012
Rales-non-SAE, NR, Mod00.012
Rash-non-SAE, NR, Mild0.0230.062
Rash-non-SAE, NR, Mod00.012
Rash Erythematous-non-SAE, NR, Mild00.012
Rash Maculo-Papular-non-SAE, Rboth, Mild00.012
Rash Pustular-non-SAE, NR, Mild00.012
Rash Pustular-non-SAE, NR, Mod0.0110
Rash Papular-non-SAE, NR, Mild00.012
Respiratory Failure-SAE, NR, Severe00.012
Respiratory Rate Increased-non-SAE, NR, Mild00.012
Respiratory Tract Congestion-non-SAE, NR, Mild00.012
Respiratory Tract Infection-non-SAE, NR, Mild0.0110.012
Respiratory Tract Infection-non-SAE, NR, Mod0.0110.037
Respiratory Tract Infection Viral-non-SAE, NR, Mod0.0110
Rhinitis Allergic-non-SAE, NR, Mild0.0110.037
Rhinitis Allergic-non-SAE, NR, Mod0.0340.012
Rhinitis Allergic-non-SAE, RIGIV, Mod0.0110
Rhinorrhoea-non-SAE, NR, Mild0.0110.012
Road Traffic Accident-non-SAE, NR, Mod00.025
Scleritis-non-SAE, NR, Mild0.0110.012
Scleritis-non-SAE, NR, Mod00.012
Scratch-non-SAE, NR, Mild0.0110
Seborrhoeic Dermatitis-non-SAE, NR, Mild00.012
Sicca Syndrome-non-SAE, NR, Mod00.012
Sinus Congestion-non-SAE, NR, Mild0.0110
Sinus Headache-non-SAE, NR, Mild0.0110
Sinusitis-non-SAE, NR, Mild0.0690.309
Sinusitis-non-SAE, NR, Mod0.1490.321
Sinusitis-non-SAE, NR, Severe00.012
Sinusitis-non-SAE, RIGIV, Mod00.012
Skeletal Injury-non-SAE, NR, Mild00.012
Skeletal Injury-non-SAE, NR, Mod00.012
Skin Hyperpigmentation-non-SAE, Rboth, Mild00.012
Skin Laceration-non-SAE, NR, Mild00.012
Skin Laceration-non-SAE, NR, Mod00.012
Skin Lesion-non-SAE, NR, Mild0.0230.012
Skin Lesion-non-SAE, NR, Mod0.0110
Skin Lesion-non-SAE, RIGIV, Mild00.025
Skin Papilloma-non-SAE, NR, Mod0.0110
Spinal Osteoarthritis-non-SAE, NR, Mild00.025
Squamous Cell Carcinoma-non-SAE, NR, Mod0.0110.012
Status Epilepticus-SAE, NR, Severe00.012
Suicidal Ideation-non-SAE, NR, Mild0.0110
Sunburn-non-SAE, NR, Mild00.012
Swelling-non-SAE, Rboth, Mild00.012
Swelling-non-SAE, Rboth, Mod00.037
Syncope-non-SAE, NR, Mild00.012
Tachycardia-non-SAE, NR, Mild0.0370
Tachycardia-non-SAE, NR, Mod00.012
Therapy Cessation-non-SAE, NR, Severe00.012
Thrombosis-non-SAE, NR, Severe00.012
Thrombosis-SAE, NR, Mod00.012
Tinea Infection-non-SAE, NR, Mild00.023
Tongue Coated-non-SAE, NR, Mild00.012
Tonsillar Hypertrophy-non-SAE, NR, Mod00.012
Tonsillar Hypertrophy-SAE, NR, Mild00.012
Tooth Abscess-non-SAE, NR, Mild0.0110
Tooth Abscess-non-SAE, NR, Mod00.012
Tooth Impacted-non-SAE, NR, Mod00.012
Tooth Infection-non-SAE, NR, Mod00.012
Toothache-non-SAE, NR, Mod00.012
Tongue Injury-non-SAE, NR, Mild00.012
Tremor-non-SAE, NR, Mild00.012
Tricuspid Valve Incompetence-non-SAE, NR, Mild00.012
Tympanic Membrane Disorder-non-SAE, NR, Mild0.0110
Tympanic Membrane Hyperaemia-non-SAE, NR, Mild00.025
Upper Airway Cough Syndrome-non-SAE, NR, Mild00.012
Upper Resp. Tract Infection-non-SAE, NR, Mild0.0800.420
Upper Resp. Tract Infection-non-SAE, NR, Mod0.0230.123
Urinary Tract Infection-non-SAE, NR, Mild0.0110.025
Urinary Tract Infection-non-SAE, NR, Mod0.0570.049
Urine Analysis Abnormal-non-SAE, NR, Mild00.012
Urticaria-non-SAE, NR, Mild00.062
Urticaria-non-SAE, NR, Mod00.012
Urticaria-non-SAE, RIGIV, Mild0.0110
Uterine Polyp-non-SAE, NR, Mod00.012
Vaginal Haemorrhage-non-SAE, NR, Mod00.012
Vascular Access Complication-non-SAE, NR, Mild0.0110
Vertigo-non-SAE, NR, Mod00.012
Viral Diarrhoea-non-SAE, NR, Mild00.012
Viral Infection-non-SAE, NR, Mild0.0340.086
Viral Infection-non-SAE, NR, Mod0.0340.037
Viral Infection-SAE, NR, Mild0.0110
Viral Upper Resp. Tract Infection-non-SAE, NR Mild0.0110.099
Viral Upper Resp. Tract Infection-non-SAE, NR, Mod0.0110.012
Vision Blurred-non-SAE, NR, Mild00.012
Vitamin D Deficiency-non-SAE, NR, Mild0.0110
Vitamin D Deficiency-non-SAE, NR, Mod00.025
Vomiting-non-SAE, NR, Mild0.0570.096
Vomiting-non-SAE, NR, Mod00.037
Vomiting-non-SAE, RIGIV, Mild0.0460.037
Vomiting-non-SAE, RIGIV, Mod0.0110.049
Vomiting-non-SAE, RIGIV, Severe0.0110
Vomiting-non-SAE, Rboth, Mod00.012
Vulvovaginal Pruritus-non-SAE, RIGIV, Mild00.012
Weight Decreased-non-SAE, RrHu, Mild00.012
Weight Decreased-non-SAE, RrHu, Mod00.012
Wheezing-non-SAE, NR, Mod00.012
WBC Count Decreased-non-SAE, RIGIV, Mild00.012
White Blood Cells Urine Positive-non-SAE, NR, Mild00.012
WBC Urine Positive-non-SAE, RIGIV Mild0.0110
SecondaryPercentage of Infusions Associated With ≥1 AE Related to Either or Both Study Drugs

Percentage of Infusions Associated With ≥1 AE Related to immune globulin intravenous (IGIV), 10%, \[administered via intravenous (IV) or subcutaneous (SC) route\], recombinant human hyaluronidase (rHuPH20) or both. The percentage of affected infusions is calculated per subject and then summarized by the median of all subjects analysed.

Time frame:
Throughout the study period (17 months)
Reported as:
Median · Percentage of infusions
Percentage of Infusions Associated With ≥1 AE Related to Either or Both Study Drugs
Percentage of infusionsIV Administration of IGIV, 10%SC Administration of IGIV, 10% With rHuPH20 With Ramp-up
Including infections0.0 (0.0 to 25.0)8.3 (6.3 to 20.8)
Excluding infections0.0 (0.0 to 25.0)8.3 (6.3 to 20.8)
SecondaryPercentage of Infusions Tolerated With IV and SC Administration at Dose Used in Study Epoch 2 (SC/rHuPH20 Treatment)

Epoch 2: subcutaneous (SC) administration of immune globulin intravenous (IGIV), 10% with recombinant human hyaluronidase (rHuPH20) after ramp-up. Dose used in Epoch 2 (after ramp-up) was 108% of dose used in intravenous (IV) administration of IGIV, 10%. The percentage of affected infusions is calculated per subject and then summarized by the median of all subjects analysed.

Time frame:
Throughout the study period (17 months)
Reported as:
Median · Percentage of infusions
Percentage of Infusions Tolerated With IV and SC Administration at Dose Used in Study Epoch 2 (SC/rHuPH20 Treatment)
Percentage of infusionsIV Administration of IGIV, 10%SC Administration of IGIV, 10% With rHuPH20 After Ramp-up
Percentage of Infusions Tolerated With IV and SC Administration at Dose Used in Study Epoch 2 (SC/rHuPH20 Treatment)100.0 (100.0 to 100.0)100.0 (100.0 to 100.0)
SecondaryMedian Rate of AEs Temporally Associated or Related to Study Drug Per Infusion

Temporally associated defined as during infusion or within 72 hours of completion of infusion. Related defined as determined by investigator to be at least possibly related to study drug (immune globulin intravenous \[IGIV\], 10% or recombinant human hyaluronidase \[rHuPH20\]). Expressed as a percentage.

Time frame:
Throughout the study period (17 months)
Reported as:
Median · Percentage of AE
Median Rate of AEs Temporally Associated or Related to Study Drug Per Infusion
Percentage of AEIV Administration of IGIV, 10%SC Administration of IGIV, 10% With rHuPH20 After Ramp-up
Including Infections0.25 (0.25 to 0.50)0.22 (0.13 to 0.31)
Excluding Infections0.25 (0.20 to 0.50)0.18 (0.12 to 0.26)
SecondaryNumber of Participants Who Developed Neutralizing Antibodies to Recombinant Human Hyaluronidase (rHuPH20)
Time frame:
Throughout the study period (17 months)
Reported as:
Number · Number of participants
Number of Participants Who Developed Neutralizing Antibodies to Recombinant Human Hyaluronidase (rHuPH20)
Number of participantsSC Administration of IGIV, 10% With rHuPH20
Number of Participants Who Developed Neutralizing Antibodies to Recombinant Human Hyaluronidase (rHuPH20)0
SecondaryPercentage of Participants Who Developed Neutralizing Antibodies to Recombinant Human Hyaluronidase (rHuPH20)
Time frame:
Throughout the study period (17 months)
Reported as:
Number · Percentage of participants
Percentage of Participants Who Developed Neutralizing Antibodies to Recombinant Human Hyaluronidase (rHuPH20)
Percentage of participantsSC Administration of IGIV, 10% With rHuPH20
Percentage of Participants Who Developed Neutralizing Antibodies to Recombinant Human Hyaluronidase (rHuPH20)0.0
SecondaryNumber of Participants Who Experienced a Hemoglobin Drop of >2.0 g/dL, With Evidence of Hemolysis on Further Analysis

Further analysis for incidences of potential hemolysis included direct Coombs' test, free hemoglobin, serum haptoglobin, LDH, urine hemosiderin and microscopic urinalysis

Time frame:
Throughout the study period (17 months)
Reported as:
Number · Number of participants
Number of Participants Who Experienced a Hemoglobin Drop of >2.0 g/dL, With Evidence of Hemolysis on Further Analysis
Number of participantsParticipants in Safety Data Analysis Set
Number of Participants Who Experienced a Hemoglobin Drop of >2.0 g/dL, With Evidence of Hemolysis on Further Analysis0
SecondaryPercentage of Participants Who Experienced a Hemoglobin Drop of >2.0 g/dL, With Evidence of Hemolysis on Further Analysis

Further analysis for incidences of potential hemolysis included direct Coombs' test, free hemoglobin, serum haptoglobin, LDH, urine hemosiderin and microscopic urinalysis

Time frame:
Throughout the study period (17 months)
Reported as:
Number · Percentage of participants
Percentage of Participants Who Experienced a Hemoglobin Drop of >2.0 g/dL, With Evidence of Hemolysis on Further Analysis
Percentage of participantsParticipants in Safety Data Analysis Set
Percentage of Participants Who Experienced a Hemoglobin Drop of >2.0 g/dL, With Evidence of Hemolysis on Further Analysis0

Adverse events

Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
IV Administration of IGIV, 10%—3/87 (3.4%)67/87 (77%)
SC Administration of IGIV, 10%, With rHuPH20 (With Ramp-up)—12/83 (14.5%)81/83 (97.6%)
Most frequent serious events
Showing 10 of 17
Most frequent serious events
EventIV Administration of IGIV, 10%SC Administration of IGIV, 10%, With rHuPH20 (With Ramp-up)
Adrenocortical Insufficiency AcuteEndocrine disorders0/871/83
GastroenteritisInfections and infestations0/871/83
Back InjuryInjury, poisoning and procedural complications0/871/83
Grand Mal ConvulsionNervous system disorders0/871/83
HeadacheNervous system disorders0/871/83
Petit Mal EpilepsyNervous system disorders0/871/83
Status EpilepticusNervous system disorders0/871/83
Cervical DysplasiaReproductive system and breast disorders1/871/83
Respiratory FailureRespiratory, thoracic and mediastinal disorders0/871/83
Tonsillar HypertrophyRespiratory, thoracic and mediastinal disorders0/871/83
Most frequent other events
Showing 10 of 48
Most frequent other events
EventIV Administration of IGIV, 10%SC Administration of IGIV, 10%, With rHuPH20 (With Ramp-up)
INFUSION SITE PAINGeneral disorders1/8737/83
SINUSITISInfections and infestations14/8735/83
UPPER RESPIRATORY TRACT INFECTIONInfections and infestations8/8732/83
HEADACHENervous system disorders24/8727/83
NAUSEAGastrointestinal disorders12/8715/83
FATIGUEGeneral disorders8/8714/83
INFUSION SITE ERYTHEMAGeneral disorders0/8714/83
ASTHMARespiratory, thoracic and mediastinal disorders7/8714/83
VOMITINGGastrointestinal disorders8/8713/83
PYREXIAGeneral disorders8/8713/83

Baseline characteristics

Age, Continuous
Age, Continuous(years)2 to <12 Years12 Years and OlderTotal
Median8.0 (4 to 11)44.0 (12 to 78)35.0 (4 to 78)
Sex: Female, Male
Sex: Female, Male(Participants)2 to <12 Years12 Years and OlderTotal
Female63743
Male83644
Region of Enrollment
Region of Enrollment(Participants)2 to <12 Years12 Years and OlderTotal
United States147286
Canada011
08

Study locations

14 sites
  • Cypress, California, United States
  • Irvine, California, United States
  • Los Angeles, California, United States
  • San Francisco, California, United States
  • Centennial, Colorado, United States
  • North Palm Beach, Florida, United States
  • Atlanta, Georgia, United States
  • Hinsdale, Illinois, United States
  • Omaha, Nebraska, United States
  • Bronx, New York, United States
  • Dallas, Texas, United States
  • Galveston, Texas, United States
  • Milwaukee, Wisconsin, United States
  • Vancouver, British Columbia, Canada
09

References and documents

Publications

  • Wasserman RL, Melamed I, Stein MR, Engl W, Sharkhawy M, Leibl H, Puck J, Rubinstein A, Kobrynski L, Gupta S, Grant AJ, Ratnayake A, Richmond WG, Church J, Yel L, Gelmont D. Long-Term Tolerability, Safety, and Efficacy of Recombinant Human Hyaluronidase-Facilitated Subcutaneous Infusion of Human Immunoglobulin for Primary Immunodeficiency. J Clin Immunol. 2016 Aug;36(6):571-82. doi: 10.1007/s10875-016-0298-x. Epub 2016 May 25. PubMed 27220317 ↗
  • Wasserman RL, Melamed I, Stein MR, Gupta S, Puck J, Engl W, Leibl H, McCoy B, Empson VG, Gelmont D, Schiff RI; IGSC, 10% with rHuPH20 Study Group. Recombinant human hyaluronidase-facilitated subcutaneous infusion of human immunoglobulins for primary immunodeficiency. J Allergy Clin Immunol. 2012 Oct;130(4):951-7.e11. doi: 10.1016/j.jaci.2012.06.021. Epub 2012 Jul 28. PubMed 22846381 ↗
  • Wasserman RL, Gupta S, Stein M, Rabbat CJ, Engl W, Leibl H, Yel L. Infection rates and tolerability of three different immunoglobulin administration modalities in patients with primary immunodeficiency diseases. Immunotherapy. 2022 Mar;14(4):215-224. doi: 10.2217/imt-2021-0256. Epub 2021 Dec 21. PubMed 34931880 ↗
10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Dec 2008 to primary completion in Nov 2010, 22 months.

Results were first posted in Dec 2015, 5 years after primary completion. A results delay was requested in Nov 2011.

Of 25 phase 3 interventional studies under Primary Immunodeficiency Diseases, half reached primary completion within 35 months of starting (the median), counting those still running; a quarter within 19 and three quarters within 41. This study's 22 months is below that.

How these figures are worked out, and which studies are left out of them.

Registered
Dec 23, 2008
First posted
Dec 24, 2008
StartActual
Dec 18, 2008
Primary completionActual
Nov 11, 2010
CompletionActual
Nov 11, 2010
Results delay requested
Nov 30, 2011
Results first posted
Dec 3, 2015
Last update
May 19, 2021
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on May 19, 2021, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT00814320
Responsible party
Sponsor
First posted
Dec 24, 2008
Start date
Dec 18, 2008
Primary completion
Nov 11, 2010
Completion
Nov 11, 2010
Results posted
Dec 3, 2015
Last update
May 19, 2021

Study contacts

Study Director
study director · Shire

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Apr 2021. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Hyaluronidase (human recombinant)

Start the discussion